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SUMMARY 
 
Classic galactosemia is a potentially lethal disease of the galactose metabolism caused by 
a severe deficiency of GALT, the second enzyme of the Leloir pathway. This disorder is 
associated with mutations in the GALT gene, and displays an autosomal recessive pattern of 
inheritance. Although apparently asymptomatic at birth, affected infants start developing 
escalating symptoms after 1 to 2 weeks of galactose ingestion due to milk feeding. Upon 
implementation of a galactose-restricted diet, infants show rapid clinical improvement and seem 
to be almost miraculously cured; however, the long-term outcome is often disappointing, as most 
patients go on to develop severe complications notwithstanding strict compliance with the dietary 
therapy. 
Despite decades of intensive research, classic galactosemia pathophysiology is still 
largely unknown, resulting in a limited and poorly effective therapy. A comprehensive 
understanding of the molecular mechanisms underlying classic galactosemia potentially opens 
new therapeutic avenues, and prompted us to develop the present work. 
The first part of this thesis (chapter 1) comprises a general introduction with a review of 
the literature concerning the molecular and biochemical basis of classic galactosemia, followed 
by an overview of the current therapeutic approaches in genetic disorders – with a special focus 
on inherited metabolic disorders – and finally the objectives of the present work. 
Our studies initiated with the molecular characterization of all patients currently followed 
by the Portuguese metabolic centers (chapter 2). The rationale for this study was the previous 
description that GALT genotype represents a valuable prognostic tool for the outcome of 
galactosemic patients. Accordingly, after genotyping 42 Portuguese galactosemic patients, we 
searched for genotype-phenotype correlations by a 3-fold evaluation. Firstly, we employed in 
silico strategies to assess the structural-functional impact of previously uncharacterized 
mutations; secondly, we evaluated the biochemical phenotype at both the metabolite and 
enzymatic levels, represented by Gal-1-P values and GALT activity in erythrocytes; and finally, 
evaluated the resulting clinical outcome. Establishment of correlations between genotype and 
biochemical or clinical phenotypes, however, was poorly attained, reiterating the complexity of 
this disease and emphasizing the idea that other modifiers – possibly genetic, epigenetic and 
environmental – contribute to the pathophysiology of classic galactosemia. 
The update of the Portuguese GALT mutational spectrum revealed the intronic mutation 
c.820+13A>G (IVS8+13A>G) as the second most prevalent variation, strongly suggesting its 
pathogenicity, which set the basis for the study described in chapter 3. We functionally 
characterized the c.820+13A>G variation by ex vivo and in vivo analyses, which were in full 
agreement with the previous in silico predictions. Indeed, we confirmed this variation is a 
disease-causing mutation, whose mechanism of action involves the activation of a cryptic donor 
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site, which, in turn, induces an aberrant splicing of the GALT pre-mRNA, thus causing a 
frameshift with inclusion of a premature stop codon. Structural-functional studies of the 
recombinant truncated GALT showed it was devoid of enzymatic activity and prone to 
aggregation. Finally, antisense oligonucleotides were designed to specifically recognize the 
mutation, and successfully restored the constitutive splicing. 
Molecular studies in several inherited metabolic disorders have led to the realization that 
only a minor part of the mutations directly disrupt functional sites of the proteins. Accordingly, in 
chapter 4, we described the structural and functional characterization of the most prevalent 
mutations in the GALT gene – p.Q188R, p.S135L, p.K285N and p.N314D – and of other five 
clinically relevant mutations – p.R148Q, p.G175D, p.P185S, p.R231C and p.R231H. 
Interestingly, the analyzed mutations did not affect the global conformational stability of the 
GALT enzyme; rather, most mutations, notwithstanding their impact on the enzyme 
functionality, increased the propensity for aggregation, which at the cellular level reflects in a 
decrease of the enzyme’s effective concentration. These results are in agreement with previous 
studies in classic galactosemia models, and suggest that GALT aggregation might be a major 
pathogenic mechanism underlying this disorder. 
Previous studies have reported a yeast galactosemia model allowing the evaluation of 
human GALT mutations severity, by assaying the sensitivity of transformed yeast cultures to 
galactose addition to the medium. Thus, in chapter 5, we developed a prokaryotic model of 
galactose sensitivity to evaluate the ability of the above referred human GALT mutants in 
alleviating the galactose-induced toxicity. This model presents the inherent advantage of being 
assayed in vivo, thus providing valuable insights on mutations’ impact on human GALT function. 
Additionally, arginine ability to ameliorate the galactose-induced toxicity was also evaluated for 
each human GALT mutant. The rationale for this approach was, not only the long-recognized 
anti-aggregation properties of arginine, but also its important therapeutic effect described in 
previous studies. In effect, arginine appears to exert a mutation-specific mode of action, 
alleviating the galactose toxicity in the p.Q188R, p.K285N, and p.G175D mutants, which 
suggests that might be of some benefit in classic galactosemia. Nonetheless, further studies are 
underway to ascertain arginine’s potential therapeutic effect in this inherited disorder of the 
galactose metabolism. 
Chapter 6 presents a general discussion and major conclusions disclosed by this work, 
framing them in the current state of the art, proving also some perspectives for future studies. 
Taken together, our results provide important insights on classic galactosemia, namely by 
shedding light on the underlying pathogenic molecular mechanisms, thus contributing for a better 
understanding of this enigmatic disorder. Finally, and importantly, these studies paved the way to 
the search, development and improvement of novel and alternative therapeutic strategies, so 
needed to overcome the overwhelming and burdensome long-term complications presented by 
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most classic galactosemic patients. 
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RESUMO  
 
Após a sua internalização celular, a galactose é rapidamente metabolizada a glucose-1-
fosfato pela acção sequencial de três enzimas: galactocinase (GALK), galactose-1-fosfato 
uridililtransferase (GALT) e uridina difosfogalactose 4’-epimerase (GALE). Estas enzimas 
permitem, respectivamente, a fosforilação da galactose em galactose-1-fosfato (GALK), a 
conversão de galactose-1-fosfato e uridina difosfoglucose em glucose-1-fosfato e uridina 
difosfogalactose (GALT), e a interconversão de uridina difosfoglucose em uridina 
difosfogalactose (GALE). Estas enzimas constituem a via de Leloir e, apesar de o fígado ser o 
principal órgão envolvido no metabolismo da galactose, encontram-se na maioria das células e 
dos tecidos.  
Uma deficiência enzimática em qualquer uma das três enzimas da via de Leloir resulta 
numa diminuição ou ausência de capacidade de metabolizar a galactose e, consequentemente, 
conduz à sua acumulação no sangue – hipergalactosémia.  
A Galactosémia Clássica (OMIM #230400), a forma mais comum de hipergalactosémia 
primária, é uma doença genética de transmissão autossómica recessiva, que afecta 1 em cada 
30.000 a 60.000 nados-vivos, apresentando uma prevalência variável entre populações, 
nomeadamente na Irlanda e Turquia onde atinge valores de 1/23.500 - 1/23.775 e no Japão onde a 
sua prevalência atinge o valor mais baixo (1/1.000.000). A ausência ou diminuição de actividade 
da GALT é causada por mutações no gene GALT, e encontram-se descritas mais de 250 
variações, reflectindo a elevada heterogeneidade alélica desta doença metabólica. Para além 
disso, a maioria dos doentes são heterozigóticos compostos, um dos factores determinantes da 
ampla variabilidade fenotípica observada. 
Aquando do nascimento, a criança aparenta ser assintomática. Os sintomas tornam-se 
evidentes após o início da ingestão de leite, e consistem inicialmente em dificuldades alimentares 
e de desenvolvimento, vómitos, diarreia, letargia e hipotonia, podendo evoluir para cataratas e 
septicémia, e eventualmente conduzir à morte. Após implementação de uma dieta restrita em 
galactose – o tratamento padrão – as crianças mostram notáveis melhorias em apenas 24 horas, e 
em apenas uma a duas semanas as disfunções hepática e renal desaparecem completamente. Esta 
resposta dramática à terapia dietética levou ao conceito da Galactosémia Clássica como uma 
doença relativamente benigna e fácil de tratar. No entanto, os doentes com Galactosémia Clássica 
desenvolvem complicações a longo prazo e a diversos níveis, como neurológico e 
psiconeurológico, crescimento e densidade óssea, e disfunção ovárica nas mulheres, os quais 
parecem ser independentes de um diagnóstico precoce e de uma adesão do doente à terapia. 
Apesar de a primeira descrição datar de 1908, a Galactosémia Clássica continua a ser um 
enigma, quer ao nível do conhecimento aprofundado da sua fisiopatologia, quer ao nível do 
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desenvolvimento de alternativas terapêuticas que permitam, sobretudo, mitigar as complicações a 
longo prazo. 
O presente trabalho pretende, assim, contribuir para a elucidação dos mecanismos 
moleculares subjacentes à patogénese das mutações GALT prevalentes na população 
galactosémica Portuguesa, assim como explorar novas estratégias terapêuticas direccionadas para 
cada tipo específico de mutação. 
 O primeiro capítulo da tese apresenta uma revisão geral da literatura sobre vários 
aspectos relacionados com a Galactosémia Clássica: as bases bioquímicas e moleculares, a 
fisiopatologia e as actuais abordagens terapêuticas.  Em seguida, descrevem-se em pormenor os 
mecanismos moleculares subjacentes à maioria das mutações que originam Erros Hereditários do 
Metabolismo (onde se inclui a Galactosémia Clássica) e que causam perca de função, 
nomeadamente as mutações missense e as que afectam o splicing, mecanismos esses que 
condicionam as novas terapias desenhadas de acordo com o tipo de mutação. Por fim, são 
descritos os objectivos delineados para o presente trabalho. 
O trabalho experimental teve início com a caracterização molecular de todos os doentes 
actualmente seguidos nos centros metabólicos nacionais de Lisboa, Porto e Coimbra, sendo o 
objectivo final averiguar se, como sugerido na literatura, o genótipo GALT pode ter um valor 
prognóstico sobre a evolução fenotípica dos doentes galactosémicos (capítulo 2). Os dados 
obtidos permitiram estabelecer o espectro mutacional da Galactosémia Clássica em Portugal e 
compará-lo com o de outras populações. O estudo de 42 doentes revelou a presença de 14 
substituições nucleotídicas, sendo 10 missense, 2 nonsense e 2 de splicing. Identificaram-se 16 
genótipos diferentes, mas metade dos doentes são homozigóticos para p.Q188R, a mutação 
prevalente não só em Portugal como a nível mundial. Surpreendentemente, a segunda mutação 
mais frequente é uma mutação de splicing, descrita até então como benigna. 
Em seguida, e recorrendo a programas bioinformáticos adequados, procedeu-se à análise 
da potencial patogenicidade das mutações ainda não caracterizadas na literatura. Os resultados 
sugeriram que a maioria destas mutações missense afectará a estabilidade e a funcionalidade da 
proteína mutada, enquanto que a mutação de splicing mais frequente deverá induzir um 
mecanismo de splicing alternativo. 
Por fim, este estudo revelou, na maioria dos casos, a ausência de uma correlação clara 
entre a gravidade das mutações prevista pela análise in silico e o fenótipo bioquímico dos 
doentes, determinado pelos níveis eritrocitários de galactose-1-fosfato, assim como com o 
fenótipo clínico e a evolução desfavorável manifestada pelos doentes. No entanto, tal resultado 
não surpreende dado a Galactosémia Clássica, apesar de ser uma doença monogénica, não 
originar fenótipos claros. Este facto prende-se com a falta de informação estrutural sobre os 
componentes enzimáticos da via de Leloir, colocando-se a hipótese de uma alteração na GALT 
poder afectar toda a via metabólica. Por outro lado, os metabolitos da galactose estão envolvidos 
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em diversas reacções fisiológicas, nomeadamente as de glicosilação que se reflectem aos mais 
variados níveis. Finalmente, a influência de outros genes modificadores, de alterações 
epigenéticas e de factores ambientais também não pode ser ignorada. 
Os capítulos seguintes são dedicados ao estudo dos mecanismos moleculares subjacentes 
às mutações prevalentes na população Portuguesa e ao desenvolvimento de novas abordagens 
terapêuticas. 
No capítulo 3 descreve-se o estudo da mutação de splicing IVS8+13A>G, até então 
considerada como benigna, mas que revelou ser a segunda mais frequente na nossa população 
galactosémica. A caracterização funcional do mecanismo patogénico foi efectuada por transfeção 
de um minigene contendo a sequência mutada em duas linhas diferentes de células eucarióticas. 
A análise dos produtos de transcrição revelou que a mutação activa um sítio críptico de splicing, 
causando um splicing anómalo do pré-mRNA GALT, o qual induz um frameshift com inclusão de 
um codão de terminação prematuro (p.D274GfsX291).  
Por outro lado, dado ter-se observado a presença do mensageiro mutado nas amostras 
biológicas dos doentes portadores desta mutação, colocou-se a hipótese de a proteína truncada ser 
produzida in vivo, o que levou à produção da proteína recombinante. Os estudos estruturais e 
funcionais subsequentes revelaram que esta proteína é propensa à formação de agregados e é 
destituída de actividade enzimática. 
Finalmente, e utilizando oligonucleótidos antisense que hibridam especificamente com o 
local da mutação, impedindo assim a ligação do spliceossoma e forçando a sua ligação ao sítio 
canónico dador de splicing, foi possível corrigir o splicing alternativo induzido pela mutação e 
obter o mensageiro selvagem. Estas experiências constituíram a prova de conceito sobre a 
aplicabilidade da terapia antisense como alternativa estratégica para a claramente insuficiente 
dieta restrita em galactose. ! O espectro mutacional da maioria dos erros hereditários do metabolismo é dominado por 
mutações do tipo missense. O capítulo 4 aborda a caracterização estrutural e funcional das quatro 
variantes GALT prevalentes a nível mundial, assim como outras cinco variantes com relevância 
clínica, nomeadamente na população galactosémica Portuguesa. Diversas metodologias foram 
empregues para determinação da actividade enzimática e do perfil de  inactivação térmica, bem 
como métodos biofísicos para avaliação das estruturas secundária, terciária e quaternária das 
proteínas mutadas. Os resultados revelaram que as mutações pontuais não afectam nenhuma das 
estruturas acima mencionadas, mas sim a propensão para uma agregação precoce destas 
variantes.  
 Este resultado constitui na realidade a principal novidade, dado que um estudo recente 
postulou que algumas mutações no gene GALT afectam o correcto folding das proteínas mutadas. 
Esta conclusão é extremamente relevante na medida em que, para além da diminuição da 
actividade uridililtransferásica,  a acumulação de agregados proteicos interfere com a homeostase 
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celular. Efectivamente, diversos estudos relataram a presença, em doentes galactosémicos, do 
aumento de actividade dos sistemas ligados ao stress do retículo endoplasmático e da unfolded 
protein response, assim como de níveis elevados de stress oxidativo, fenómenos característico de 
uma proteotoxicidade. 
 Estes dados levam-nos então a colocar como potencial e nova hipótese terapêutica a 
utilização de moduladores da proteostase, os quais prolongam a semi-vida celular das variantes 
GALT, compensando assim parcialmente a diminuição de actividade enzimática e 
simultaneamente prevenindo a acumulação de agregados proteicos. 
 No capítulo 5 desenvolvemos um modelo procariótico de sensibilidade à galactose que 
permitisse avaliar, não só o impacto causado pelas diversas mutações missense, mas também o 
efeito de compostos com potencial acção terapêutica. Utilizámos uma estirpe de E. coli com o 
gene galT endógeno deletado, de modo que toda a actividade GALT detectada é proveniente do 
mutante nela transformado. Os resultados, embora ainda preliminares, confirmaram a validade do 
modelo delineado e permitiram obter dados a dois níveis. Por um lado, replicámos in vivo os 
resultados previamente obtidos in vitro quanto à capacidade de aliviar a toxicidade induzida pela 
galactose, por comparação com a enzima selvagem. Por outro lado, e muito relevante, 
verificámos que o modelo é válido para testar moléculas com potencial terapêutico. 
Efectivamente, algumas destas enzimas mutadas revelaram-se sensíveis à arginina, um composto 
amplamente reconhecido como estabilizador de proteínas e  
anti-agregante, aliviando desse modo a toxicidade da galactose para a bactéria.  
 A presente tese termina com o capítulo 6 no qual se apresenta uma discussão dos 
resultados obtidos, incluindo uma análise integrada de todo o trabalho e respectivas conclusões, 
bem como algumas perspectivas de trabalho futuro. 
 Em suma, este trabalho contribuiu para um melhor conhecimento da Galactosémia 
Clássica em Portugal e para a elucidação dos mecanismos patogénicos subjacentes às mutações 
prevalentes, bem como para a descoberta e desenvolvimento de novas alternativas terapêuticas, 
tão necessárias para minorar as graves sequelas que a maioria dos doentes galactosémicos 
apresenta a longo termo. 
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1.1. Pathways of galactose metabolism 
The main source of galactose is the disaccharide lactose, present in milk and dairy 
products (1, 2). After its ingestion, lactose is hydrolyzed in the intestinal lumen by the 
disaccharidase lactase into its constituent monosaccharides, glucose and galactose. Galactose is 
then transported across the brush border membrane of the enterocyte by the SGLT1 active 
transporter, which uses the electrochemical gradient provided by the basolateral Na+/K+ ATPase 
pump to transport galactose into enterocytes against its concentration gradient, or through 
facilitated diffusion, by the GLUT2 transporter (3, 4). Across the basolateral membrane of the 
enterocyte, galactose is then transported by GLUT2 out of the enterocyte toward the blood 
stream, and is delivered by the portal blood to the liver, the major site of galactose metabolism, 
where it is internalized by GLUT2 (KM ≈ 92 mM) (3-7). 
 
1.1.1. The Leloir pathway 
Galactose is often present as an anomeric mixture of α-D-galactose and β-D-galactose, 
which spontaneously interconvert in aqueous solution (1, 8-10). In the cytoplasm, however, the 
rate of the spontaneous interconversion is insufficient to provide the needs of metabolic 
pathways, since many enzymes of carbohydrate metabolism exhibit specificity for one anomer or 
the other (10). In fact, when released from the breakdown of lactose, galactose is in the beta 
conformation (1). Once inside the cells, however, β-D-galactose must be epimerized to α-D-
galactose through the action of galactose mutarotase (GALM, EC 5.1.3.3), in order to provide the 
anomer specific of the first enzyme of the Leloir pathway (1, 8, 10-12). 
Once in the alpha conformation, D-galactose is converted to glucose-1-phosphate  
(Glc-1-P) by the action of three consecutive enzymes: galactokinase (GALK), which converts  
α-D-galactose into galactose-1-phosphate (Gal-1-P); galactose-1-phosphate uridylyltransferase 
(GALT), which converts Gal-1-P and uridine diphosphate-glucose (UDP-Glc) into Glc-1-P and 
uridine diphosphate-galactose (UDP-Gal); and UDP-galactose 4’-epimerase (GALE), which is 
responsible for the interconversion of UDP-Glc and UDP-Gal (Figure 1.1) (1). UDP-Glc thus 
formed can then enter the reaction again in a cyclical fashion until all of the galactose coming 
into the pathway is converted to glucose via Glc-1-P (13). 
These enzymes constitute the Leloir pathway, named after Luis Federico Leloir, one of 
the major contributors to the identification of this pathway, and ensure that most of the ingested 
galactose is rapidly converted into Glc-1-P (1, 11, 14, 15). The Glc-1-P produced by the Leloir 
pathway is converted by the enzyme phosphoglucomutase into glucose-6-phosphate, which can 
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be further metabolized via one of the following pathways: i) the glycolytic pathway; ii) the 
pentose phosphate pathway; or iii) the gluconeogenic pathway (14, 16, 17). 
Although the liver is the major organ of galactose metabolism, enzymes of the Leloir 
pathway have been detected in many cell types and tissues, including red and white blood cells, 
fibroblasts, and amniocytes (1, 11). 
 
 
Figure 1.1. The Leloir pathway. Galactose is converted to glucose-1-phosphate (Glc-1-P) by the action of three 
consecutive enzymes: galactokinase (GALK), galactose-1-phosphate uridylyltransferase (GALT) and UDP-galactose 
4’-epimerase (GALE), which constitute the Leloir pathway, the main pathway of galactose metabolism. 
 
1.1.2. Hypergalactosemia  
Hypergalactosemia refers to the presence of high levels of galactose in the blood (“emia” 
in Greek) and results from an impaired ability to metabolize galactose (1, 2). When an infant 
presents hypergalactosemia, the first question is whether this is primary hypergalactosemia or 
secondary hypergalactosemia (18). 
There are several etiologies of secondary hypergalactosemia. They all center on liver 
dysfunction since the liver is the primary organ responsible for whole body galactose metabolism 
and disposal. In the presence of liver dysfunction, galactose ingestion leads to high levels of 
plasma galactose and erythrocyte Gal-1-P, even in the presence of normal erythrocyte GALT 
activity. Causes of liver dysfunction include: congenital infectious hepatitis; congenital hepatic 
arterio-venous malformations; patent ductus venosus; Fanconi–Bickel syndrome; and tyrosinemia 
type I, citrin deficiency (including citrullinemia type II), and other metabolic disorders producing 
hepatocellular disease (18). 
Primary hypergalactosemia disorders result from a defect in the Leloir pathway, and 
include: GALK deficiency, GALT deficiency, and GALE deficiency (18). Although all forms of 
primary galactosemia are the result of impaired galactose metabolism, clinical presentation and 
severity vary widely among these patients (1). 
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1.1.2.1. GALT deficiency or type I galactosemia 
Classic galactosemia or type I galactosemia (OMIM #230400) is caused by deficiency of 
galactose-1-phosphate uridylyltransferase (GALT; UDP-glucose:α-D-galactose-1-phosphate 
uridylyltransferase, EC 2.7.7.12), the second enzyme of the Leloir pathway, and is the most 
common cause of primary galactosemia (1, 19, 20). As the main theme of this thesis, it will be 
detailed further ahead. 
 
1.1.2.2. GALK deficiency or type II galactosemia 
In all living cells, α-D-galactose metabolism begins with the phosphorylation of 
galactose by galactokinase (GALK, EC 2.7.1.6), the first metabolic enzyme of the Leloir pathway 
(1, 21, 22). This enzyme phosphorylates the carbon-1 hydroxyl group of α-D-galactose at the 
expense of ATP (23). Despite GALK phosphorylating galactose, it does not belong to the same 
family of other sugar kinases, like hexokinase and glucokinase. GALK belongs to the family of 
small molecule kinases, the GHMP kinase superfamily, originally called GHMP due to its 
members constitution: galactokinase, homoserine kinase, mevalonate kinase and 
phosphomevalonate kinase (23-26). The members of this family share a highly conserved motif, 
which is thought to be involved in nucleotide binding (25, 26). In fact, the reaction mechanism is 
sequential, such that MgATP binding induces a conformational change in the enzyme, thereby 
creating a functional binding site for α-D-galactose; the reaction products, ADP and Gal-1-P, are 
released only after the binding of both substrates (1, 23, 24). 
GALK deficiency (OMIM #230200) is an autosomal recessive disorder, associated with a 
markedly reduced erythrocyte GALK activity and an elevated blood galactose level (18). 
Deficiencies in this enzyme lead to type II galactosemia, of which the main symptom is early 
onset cataracts, and is less severe than the other primary hypergalactosemia disorders, GALT and 
GALE deficiencies (21, 24). 
Provided GALK deficiency is detected early in life and patients are kept under a 
galactose-restricted diet throughout life, long-term complications should not develop (20, 24). 
This point is extremely important, as it provides compelling evidence that it is not the 
accumulation of galactose, but rather of Gal-1-P, or of some metabolic derivative of Gal-1-P, that 
leads to the complications, beyond cataracts, observed in treated patients with classic 
galactosemia (20). Indeed, the differences in clinical outcome between GALK and GALT 
deficiencies reflect the differences in tissue response to the characteristic changes in the levels of 
galactose metabolites originating from the respective enzyme deficiencies (8). 
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1.1.2.3. GALE deficiency or type III galactosemia 
The third and final enzyme of the Leloir pathway is UDP-galactose 4’-epimerase (GALE, 
EC 5.1.3.2), which has a particularly important role, since it interconverts UDP-Gal and  
UDP-Glc, enabling endogenous synthesis of UDP-Gal in the absence of exogenous sources of 
galactose, and thereby rendering galactose a non-essential nutrient (1, 2, 20). In nearly all cells, 
GALE steady-state activity confers a ratio of UDP-Glc to UDP-Gal of about 3:1 (13). GALE also 
catalyzes the interconversion of a pair of larger substrates, uridine diphosphate-N-acetyl-
galactosamine (UDP-GalNAc) and uridine diphosphate-N-acetyl-glucosamine (UDP-GlcNAc) 
(1, 20, 27, 28). GALE deficiency is the least understood type of galactosemia (27). However, it is 
relatively common in the African-American and Japanese populations with occurrence rates of 
1/10,000 and 1/25,000 respectively (27). 
GALE deficiency or type III galactosemia (OMIM #230350) is an autosomal recessive 
disorder, characterized by a partial to complete enzyme activity. GALE deficiency, initially 
thought to be a binary condition, is actually a continuum disorder, in which can be distinguished 
three forms of the disease: a benign peripheral form, where subjects only show impaired activity 
in their red blood cells (RBC) with consequent elevation of blood Gal-1-P levels; a severe 
generalized form, where impaired GALE activity and elevated Gal-1-P levels are detected in all 
tissues; and an intermediate form, where subjects demonstrate partially impaired GALE activity 
in nonperipheral cells and Gal-1-P levels in-between those of the mild and severe forms (1, 27, 
29, 30). 
 One of the hallmarks of GALE deficiency is its variability: allelic heterogeneity, 
variability in the degree of enzyme defect, variability in which substrate pair is most affected by 
the enzyme defect (UDP-Gal/UDP-Glc or UDP-GalNAC/UDP-GlcNAc), and variability in most 
affected tissues. Variability in clinical outcome is therefore not surprising (1). 
Patients with GALE deficiency accumulate intracellular Gal-1-P, and they may have 
hepatic and renal disease (31). Some present developmental or growth delay, cataracts or even 
seizures, emesis and hypoglycemia in response to lactose ingestion, but a cause and effect 
relationship between GALE deficiency and the clinical findings has not been established in each 
patient. The need for treatment remains unknown (18). 
 
1.1.3. Accessory pathways of galactose metabolism 
Even though the Leloir pathway is the predominant route for galactose disposal, three 
accessory pathways have been described (1, 11, 20). These include: i) reduction of galactose to 
galactitol by aldose reductase, ii) oxidation of galactose to galactonate, presumably by galactose 
dehydrogenase, and iii) conversion of galactose to UDP-Glc by the sequential activities of 
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GALK, UDP-glucose/galactose pyrophosphorylase (UGP) and GALE (Figure 1.2) (20). Under 
physiological conditions, these pathways are thought to collectively metabolize only trace 
quantities of galactose. In galactosemic patients, however, there is a raise in galactose 
intracellular levels, thereby approaching or exceeding the KM parameters of the relevant enzymes, 
and causing these alternative pathways to assume a significant role (20). 
The flow of galactose through these alternate pathways may limit the accumulation of 
potentially toxic intermediates, thereby mitigating negative outcomes, but, on the other hand, 
may also result in the accumulation of other end products that are themselves problematic (20). 
 
 
Figure 1.2. Acessory pathways of galactose metabolism. Galactose can be reduced to galactitol by aldose reductase, 
oxidized to galactonate, presumably by galactose dehydrogenase, or be converted into UDP-Glc, via the 
pyrophosphorylase pathway, by the sequential activities of GALK, UDP-glucose/galactose pyrophosphorylase (UGP) 
and GALE (PPi – pyrophosphate). 
 
1.1.3.1. Galactose reduction  
Galactose reduction is catalyzed by aldose reductase, the first enzyme of the polyol 
pathway (1, 32). This pathway consists of two enzymatic reactions involving aldose reductase 
(EC 1.1.1.21), which requires NADPH as a cofactor, and sorbitol dehydrogenase (EC 1.1.1.14), 
which uses NAD+ as coenzyme (Figure 1.3) (32, 33). 
Aldose reductase is a NADPH-dependent oxidoreductase, belonging to the aldo-keto 
reductase family (33, 34). Its transcription is highly regulated and appears to be tissue-specific 
(33). The proximal promoter of the aldose reductase gene, AKR1B1, presents several features of a 
regulated gene, namely a TATA box, a CCAAT box and an androgen-like response element, 
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whereas the region 1200 bp upstream the promoter presents three osmotic response elements (35, 
36). In fact, aldose reductase is highly expressed the inner medulla of kidney, where it has an 
important role in the renal osmoregulation (33, 35, 37). Aldose reductase is also abundant in the 
sciatic nerve, lens, testis, heart, and cornea; and with lesser concentrations in liver, renal cortex, 
stomach, spleen, lung, small intestine, and colon (36). Several polymorphisms associated with 
increased susceptibility to diabetic complications have been described in the AKR1B1 gene, as 
well as polymorphisms associated with inter-individual variability in aldose reductase levels in 
certain tissues (36). 
Aldose reductase has broad specificity for monosaccharides, and can metabolize both 
glucose and galactose, yielding respectively sorbitol and galactitol (2, 32). Although both sugars 
are similarly processed, sorbitol can be converted to fructose via the sorbitol dehydrogenase, 
whereas galactitol is not a substrate for this enzyme and will, consequently, accumulate in cells 
and tissues (1, 11, 32). Galactitol accumulation produces a hyperosmotic effect, which results in a 
water uptake, via aquaporins 1 (AQ1) and 0 (AQ0), aiming to counter the osmotic gradient, 
leading to swelling of the cells, with consequent cell death and cataract formation (8, 24, 32). 
 
 
Figure 1.3. Galactose reduction into galactitol. The polyol pathway is comprised of the enzymes aldose reductase 
and sorbitol dehydrogenase. Aldose reductase has broad specificity for monosaccharides, and can metabolize both 
glucose and galactose, yielding respectively sorbitol and galactitol. Sorbitol is further metabolized by the second 
enzyme of the pathway, sorbitol dehydrogenase, whereas galactitol is not a substrate for this enzyme and will 
accumulate in cells and tissues. 
 
1.1.3.2. Galactose oxidation 
A further route of galactose disposal is its oxidation to galactonate. Galactonate was first 
identified in galactosemic patients by Bergen et al., more than 40 years ago, and it is now well 
established that galactosemic patients produce galactonate (2, 38, 39). However, the route 
whereby galactonate is formed is still a controversial matter (1, 2). 
The first description of the presence of galactose dehydrogenase in mammalian cells 
came from Cuatrecasas and Segal, who reported it in the liver of a variety of species and, 
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particularly, in the human liver (40). Indeed, galactose oxidation to galactonate is believed to 
reflect the activity of a soluble NAD+-dependent galactose dehydrogenase  
(D-galactose:NAD+oxidoreductase, EC 1.1.1.48) that converts galactose to galactonolactone, 
which then spontaneously or enzymatically converts to galactonate (1). However, the existence of 
this apparently highly active and soluble NAD+-dependent galactose dehydrogenase has been 
questioned as a possible artifact, and the way by which galactonate is formed remains to be 
clarified (1, 2). 
After galactose oxidation into galactonate, it can be excreted directly in this form or 
further metabolized via the reactions of the pentose phosphate pathway, where it is converted to 
β-keto-D-galactonate, which subsequently undergoes decarboxylation, liberating carbon-1 to 
form xylulose (Figure 1.4) (1, 13, 41). 
 
 
Figure 1.4. Galactose oxidation into galactonate. Galactose is first converted into galactonolactone, which then 
spontaneously or enzymatically is converted into galactonate. Galactonate can be excreted directly in this form or 
further metabolized via the reactions of the pentose phosphate pathway, where it is converted to β-keto-D-galactonate, 
which subsequently undergoes decarboxylation, liberating carbon-1 to form xylulose. Adapted from Wehrli et al., 1997 
(41). 
 
In an attempt to quantitate galactose oxidation through this pathway, Segal and 
Cuatrecasas developed a study in which [1-14C]galactose and [2-14C]galactose were administered 
intravenously to both controls and patients, and its oxidation to 14CO2 was quantified. They 
reported galactosemics oxidized greater amounts of administered [1-14C]galactose to 14CO2 than 
[2-14C]galactose comparatively to healthy subjects, who showed no difference in the 14CO2 yield 
from these specifically labeled galactoses, and put forward the hypothesis that the carbon-2 
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oxidation represented residual GALT activity, whereas carbon-1 represented direct oxidation of 
galactonate, which thereby plays an important role in the galactose metabolism of classic 
galactosemic patients (41, 42). 
More recently, Berry et al. described a patient with a GALT deletion in homozygosity 
that could oxidize [1-13C]galactose to 13CO2 over a 24 hours period, thus providing unambiguous 
evidence for an alternate pathway of galactose utilization in the absence of any possible GALT 
mediation (42, 43). 
 
1.1.3.3. Pyrophosphorylase pathway 
The pyrophosphorylase pathway was first speculated by Isselbacher in 1957, as an 
explanation for the perceived ability to tolerate an increasing intake of galactose with age (44, 
45). This pathway involves the phosphorylation of galactose to Gal-1-P, catalyzed by GALK, 
followed by a reversible UTP-dependent pyrophosphorylase reaction, in which the galactose 
moiety is incorporated into UDP-Gal (11, 45). UDP-Gal is then epimerized by GALE into  
UDP-Glc, from which a second pyrophosphorylase reaction generates Glc-1-P and UTP (Figure 
1.2) (1, 44). 
Neither the galactitol pathway nor the galactonate pathway involve any of the three 
Leloir enzymes (1, 20). This third alternative pathway, however, depends on the action of GALK 
and GALE. Indeed, the two reactions that are unique to this alternative pathway are the 
pyrophosphorylation reactions, both catalyzed by a single enzyme – UTP-dependent 
glucose/galactose pyrophosphorylase (UGP), also sometimes referred to as UTP-hexose-1-
phosphate uridylyltransferase (EC 2.7.7.10) (1, 20, 44). 
Essentially, conversion of Gal-1-P to UDP-Gal may be catalyzed either by GALT or by 
UGP (46). This observation led to the proposal that the enzyme UGP provides a  
GALT-independent backdoor route for galactose metabolism in classic galactosemia, catalyzing 
the conversion of Gal-1-P to UDP-Gal, albeit via a different mechanism and at a much lower rate 
than GALT (22, 47). Thus, UGP would play an important role in GALT deficiency, since it 
would reduce the intracellular levels of Gal-1-P and would replenish UDP-Gal (16). 
However, in 1969, Gitzelmann presented evidence that the pyrophosphorylase pathway is 
probably more active in the reverse direction than that initially considered by Isselbacher, 
presenting scientific evidence of Gal-1-P production in GALT-deficient cells deprived of 
galactose, and suggested for the first time, an endogenous production of galactose (46, 48). 
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1.1.4. Endogenous synthesis of galactose 
Gitzelmann was the first to propose the existence of a pathway for the endogenous 
synthesis of galactose and its derivatives (1, 48). Evidence for endogenous synthesis of galactose 
came from a case of a pregnant woman, to whom had been prescribed a galactose-restricted diet 
on the last six months of pregnancy. After birth, the child was put immediately on a soybean 
formula but, unexpectedly, presented gradually increasing levels of Gal-1-P in RBC (48). 
Intrigued by this case, Gitzelmann used erythrocytes from galactosemic patients to show, 
in vitro, that Gal-1-P could be generated from UDP-Gal. Since UDP-Gal may be synthesized 
from UDP-Glc by GALE, he later introduced the concept of ‘‘self-intoxication’’, proposing that a 
pyrophosphorylase reaction with UDP-Gal and pyrophosphate as substrates is the biochemical 
basis for de novo synthesis of galactose (48, 49). According to this mechanism, the critical step is 
the epimerization of UDP-Glc to UDP-Gal, which produces galactose-containing substances 
necessary for normal growth and development independent of dietary galactose intake (50). 
More recent studies have led to the proposal that the mechanism of endogenous galactose 
production involving the pyrophosphorylase pathway includes UDP-Glc epimerization by GALE 
to UDP-Gal, which is then cleaved by UGP to produce UTP and Gal-1-P, which finally is 
cleaved by inositol monophosphatase (IMPase) to yield free galactose (1, 16, 51, 52). 
Additionally, galactose may also derive from the turnover of glycoconjugates, in which 
lysosomal hydrolysis of glycoproteins and glycolipids releases free galactose (50, 53). 
Several studies have provided quantitative evidence for whole body de novo galactose 
synthesis in healthy subjects and classic galactosemic patients (38, 49, 50, 54). In GALT-
deficient patients, the calculated production rate of galactose was between 0.49 and 1.09 mg/kg 
per hour (1). Later studies aimed at the elucidation of the age dependence of endogenous 
galactose formation in galactosemia, and concluded the endogenous galactose burden is 
considerably higher in infants and children than in adults, gradually relieved with increasing age 
until adulthood, and that, therefore, the tolerance for dietary galactose increased with age in 
galactosemic patients (1, 38, 49). 
A more recent study further demonstrated that the rate of endogenous galactose 
production is not influenced by short-term exogenous galactose intake, neither in patients with 
classic galactosemia nor in healthy individuals (55). As postulated by Gitzelmann and colleagues 
in 1975, endogenous production of galactose may be vital for biosynthesis of membrane 
constituents, but, at the same time, it may represent a process toxic to the galactosemic cell,  
since galactose, Gal-1-P, galactitol and galactonate accumulate, and may lead to a state of  
auto-intoxication, thereby contributing to long-term complications!(50, 53, 54). 
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1.2. Classic galactosemia or GALT deficiency  
Classic galactosemia is a potentially lethal disease of galactose metabolism, presenting an 
autosomal recessive pattern of inheritance (20, 56). It is secondary to a severe reduction or 
absence of GALT activity, caused by mutations in the GALT gene (57). 
 
1.2.1. GALT gene 
The GALT locus is located in the short arm of chromosome 9, in the region 9p13 (1, 58). 
The human GALT cDNA and gene have been cloned and characterized, which provided a means 
of studying the genetic basis of classic galactosemia (1, 59, 60).  
The GALT gene is arranged into 11 exons, spanning ~4.0 kb of genomic DNA 
(NG_009029.1), and the GALT cDNA is 1407 bp in length (NM_000155.2). Some exons are 
highly conserved among species, notably exons 6 (which encodes the active site), 9 and 10, 
whereas others, such as exons 1, 2, 5, and 7, are poorly conserved (1). 
Analysis of approximately 4 kb of the GALT promoter identified three GC-rich Sp1 sites, 
an imperfect non-palindromic AP-1 site (TCAGTCAG at -126 to -119), a CAAT box, two E-box 
motifs spaced 23 bp apart (CAGGTG at -146 to -141 bp and CACGTG at -117 to -112 bp); and 
no TATA box sequence (1, 61-63). 
Despite the highly inducible nature of GALT expression in Escherichia coli (E. coli) and 
yeast, the mammalian gene appears to be expressed as a housekeeping gene (1). Indeed, there is 
no clear evidence of galactose induction and the 5' flanking region of GALT is very GC rich and 
lacks a TATA box, both features observed in housekeeping genes (1, 64). The classification of 
GALT as a housekeeping gene, however, does not imply lack of transcriptional regulation (63). 
An Alu repeat motif with evidence of length variation has been identified in intron 10 
(65). It consists of a polyadenine nucleotide repeat with three length variants, (A)17, (A)24 and 
(A)29 at frequencies of 47.5%, 50.0%, and 2.5%, respectively. These length variants have 
defined associations with particular GALT alleles. The p.Q188R and p.K285N mutant alleles 
were associated with the (A)17 and (A)24 Alu variants, respectively, while the (A)29 variant was 
found only in samples carrying the p.N314D allele (explained below) (1, 65). 
At present, there are 266 different variations described at the GALT locus (available at: 
http://www.arup.utah.edu/database/GALT/GALT_display.php, last surveyed December 2013) 
(66). Out of the described variations, the great majority are missense mutations (62.0%), a 
common observation in genetic disorders. Additionally, 19 silent (7.1%), 17 nonsense (6.4%), 17 
small deletions (6.4%), 6 insertions (2.3%), 3 indel (1.1%), 3 large gene deletions (1.1%),  
2 no-stop changes (0.8%) and 1 frameshift (0.4%) mutations have also been reported. Regarding 
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non-coding regions, 15 splice site variations (5.6%) have been described. The remaining 18 
variations are classified either as benign (16; 6.0%) or as uncertain (2; 0.8%) (66). 
Even though a few of these mutations are common, and usually highly prevalent in 
particular populations or ethnic groups, most are rare (1). Of those mutations that have been 
characterized in vitro, it is clear that some are true nulls, whereas others are hypomorphs (1). 
Furthermore, classic galactosemic patients show phenotypic variability, which can be partially 
explained by the high allelic heterogeneity and the high prevalence of compound heterozygotes 
(63, 67-70). 
 
1.2.2. Mutations at the GALT locus 
GALT sequencing opened new avenues of research in classic galactosemia, allowing 
molecular studies of galactosemic patients and thereby providing new insights into this disorder. 
Indeed, mutational analysis of galactosemic patients has provided new understanding of the 
GALT protein, by pinpointing functionally and/or structurally important regions of the enzyme, 
and has uncovered a multiplicity of mutations and polymorphisms, which is noteworthy in light 
of the clinical heterogeneity of classic galactosemia (19, 60). 
 
1.2.2.1. p.Q188R 
The p.Q188R is the most frequent GALT mutation associated with classic galactosemia, 
accounting for 63%–64% of all galactosemic alleles in the Caucasian population, and was first 
reported in 1991 (1, 71, 72). It results from an A→G transition at nucleotide c.563 in exon 6 
(CAG → CGG, conserved residue), leading to a substitution of a glutamine to an arginine at 
amino acid 188 of the GALT protein (1, 63, 66, 70, 73, 74). 
This mutation is the most common mutation among people with European ancestry, 
particularly in Northwestern Europe (71, 72). The mutation shows a gradient increasing 
frequency through Europe in a North-Westernly direction, reaching its highest frequency in 
Ireland, where it accounts for 92%–94% of galactosemic alleles (71, 72, 75-77). In fact, p.Q188R 
was found to be the sole mutant allele among the Traveller population of the Republic of Ireland, 
where its incidence is estimated to be 1 in 480 (75). Interestingly, p.Q188R has never been 
identified in Asian patients or in Asian descendant patients (1, 70, 71, 78, 79). 
This mutation is particularly remarkable due to its location, since it occurs two amino 
acids downstream from the active site His-Pro-His sequence (63). Glutamine located at 188 is 
essential for the imidazole-N interaction with the uridylyl intermediate, and the change in charge 
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imparted by p.Q188R has been proposed to alter protein conformation in the active site region 
(74, 80, 81). 
When this mutation was initially expressed in monkey COS cells, it yielded 
approximately 10% of the wild-type GALT control activity. This incorrect observation was 
caused by endogenous GALT present in the monkey COS cells (73, 82). The same mutation 
expressed in bacterial and yeast systems, both devoid of endogenous GALT, presented essentially 
no GALT activity, and transformed lymphoblasts from homozygous-p.Q188R galactosemic 
patients presented less than 2% of control activity (69, 74, 82). 
Patients homozygous for the p.Q188R mutation demonstrate essentially no residual 
GALT activity in RBC, and homozygosity for this allele represent a significant risk factor for 
developmental verbal dyspraxia and has been associated with a poor cognitive outcome (70, 83-
85). 
 
1.2.2.2. p.K285N 
The second most common mutation of European origin is p.K285N (71, 86-89). 
Conversely, unlike p.Q188R, this mutation is particularly frequent in countries of Central and 
Eastern Europe, where it accounts for 26%–34% of galactosemic alleles (86-89). In fact, the 
Czech, Slovak, Polish and Austrian galactosemic populations present the highest frequencies of 
p.K285N mutation relatively to other European populations, which has led Kozák et al. to 
suggest this mutation could have a Slavic origin (86-89). This hypothesis was later confirmed by 
Lukac-Bajalo et al. (86). Notably, this mutation has never been identified in the Portuguese 
population (80). Analogously to p.Q188R, p.K285N has never been identified in Asian patients 
(70, 71, 78, 79). 
The p.K285N mutation was first reported in 1992, and results from a G→T transition at 
nucleotide c.855 in exon 9 (AAG → AAT, non-conserved residue), leading to a substitution of a 
lysine to an asparagine at amino acid 285 of the GALT protein (1, 63, 66, 70, 74). This mutation 
is associated with essentially no GALT activity in RBC, and with a severe clinical phenotype, 
namely poor cognitive outcome and pronounced speech abnormalities (70, 89). 
 
1.2.2.3. p.S135L 
The p.S135L mutation is found almost entirely in individuals of African origin, 
accounting for approximately 48% of African American and 91% of South African GALT alleles 
(70, 90, 91). The p.S135L mutation was first reported in 1992 by Reichardt et al., and results 
from a C→T transition at nucleotide c.404 in exon 5 (TCpG → TTG , non-conserved residue), 
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leading to a substitution of a serine to a leucine at amino acid 135 of the GALT protein (1, 63, 66, 
70, 74, 92). 
Notably, this mutation appears to exhibit some tissue specificity: homozygous patients 
have essentially no GALT activity in RBC, presenting approximately 5.5% of control activity in 
leukocytes, while liver and intestinal mucosa biopsy specimens express about 10% of normal 
GALT activity (91). Additionally, homozygous are capable of converting galactose to CO2 at a 
rate comparable to control subjects (50, 91). In fact, this mutation is said to have a protective 
effect and p.S135L homozygosity is often associated with milder clinical outcomes (83, 91, 93). 
Nevertheless, patients carrying p.S135L should be diagnosed very early in life and diet should be 
implemented immediately (90, 91, 94). 
 
1.2.3. GALT protein 
GALT is an ubiquitous enzyme in living organisms and highly conserved through 
evolution (69, 74, 95). Comparison of the human (NP_000146.2) with the E. coli (NP_415279.1), 
Saccharomyces cerevisiae (NP_009574.1) and rat (NP_001013107.1) GALT amino acid 
sequences revealed overall identities of 51%, 40%, and 88%, respectively. 
The three-dimensional structure of the human GALT has still not been experimentally 
solved. However, the E. coli GalT structure has been solved by X-ray crystallography, which 
revealed this enzyme is a dimer with two active sites, each one formed by amino acid residues 
from both subunits (12, 96-98). Furthermore, a direct comparison of the bacterial and human 
GALT sequences revealed these enzymes are superimposable, starting from the 20th amino acid 
of the human sequence, i.e., an extra 20 amino acids at the amino-terminus are present in the 
deduced human GALT sequence (63, 96, 99, 100). 
GALT is a member of the transferase branch of the histidine triad (HIT) family of 
enzymes, so-called because of a hisφhisφhisφφ motif (φ referring to a hydrophobic amino acid) 
(101, 102). The active human enzyme is a homodimer (86.6 kDa), in which each monomer is 
constituted by a polypeptide of 379 amino acids (43.3 kDa). The active site sequence His-Pro-His 
is conserved among all known uridylyltransferases, and was firstly identified in E. coli GalT at 
residues 164 to 166, corresponding to residues 184 to 186 in the human sequence (63, 96, 99, 
100). 
GALT catalyzes the transfer of an uridyl group from UDP-Glc to Gal-1-P through a 
double displacement mechanism whereby a histidine residue is transiently modified (Figure 1.5) 
(12, 97, 103, 104). Detailed structural analyses of the dimeric protein from E. coli have revealed 
that each monomer displays a “half-barrel” motif and that His166 is the active site base (101, 
105). In the first step of the ping-pong mechanism, a pair of electrons on the nitrogen ring of a 
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histidine residue (His166 in E. coli and His186 in humans) in the active site attacks the 
α-phosphate of UDP-Glc (12, 106). The result of this reaction is an UMP-enzyme adduct and 
Glc-1-P, which is released. In the second stage of the reaction, the UMP group is displaced from 
the enzyme by Gal-1-P, thereby regenerating the active site of the enzyme and producing the 
second product, UDP-Gal (12, 103, 106).  
 
 
Figure 1.5. The catalytic mechanism of GALT. In the first step of the reaction, the Nε2 of the His186 attacks the 
α-phosphate of UDP-Glc, releasing Glc-1-P and forming the covalent uridylyl-enzyme intermediate; in the second half 
of the reaction, the intermediate reacts with Gal-1-P to produce UDP-Gal. Reproduced from McCorvie and Timson, 
2011 (12). 
 
Each monomer of the bacterial enzyme has been described as containing one zinc (II) ion 
and one iron (II) ion, in which the zinc ion is believed to be essential for activity, whereas the 
iron ion is thought to play a role in stabilizing the structure (22, 107, 108). The iron ion is 
coordinated by three histidine residues and a glutamate residue in a hydrophobic region close to 
the subunit interface, whereas the zinc ion is coordinated by two cysteine and two histidine 
residues and helps to orientate residues in, and close to, the active site of the enzyme. However, it 
has been noted that the human enzyme is different from E. coli GalT in that the zinc binding 
residues are not conserved and hence there is a considerable possibility that it may bind only one 
metal ion per monomer. In fact, the crystal structure predicted His115 to be the bacterial residue 
to serve as a ligand for zinc, which would correspond to Ser135 in the human GALT, raising thus 
the important question of whether human GALT is a metalloenzyme, and, if so, whether Ser135 
could serve as a ligand to zinc in the human GALT (109, 110). In fact, considering serine is 
chemically unlikely to suffice as a ligand for zinc, it was suggested that the neighboring His132 
would most likely serve as the corresponding zinc ligand in human GALT (109). To clarify these 
Further, and convincing, evidence for the substituted enzyme
mechanism of GALT came from detailed X-ray crystallographic
studies. Although the str cture f human GALT has not been
solved, the E. coli enzyme has been (PDB IDs: 1HXQ, 1HXP,
1GUP, and 1GUQ) (29–31). In addition, structures of a GALT-
like protein from thale cress (Arabidopsis thaliana) have been
deposited in the Protein Data Bank (PDB IDs 2Q4H, 2Q4L,
1ZWJ, and 1Z84); however, this is likely to be an ADP-glucose
phosphorylase (32). The lack of a human structure may result
from the physical properties of the enzyme. The purified,
recombinant enzyme has a tendency to aggregate and precipitate
(TJM and DJT, unpublished data), and it may be difficult
to obtain the high concentrations normally required for
crystallization.
Like the human enzyme, E. coli GALT is a homodimer with
a functional active site in each subunit (Fig. 3). Each subunit
contains one zinc (II) ion and one iron (II) ion (Fig. 4a) (33).
Although the zinc ion is believed to be essential for activity,
the iron ion is thought to play a role in stabilizing the structure
(34). This iron ion is coordinated by three histidine residues
and a glutamate residue in a hydrophobic region close to the
subunit interface (Fig. 4b) (29). Removal of the ion would prob-
ably result in destabilization of this region and, consequently,
disrupt the dimer. The zinc ion is coordinated by two cysteine
and two histidine residues and helps to orientate residues in,
and close to, the active site of the enzyme (Fig. 4c) (29). How-
ever, it has been noted that the mammalian enzyme is different
from E. coli GALT in that the zinc co-orientating residues are
not conserved and that, therefore, it may only bind one metal
ion per monomer (29). This active site includes residues from
Figure 2. The catalytic mechanism of GALT. In the first step of the ping-pong (or substituted enzyme) mechanism, a lone pair of
electrons on the ring nitrogen of a histidine residue (His-166 is E. coli and His-186 in humans) in the active site of GALT attacks
the a-phosphate of UDP-glucose. The result of this reaction is a covalent UMP-enzyme adduct and glucose1-phosphate, which is
released. In the second stage of the reaction, the UMP group is displaced from the enzyme by galactose 1-phosphate (the product
of the first reaction of the Leloir pathway). This regenerates the active site of the enzyme and produces the second product, UDP-
galactose. U represents the uridine moiety of UDP-glucose and UDP-galactose, Glc, a glucose moiety and Gal a galactose moiety.
Figure 3. The overall stru ture f E. coli GALT. The enzyme
is a homodimer. In this figure, the two subunits are colored
dark and light gray. The figure was created in PyMol (www.
pymol.org) using PDB file 1HXP (29).
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questions, Wells et al. evaluated the zinc content in both wild-type and S135L human GALT, and 
demonstrated that both proteins contained stoichiometrically indistinguishable levels of zinc 
(109). 
 
1.2.4. Duarte and Los Angeles variants  
The first known variant of classic galactosemia was the Duarte variant, which was first 
described by Beutler et al. in 1965 and named after the city in which it was first defined (1, 62, 
74). 
The Duarte allele – or Duarte-2, D2 or simply D – is biochemically defined by an 
isoform distinguishable by gel electrophoresis and isoelectric focusing, and by a reduction of 
enzyme activity to approximately 50% of the wild-type allele levels (71, 111-113). Indeed, 
hemolysates of heterozygotes for Duarte allele present 75% of GALT activity, homozygotes 
present 50% activity, and compound heterozygotes for the Duarte allele and a classic 
galactosemia allele present 25% activity (74, 114).  
In the early 1970’s, Ng and colleagues reported several individuals that exhibited the 
same electrophoretic mobility profile than the Duarte variant, but presented mildly elevated 
rather than impaired activity, which led them to define a new variant – the Los Angeles variant, 
also known as Duarte-1, D1 or LA variant (62, 115). 
After the molecular characterization of the GALT cDNA, Reichardt and Woo reported, 
for the first time, the p.N314D mutation, which results from an A→G transition at nucleotide 
c.940 in exon 10 (AAC → GAC, non-conserved residue), and leads to a substitution of an 
asparagine to aspartate at amino acid 314 of the GALT protein (19, 66, 70, 74, 116). This 
mutation was later shown to be associated with the Duarte and Los Angeles alleles, which posed 
an enigma, as p.N314D was associated in the Duarte variant with a decrease of enzymatic 
activity, and in the Los Angeles variant, with an increase of enzymatic activity (62, 63, 111). 
The functional significance of the p.N314D mutation in both Duarte and Los Angeles 
alleles was a point of intense controversy and examination in the 1990’s. p.N314D expression in 
a COS cell expression system showed 129% of the control activity, and so it was classified  as a 
polymorphism. Later studies using a yeast expression system supported that this substitution 
produced an enzyme with activity and abundance levels indistinguishable from those of the wild-
type protein. Additionally, this study demonstrated that the p.N314D mutation altered the 
protein’s charge and therefore accounted, per se, to the aberrant migration on native starch and 
altered migration on isoelectric focusing electrophoresis (1, 19, 78, 117).  
As the expression systems failed to detect impaired GALT activity with the p.N314D 
mutation, other undetected causes for altered enzyme activity were speculated, such as intron or 
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promoter variations (117). A study by Langley et al. identified the neutral polymorphism 
p.L218L (c.652C>T; CTA → TTA) in cis with p.N314D exclusively in the Los Angeles 
phenotype and, thus, suggested that the increased enzymatic activity in this variant was actually 
due to a “codon bias” increased translation, with subsequent increased abundance of protein, 
since the rarer leucine codon TTA could produce a more efficient translation than the CTA 
codon. Additionally, this study identified no point mutation other than p.N314D in fully 
sequenced Duarte alleles, which reinforced the later study by Lai et al. that showed that p.N314D 
caused a destabilization of the GALT protein and proposed this was the only molecular 
pathogenic mechanism in this variant, since the mRNA abundance was not affected in the Duarte 
alleles (118). However, later studies demonstrated the p.N314D allele does indeed give rise to the 
two variant forms depending on the presence of additional base changes: the Los Angeles allele 
carries p.N314D in linkage disequilibrium exclusively with the translationally silent mutation 
p.L218L, whereas the Duarte allele carries p.N314D in linkage disequilibrium with c.378-27G>C 
(IVS4-27G>C), c.507+62G>A (IVS5+62G>A), c.508-24G>A (IVS5-24G>A) and a 4-bp 
deletion in the 5’ untranslated region 116 to 119 bases upstream from the first methionine codon 
(c.-119_-116delGTCA) (1, 66, 76, 87, 112, 113, 117, 119-121). 
As previously mentioned, the GALT promoter presents an AP-1 site (TCAGTCAG from -
126 to -119 bp) and two E-box motifs (at -146 to-141 bp – CAGGTG – and at -117 to -112 bp – 
CACGTG perfect). The -119 to -116 GTCA deletion removes the first two nucleotides of the -
117 to -112 bp E-box motif (CA, located at -117 and -116 bp), which however does not change 
the E-box motif of CACGTG from -117 to -112 bp, since there are three repeats of GTCA in 
sequence, and the middle tetrad GTCA fills the deleted CA of the E-box motif (Figure 1.6). 
There is, however, a reduction in the spacing between the two E-box motifs that most likely alters 
trans–acting factors binding and thus impairs the positive regulation of GALT gene expression. 
Furthermore, the -119 to -116 GTCA deletion also affects the AP-1 site from -124 to -117 bp 
with the sequence TCAGTCAG, as it removes the terminal guanine of this octomeric domain, 
which can also reduce GALT gene expression (61, 122). In fact, a computer search for potential 
regulatory elements in the area of the deletion showed that it potentially eliminates the binding 
sites for the two activator proteins AP1Q2 and AP1Q4 (1, 61, 119, 122). 
Functional analyses carried out by two independent groups – Trbušek et al. and Elsas et 
al. – strongly support the hypothesis that the GTCA deletion in the GALT promoter is indeed the 
major factor contributing to the diminished expression and activity of the Duarte variant (1, 61, 
122).  
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Figure 1.6. The 4-bp deletion in the 5′ untranslated region of the GALT gene. The GALT promoter presents an  
AP-1 site from -126 to -119 bp (TCAGTCAG) and two E-box motifs from -146 to -141 bp (CAGGTG) and from -117 
to -112 bp (CACGTG). The -119 to -116 GTCA deletion removes the first two nucleotides (in bold) of the -117 to 
 -112 bp E-box motif. The middle tetrad GTCA fills the deleted CA of the E-box motif; however, the spacing between 
the two E-box motifs is reduced, and the terminal G of the AP-1 site is removed. Nucleotide +1 is the A of the ATG-
translation initiation codon. Adapted from Elsas et al., 2002 (62). 
 
At present, p.N314D is a common variant with an allele frequency of approximately 11% 
in European populations (Centre d’Etude du Polymorphisme Humain) and lower frequencies in 
other populations, for a pan-ethnic frequency of 8.3% (71, 112). 
Interestingly, a study on the origin and distribution of the Duarte allele demonstrated that 
the p.D314 allele is, in fact, the ancestral allele, and that its distribution pattern suggests the 
p.D314N variant arose in Africa very early in human evolution. Furthermore, the persistence of 
the p.D314 allele in European and, to a lesser extent, Asian populations most likely reflects a 
founder effect acting upon descendants after the human migration out of Africa (112). 
 
1.2.5. Abnormal accumulation of metabolites 
Patients with classic galactosemia present a characteristic pattern of biochemical 
abnormalities: Gal-1-P, the substrate of the GALT enzyme, accumulates within cells, and surplus 
galactose is reduced to galactitol or oxidized to galactonate (123). Indeed, severe GALT 
deficiency results in the accumulation of toxic galactose metabolites and causes a decrease in 
UDP-Gal, a sugar required for the galactosylation of glycoproteins and glycolipids (77). 
 
1.2.5.1. Galactose 
Galactose is a hexose that differs from glucose only in the configuration of the hydroxyl 
group at the carbon-4 position (8). However, galactose is less stable, more susceptible to the 
formation of nonspecific glycoconjugates, and is incorporated into glycogen more efficiently than 
glucose, which would explain why glucose is the primary metabolic fuel for humans and most 
other species (1, 124, 125). 
The human body is able to metabolize large amounts of galactose, as evidenced by rapid 
clearance of galactose from blood: 50% of radiolabeled galactose is found in glucose pools 
within 30 minutes after being administered intravenously (126). For nursing infants, galactose 
E-boxAP-1
-150
-126 to -119
CCCCCAGGTGGCAGGGCAGCCCA GTCA GTCA GTCACGTGCTGG
E-box
-146 to -141 -117 to -112
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conversion to glucose is crucial to maintain euglycemia, since 40% of calories derives from the 
hydrolysis of lactose to galactose and glucose (126). Indeed, the rapid conversion of galactose to 
glucose is of great biological importance, and explains the evolution and strong conservation of 
the Leloir pathway (1). 
In opposition to healthy infants who rapidly metabolize galactose to glucose after a milk 
meal, newborn infants with classic galactosemia will accumulate galactose in the blood, as well 
as in other cells and tissues, and will present high galactose urinary concentrations, whereas 
blood glucose levels can fall to hypoglycemic levels (1, 8). Upon initiation of dietary galactose 
restriction, blood galactose levels fall quickly, but always remain elevated when compared with 
controls. In fact, in a study by Ning and Segal, the mean value of plasma galactose in 27 
galactosemic patients was less than 2-fold higher than in controls; it was, however, about 4-fold 
higher than the levels in healthy infants on a galactose-restricted diet (1, 127). 
When compared to other metabolites, blood galactose pool is very small. It may be that 
the galactose pool is maintained at its steady-state level because there is a high rate of conversion 
to RBC Gal-1-P and to alternate-pathway metabolites such as galactitol and galactonate in tissues 
(127). 
 
1.2.5.2. Galactose-1-phosphate  
Once galactose enters the cell, it is converted to Gal-1-P by GALK. In GALT deficiency, 
Gal-1-P cannot be further metabolized and accumulates in cells and tissues, namely RBC, liver, 
kidney, brain, tongue, adrenal, heart, and ocular lens (1, 11). In fact, Gal-1-P accumulation is a 
cardinal feature of the classic galactosemia phenotype, and it was its accumulation that first 
helped to pinpoint the position of the metabolic block in this disorder (1, 50, 128). 
Schwarz et al. were the first to describe the accumulation of Gal-1-P in GALT-deficient 
patients’ cells, and to conclude that the enzyme block was at the point of conversion of Gal-1-P 
to Glc-1-P (128). This observation was quickly confirmed by Kalckar et al., who clearly 
demonstrated that the clinical picture was due to GALT deficiency and not to any deficiency of 
UDP-Glc (30). Furthermore, Komrower et al. used RBC as a representative of body tissue to 
evaluate Gal-1-P accumulation and, ever since, its measurement in RBC has become standard 
practice to assess the biochemical results upon initiation of a galactose-restricted diet in recently 
diagnosed newborns, as well as to monitor the adherence to diets during later life (30, 128, 129). 
At the time of diagnosis, patients fed with galactose-containing milk present high  
Gal-1-P concentrations in RBC, which can be over 2.5-6.5 mM (1, 11). Following dietary 
restriction of galactose, Gal-1-P values in RBC fall dramatically, although they always remain 
elevated when compared to healthy controls (0.1-0.2 mM down to undetectable) (1, 11). 
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Gal-1-P levels in RBC at the time of diagnosis were initially thought to reflect the 
amount of Gal-1-P to which the infant had been exposed in the newborn period (130). However, 
it is now known that Gal-1-P also accumulates abnormally in patients prior to birth: two 
galactosemic fetuses at 20 weeks’ gestation exhibited levels of Gal-1-P in their livers comparable 
with levels seen in newborns that died from the disorder (1). 
 
1.2.5.3. Galactitol 
Galactitol has been found in high levels in blood, tissues and urine of galactosemic 
patients, and thereby also constitutes a key element in the biochemical phenotype of affected 
individuals (1, 131-134). Galactitol accumulates in tissues with a high activity of aldose 
reductase, such as lenses and ovaries. Its effects are particularly notable in the lens, where 
galactitol causes osmotic swelling and cataract formation (135). Additionally, high levels of 
galactitol have also been found in the brain, where galactitol concentration is associated with 
diffuse white matter abnormalities, and in the liver of galactosemic patients (131, 133, 136, 137). 
Galactitol builds up until dietary treatment is started, and is then cleared via urine, but it 
persists and does not entirely disappear most likely because of the generation of galactose by 
endogeneous metabolic reactions (132). Several studies have been conducted to understand 
galactitol relation to galactose and Gal-1-P levels, and its role in the pathogenesis of classic 
galactosemia. 
In 1995, a study by Jakobs and colleagues demonstrated urinary galactose and galactitol 
excretion in controls is diet- and age-dependent, with the highest excretion at a younger age 
(132). In fact, untreated patients with null GALT activity excrete enormous amounts of galactitol 
in their urine that can reach 69,000 mmol/mol creatinine in the newborn toxic period. With 
dietary lactose restriction, however, urinary galactitol excretion decreases, ranging from  
358-900 mmol/mol creatinine (n=3; <1y), while controls present a range of 3-81 mmol/mol 
creatinine (n=20; <1y) (132). Additionally, urinary galactitol excretion further declines with age, 
ranging from 120-890 mmol/mol creatinine in children with 1 to 6 years old (n=23) and ranging 
from 45-350 mmol/mol creatinine in children over 6 years (n=49) (132). 
In a later study, Palmieri and colleagues reiterated the conclusions of Jakobs et al., 
distinguishing three major age groups delineated according to urinary galactitol excretion (133). 
Additionally, Palmieri et al. found that classic galactosemic patients homozygous for the severe 
mutation p.Q188R, on a lactose-restricted diet, excrete 5 to 10-fold more urinary galactitol than 
controls, and over the age of 6 excrete on average about half the amount of younger patients 
(133). This study also reported, for the first time, a good agreement between RBC Gal-1-P and 
urinary galactitol excretion in a p.Q188R/p.Q188R patient, evaluated from the time the lactose-
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restricted diet was instituted and over a 4-year period. The trends for the values of both 
compounds appeared similar over the 4-year period evaluation, with the high levels of both 
compounds from the newborn period decreasing over time, and reaching a relatively constant 
level by 6 months of age (133). Furthermore, Palmieri et al. also established a statistical 
correlation between RBC Gal-1-P and urinary galactitol excretion in 47 galactosemic patients 
(corresponding to 112 simultaneous measurements), with, however, a wide scatter, as pointed out 
by the authors (133). A previous study by Schweitzer et al. had already attempted to establish a 
correlation between these two parameters, but without success (133, 138). 
In opposition to the decrease in urinary galactitol with age, Palmieri et al. further 
demonstrated that galactosemic patients do present increased galactitol levels in the plasma, 
which, however, remain in a narrow concentration range and do not vary with age or genotype 
(133). In contrast, healthy subjects present undetectable levels of plasma galactitol (133).  
Similarly to Gal-1-P levels, galactitol has been found in the amniotic fluid of affected 
fetuses, which has been demonstrated not to be influenced by the strictness of the maternal 
dietary regime (30, 133). 
 
1.2.5.4. Galactonate  
It is still a matter of debate whether galactonate is rather disposed completely via the 
urine or partially degraded via the so-called galactonate pathway (16). Nevertheless, galactonate 
is generally regarded as terminal product of this alternative pathway, since it is excreted in 
significant amount in patients’ urine (2). 
In fact, analogously to galactitol, galactonate has been detected in urine and in several 
tissues of galactosemic patients (139). Unlike galactitol, however, galactonate is not detectable in 
the plasma of galactosemic patients, most likely because it is below the level of detection, and is 
not elevated in the RBC of all galactosemic patients, as several patients present RBC galactonate 
within the normal range (41, 127, 139). 
Urinary galactonate excretion has not been thoroughly studied as galactitol urinary 
excretion (41). Nevertheless, it is well established that galactosemic patients present markedly 
increased urinary excretion of galactonate and, a study by Schadewaldt et al. reported a high 
statistically significant inverse correlation between urinary galactonate excretion with age and 
galactose endogenous synthesis (38, 42). 
Therefore, urinary galactonate measurement offers a new parameter in addition to RBC 
Gal-1-P assay and urinary galactitol excretion to assess the metabolic status of galactosemic 
patients (41). 
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The levels of RBC Gal-1-P, galactitol and galactonate would be expected to reflect 
different aspects of galactose metabolism. Gal-1-P is a metabolite accumulating behind the block 
imposed by GALT deficiency while galactitol and galactonate are formed by two different 
enzymes with different metabolic fates. The measurement of all three RBC metabolites could 
further expand the clinical practice of RBC Gal-1-P determination as a means of following the 
efficacy of galactose-restricted diets in the treatment of galactosemics and monitoring dietary 
adherence (139). Furthermore, these pathways, and the genes and enzymes that comprise them, 
represent logical candidate modifiers of patient outcome in galactosemia, and represent 
potentially novel targets for small-molecule therapeutic intervention (20). 
 
1.2.6. Epidemiology 
The incidence of classic galactosemia in Western Europe has been estimated to be 
between 1/30,000-60/000, being relatively prevalent (1/23,775) in the Turkish population, 
because of a high consanguinity marriage rate, and relatively rare in Sweden (1/100,000) (1, 140, 
141). Much higher frequencies have been observed in the Irish Travellers, in which the relative 
frequency among is 1/480, most probably due to the high degree of consanguinity and to a 
possible founder effect within the Traveller community (77). 
The incidence in the United States, with most cases ascertained by newborn screening, is 
currently estimated at 1/50,000; while in Canada is reported to be in the range of 1/35,000 to 
1/73,296 (142, 143). 
In Japan, the frequency of the classic galactosemia is 1/20th less than that in the United 
States (78). 
 
1.2.7. Acute clinical presentation  
Infants with classic galactosemia generally appear asymptomatic at birth. However, after 
one to two weeks of galactose ingestion through milk feeding, children start developing life-
threatening symptoms that, if undiagnosed and untreated, may lead to death (144-146). 
Initial symptoms include poor feeding with poor weight gain, vomiting and diarrhea, 
lethargy, and hypotonia (1). Failure to thrive is the most common presenting symptom and occurs 
in almost all patients, whereas vomiting or diarrhea may occur in 95% of patients (126). 
Progression of this acute neonatal toxicity syndrome may include the development of E. coli 
septicemia in the second week of life, hyperchloremic metabolic acidosis with aminoaciduria, 
vitreous hemorrhage, and pseudotumor cerebri causing a bulging fontanel (11, 123). Many 
infants present coagulopathy as a result from liver disease, with prolonged bleeding after venous 
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or arterial sampling or excessive bruising (1, 44, 126). Cataract may be detected on slit lamp 
examination (11). Among atypical presentations, purpura fulminans, hemophagocytic syndrome, 
hypothyroidism, hydrocele, and inguinal hernia have also been reported (140, 147, 148). 
The results of initial investigations indicate liver disease – unconjugated or combined 
hyperbilirubinemia, raised liver transaminases, raised plasma amino acids, particularly 
phenylalanine, tyrosine, and methionine – and also renal tubular disease – metabolic acidosis, 
galactosuria, glycosuria, albuminuria, and aminoaciduria. In addition, hematologic abnormalities 
are common, disordered clotting results from liver disease, and hemolytic anemia may occur (1, 
44, 149, 150). The early clinical presentation of galactosemia is by no means specific, and a high 
index of suspicion is necessary, particularly in countries where galactosemia is not included in a 
newborn screening program (1, 44). 
 
1.2.8. Diagnosis 
There are several approaches for classic galactosemia diagnosis, namely i) analysis of 
reducing substances in the urine, ii) quantitative analysis of galactose and galactose 
metabolite(s); iii) GALT activity analysis, the gold standard of diagnosis; and iv) GALT 
mutational analysis. 
 
1.2.8.1. Reducing substances in the urine  
Determination of the reducing substance in urine can be used as a first step screening test 
for classic galactosemia (11). The presence of reducing substances or galactose in the urine is 
neither sensitive nor specific and should not be used to either confirm or refute a diagnosis (1). 
Indeed, a positive result may be due to fructosuria, lactosuria resulting from intestinal lactase 
deficiency, or to other conditions that impair blood galactose clearance, such as severe liver 
disease (126). Moreover, glucose is also a reducing sugar, therefore its presence in the urine 
should be discriminated by a glucose dipstick test (11). On the other hand, it should not be used 
to reject the diagnosis, since galactosuria occurs only intermittently during periods of substantial 
food intake and completely resolves within 3–4 days of intravenous feeding (126). Indeed, no 
galactose will be present in the urine if the child is on intravenous fluids, as is often the case 
during a neonatal crisis (11). 
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1.2.8.2. Galactose and galactose metabolite(s) 
A more specific approach is measurement of specific metabolites, such as galactose, Gal-
1-P and/or galactitol, either in the blood and/or in urine (11). 
Nursing infants accumulate galactose in blood, as well as in other cells and tissues, and 
present high galactose urinary concentrations. Upon implementation of a galactose-restricted diet, 
however, these levels fall quickly (1, 8, 11). Conversely, Gal-1-P and galactitol will always be 
detected, in spite of galactose elimination from the diet and in spite of RBC transfusions, and are, 
therefore, the most common metabolites measured in case of suspicion of classic galactosemia (1, 
11). 
Indeed, galactosemic patients present invariably high levels of Gal-1-P in RBC that 
decrease slowly over a period of weeks to months following implementation of a galactose-
restricted diet (1). However, even though measurement of accumulated Gal-1-P in RBC 
represents an unquestionable diagnostic asset, benign variants can also present increased levels of 
this metabolite, particularly if the infant is consuming galactose, and caution should be taken 
before making a diagnosis of classic galactosemia (123). 
Measurement of hemolysate Gal-1-P can be accomplished by a variety of methods: by 
indirect enzymatic assays, by isotope-dilution gas chromatography-mass spectrometry (GC/MS), 
or by tandem MS (MS/MS) (1, 129, 151, 152). Another approach is the Paigen test, which 
quantifies total galactose – galactose and Gal-1-P – by a microbiological assay. This test is, 
however, not suitable for automation and is sensitive to antibiotic treatment of newborns or their 
mothers (152, 153). 
Nursing infants also excrete enormous amounts of galactitol in their urine and present 
high plasmatic levels of this metabolite, which are kept higher than in controls, even upon diet 
implementation. Galactitol can be measured in the urine by nuclear magnetic resonance (NMR) 
or by GC/MS, whereas in RBC more sensitive methods are required, and galactitol levels of 
galactosemic patients on diet can only be measured by GC/MS (41, 133, 139, 154, 155). 
However, despite its important informative value, many laboratories do not display a galactitol 
measurement method (11). 
 
1.2.8.3. GALT activity  
The gold standard for diagnosis is the measurement of GALT activity in RBC, which can 
be done by the semi-quantitative Beutler fluorescent spot test or by an actual quantitative assay 
(1, 11, 31, 123, 141, 156, 157).  
The Beutler test uses the successive reactions from GALT, phosphoglucomutase (EC 
5.4.2.2) and glucose-6-phosphate dehydrogenase (EC 1.1.1.49), all naturally present enzymes in 
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RBC, to visually evaluate the fluorescence produced by NADPH under UV-light. Indeed, if 
GALT is active, Glc-1-P will be produced and will be converted into Glc-6-P by 
phosphoglucomutase, which is then oxidized by glucose-6-phosphate dehydrogenase with the 
concomitant reduction of NADP+ to NADPH, thereby producing fluorescence (1, 141, 158). This 
test does not demand a heavy workload and allows for immediate identification of patients with 
classic galactosemia, even in children that are not under a milk-based formula (141, 158). 
Conversely, the Beutler test also presents notable disadvantages, particularly regarding 
false-positives results, which constitute a major concern for this screening test. Indeed, this assay 
yields a high rate of false-positives, as a result of several interfering factors, namely: samples 
exposure to high temperatures and humidity, which can deteriorate the GALT enzyme; collection 
of blood into EDTA tubes; benign deficiencies of any of the assay coupling enzymes; 
fluorescence quenching by hemoglobin; and finally from the fact that the result depends on visual 
evaluation (1, 141, 153, 158, 159). Additionally, this test is not suitable in children that have been 
subjected to blood transfusion within the last 3 to 4 months, since a false-negative might result (1, 
149). Quantitative assays of both parents can be informative in these circumstances since they 
can determine potential carrier status (157).  
Quantitative measurement of GALT activity, though more labor intensive, overcomes 
many of the weaknesses of the Beutler test, presenting the additional advantage of being able to 
distinguish variants with residual activity (157). 
GALT activity quantification can be done indirectly, by an enzymatic assay, or directly 
by quantifying radioactively labeled Gal-1-P conversion to UDP-Gal or, alternatively, by 
quantifying unlabeled substrates and products by high-performance liquid chromatography 
(HPLC) (1, 11, 160, 161). Classic galactosemic patients usually present undetectable GALT 
activity or detected at less than 5% of controls levels (80, 162).  
Many laboratories present a two-tier approach, in which a first analysis is performed and, 
in case of a positive result, the diagnosis suspicion is further confirmed by a second assay. The 
Beutler test is often used as a first approach and, in case of a positive result, a second test – 
usually involving metabolite determination – is done, thereby reducing the false-positive rate (1, 
141, 152). 
 
1.2.8.4. Mutational analysis 
DNA analysis of the most common mutations is rapidly available in many laboratories, 
and has been used in some newborn screening programs to refine the screening process. 
However, as with other mutation-selective DNA-based assays, because of the large number of 
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distinct mutations, a positive result has predictive value, but a negative result does not exclude 
disease resulting from other mutations (123). 
 
1.2.9. Newborn screening 
The success of neonatal screening for several inherited metabolic disorders (IMD), 
particularly with phenylketonuria (PKU, OMIM #261600), in addition to the advent of rapid 
screening techniques, has resulted in an increased impetus to expand neonatal screening 
programs (143). Methods for mass screening of newborns for galactosemia have been available 
since 1964 and, ever since, newborn screening has been implemented in several countries, 
allowing for presymptomatic diagnosis and intervention (1, 163). 
 
1.2.9.1. Galactosemia newborn screening – the eternal controversy  
The efficacy of universal neonatal screening for galactosemia has been debated for years, 
but no consensus has been reached (143). 
For many years, the principles originally articulated by Wilson and Jungner for 
screening, and later expanded by Pollitt et al., have been accepted as the criteria for neonatal 
screening (164). In general, decisions to include a genetic disorder on the panel are based on 
frequency of the disorder, the feasibility and accuracy of the screening, the ability of early 
intervention to improve outcomes, the availability of treatment, and the cost of screening (165). 
Therefore, galactosemia has been excluded from some newborn screening programs based on 
three major arguments: 
i) the disease can be diagnosed clinically, 
ii) it presents a historically high rate of false positives, 
iii) long-term complications still develop in spite of early treatment (141). 
 
In 1997, two studies regarding newborn screening were published, and both concluded 
universal neonatal screening for galactosemia was not sustained (166, 167). Even though Pollitt 
et al. recognized that the availability of effective treatment was not an absolute prerequisite for a 
disease to be included in newborn screening programs, galactosemia specific screening was still 
not recommended. Nevertheless, the reviewers strongly advised all samples with increased 
phenylalanine to be screened for galactosemia as a secondary test (167). 
A later study in favor of the early diagnosis by neonatal screening compared 139 children 
with metabolic diseases identified by neonatal screening (17 galactosemic) to 124 identified on 
the basis of clinical symptoms (9 galactosemic). Despite the similar rate of hospitalization (64% 
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versus 77%, respectively), 47% of the clinically identified children had mental retardation 
compared to only 14% of those identified by newborn screening, and parental stress tended to be 
greater in families of children identified clinically (57, 168). Indeed, early treatment 
implementation does not necessarily prevent long-term complications, but early diagnosis 
reduces the immediate impact of high doses of galactose, by cutting short the duration of 
exposure to the harmful metabolites and can, therefore, limit early morbidity and mortality from 
the disease (169). 
 
1.2.9.2. Newborn screening worldwide 
In contrast to newborn screening for PKU, which has become almost universal, 
galactosemia screening is included only in a minority of European newborn screening programs, 
namely Austria, Germany, Hungary, Ireland, Sweden, and Switzerland; while other four 
countries, specifically Turkey, Spain, Italy, and Belgium, present pilot programs (140, 141, 170). 
Ireland presents a high prevalence of classic galactosemia, especially in the Traveller 
population, and newborn screening for classic galactosemia has been performed since 1972 as 
part of the National Newborn Screening Programme (77). Irish newborns undergo newborn 
screening within 72 to 120 hours after birth, while all high-risk Traveller neonates perform it at 
day 1 or 2 (77). 
On the other hand, Sweden presents a relatively low frequency (1/100,000) and yet 
newborn screening for galactosemia has never been questioned. In fact, Sweden has a well-
working strategy for the screening procedure, with screening methods well established, 
inexpensive, that do not demand a heavy workload, and, more importantly, with a low false-
positive rate (141). 
Other countries, such as France and The Netherlands do not offer neonatal screening and 
some, like Norway and Denmark, have stopped their programs (143, 170-172). In the United 
Kingdom, there is no screening program for classic galactosemia in England, Wales and Northern 
Ireland, but there is one in Scotland (143, 170).  
In the United States of America, screening for galactosemia is currently offered in all 
states, and in Canada, in 1991, only 2 out of 10 provinces offered universal screening (1, 143). 
 
1.2.9.3. Classic galactosemia newborn screening in Portugal 
In 1979, the program for neonatal screening, so-called Portuguese Neonatal Screening 
Program (PNSP), was established in Portugal by the Ministry of Health with PKU screening, and 
further expanded in 1981 to congenital hypothyroidism (173, 174).  
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The later development of electrospray ionization tandem mass spectrometry (ESI-
MS/MS) allowed, in 2004, expanding the screening to a total of 25 disorders, in which only 
potentially treatable diseases were authorized by the Ethics Committee to be included in the 
program (174). Despite galactosemia not being included in the PNSP, all samples with increased 
phenylalanine and/or tyrosine are screened for classic galactosemia, by a semi-quantitative 
GALT activity evaluation with the Beutler fluorescent spot test, followed by total galactose 
quantification by a colorimetric assay (Hugo Rocha, personal communication, November 8, 
2013). 
 
1.2.10. Therapy and long-term outcome 
1.2.10.1. Initial management 
In the first weeks of life, the most important part of managing patients with classic 
galactosemia is removing all galactose from the diet, immediately after starting the diagnostic 
investigations and without awaiting results, in order to prevent further life-threatening 
complications (175). Nevertheless, even after the removal of all galactose from the diet, the 
infant may be seriously ill and require additional therapy. Supportive care with intravenous 
fluids, phototherapy, antibiotics, and treatment of coagulopathy should be initiated as needed (1, 
123). 
Clotting abnormalities, derived from liver failure, may be managed by vitamin K and 
fresh-frozen plasma. Unconjugated hyperbilirubinemia is usually not severe enough to warrant 
phototherapy or exchange transfusion, but infants may be at increased risk of kernicterus, if 
albumin levels are particularly low secondary to liver dysfunction (1). In case of sepsis, gram-
negative infection should be assumed, and an appropriate antibiotic should be administered 
intravenously (1). 
Most children at diagnosis are able to tolerate enteral feedings, although these may have 
to be given initially by nasogastric tube because of poor sucking ability (1). If the infant is too 
sick to tolerate enteral feeding for more than 1 or 2 days, then parenteral feeding should be 
considered but prescribed cautiously if there is significant liver disease or thrombocytopenia (1). 
After the initial management of the acute presentation, the infant is put on a galactose-
free formula, and is checked regularly for pediatrician and nutrition support (1, 149, 176). 
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1.2.10.2. Therapy  
Lifelong dietary restriction of galactose has been the basis of therapy of classic 
galactosemia since Mason and Turner, in 1935, described how removing galactose from the diet 
eliminated the acute toxicity syndrome (13).  
As soon as there is a suspicion for galactosemia, breastfeeding or milk-based formula, 
which contain a significant amount of galactose, must be ceased immediately and replaced by a 
galactose-free formula (1, 146, 149, 176). 
Commercial infant formulas appropriate for use in the management of classic 
galactosemia include elemental formulas and soy formulas (1, 126, 149). Infant soy formulas are 
most appropriate, unless there is significant liver disease, in which casein-based protein 
hydrolyzate formulas, that contain medium-chain triacylglycerol oil, should be used (1, 126, 
149). In the absence of significant liver disease, however, casein hydrolyzates should be avoided, 
since they do contain small amounts of galactose (60 to 90 mg/100 ml). In that case, soy formulas 
are the formula of choice (1, 126, 149). 
Most symptomatic infants with classic galactosemia show rapid clinical improvement 
following dietary restriction of galactose. Within 24 hours of removing galactose from the diet, 
the symptoms improve and, within 2 to 3 days, the infants seem to be almost miraculously cured 
(145). Features such as hepatomegaly, abnormal liver function, and renal tubular disease usually 
resolve fully within a week or two. Acceptable levels of Gal-1-P in RBC are usually achieved 
within 2-3 months of starting treatment, but may take up to 1 year (176). 
 
1.2.10.3. Long-term complications 
The dramatic response to dietary therapy for galactosemia led to the belief that this 
disorder was relatively benign and easy to treat (145). While the success of early treatment on the 
acute neonatal symptoms is unquestioned, the long-term outlook is not as good as expected (145). 
Indeed, even with early treatment commencement and optimal dietary compliance, patients often 
develop cognitive and neurologic complications. The complications may appear individually, as a 
complex, or not at all (56, 123). 
Whether the long-term complications observed result from subtle developmental 
abnormalities initiated in utero, chronic exposure to endogenously produced galactose or other 
factors remains unknown.  
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1.2.10.4. Neurological and psychoneurological outcome  
One of the most well-established long-term complications is cognitive disturbance, which 
affects approximately 50% of all treated patients (177). Indeed, after Komrower and Lee 
statement, in 1970, that “the intelligence of the early diagnosed and well treated is below 
average”, several subsequent studies have supported cognitive impairment (138, 145, 178-181). 
Across most studies, intelligence quotient (IQ) has been found to be in the typical (85–115) to 
borderline-low (60–84) range, with considerable inter-individual variability (178, 181). There 
are, however, conflicting results regarding the IQ scores change with increasing age (178). In an 
international survey, Waggoner et al. reported a progressive decline in IQ scores over time, with 
patients who had had IQ scores evaluations at both 3-5 and 6-9 years presenting a mean decrease 
of 6.2 IQ points between the two ages (n = 42), and with patients who had had IQ scores 
evaluations scores at both 6-9 and 10-16 years presenting a mean decrease of 4.4 points (n = 46) 
(145). However, a later longitudinal study examining this hypothesis found no evidence of 
progressive decline in overall cognitive functioning with age (182). Regardless of the possibility 
of progressive neurodegeneration, studies concur that IQ scores do not appear to correlate with 
time of diagnosis, initiation of treatment, dietary compliance, exposure to Gal-1-P levels, or 
genotype (60, 123, 183). 
Motor disturbances, such as coordination, gait, balance, fine motor tremors, and severe 
ataxia, are also quite frequent (11, 138, 145). Other neurologic findings, such as epilepsy and 
microcephaly, have also been reported, though more rare (11, 138). 
Neuroradiologic studies of individuals with galactosemia have demonstrated white-
matter abnormalities, although magnetic resonance imaging findings do not appear to correlate 
with severity of illness or IQ (178).  
Moreover, several studies have estimated that 38–65% of children with galactosemia 
have neurodevelopmental speech disorders, of which more than 90% have been reported to have 
co-occurring language disorders, which include vocabulary and word retrieval deficits (145, 184). 
In fact, in Waggoner’s retrospective study, problems with speech were reported in 56% of cases 
(> 3 years old), of which 92% were described as having delayed vocabulary and 90% had 
articulation problems (145). 
Speech disorders in children with galactosemia have a neurologic origin and, in a study 
by Potter et al., were divided into three subtypes of motor speech disorders: i) childhood apraxia 
of speech – CAS, a deficit in motor planning or programming; ii) dysarthria, a deficit in 
neuromuscular control; and iii) motor speech disorder-not otherwise specified – MSD-NOS, a 
cover term for speech, prosody, and voice behaviors that are consistent with a motor speech 
disorder, but not specific for CAS or dysarthria (177). Effectively, galactosemic children with 
speech disorders have a high co-occurrence of motor disorders, namely in strength and 
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coordination, which suggest a common underlying etiology (145, 177). Additionally, Potter et al. 
have also reported that galactosemic children with CAS or dysarthria presented poorer balance 
and manual dexterity than most of the children with MSD-NOS, and exhibited more speech 
errors and were less intelligible than the children with MSD-NOS. Accordingly, these authors 
concluded that speech, coordination, and strength disorders are most likely associated with 
diffuse cerebellar damage, since the cerebellum is involved with motor movements, refining 
speech and balance control (177). Indeed, histopathological brain examinations and multiple 
neuroimaging studies revealed cerebral and cerebellar atrophy, with demyelination of the white 
matter in galactosemic patients (77, 123, 138, 185, 186). The mechanism(s) for white matter 
lesions is unclear. It is possible that GALT deficiency leads to defective synthesis of 
glycoproteins and glycolipids critical for myelin synthesis, possibly as a result of defective 
transfer of galactose from UDP-Gal (11, 123, 185, 187-189). 
Visual and perceptual impairments are also common in galactosemia and seem to be 
independent of IQ (138, 178, 186). Memory difficulties have also been reported, although these 
impairments do correlate with IQ (178, 186). Handwriting, reading, and mathematics difficulties 
are also common, and children with galactosemia are often academically retained (138, 178). In 
fact, school achievements are below the grades achieved by healthy siblings and a comprehensive 
multidisciplinary study on the adult galactosemic phenotype reported an average schooling of 1 
to 2 years of college, with an occupational level of skilled manual laborer (138, 142, 179). 
Furthermore, as had been described by Bhat et al., in a study concerning the social outcome of 
treated patients with IMD, many patients have no educational qualifications and are unemployed 
(190). Actually, the cognitive delay and the speech difficulties characteristic of galactosemia 
most likely interfere with the development of social skills and educational attainment (181, 191-
193). Indeed, galactosemic patients are often described as shy and reserved, which may be related 
to word retrieval difficulties, and generally do not present with behavioral dysregulation – there 
are only a few reports of hyperactivity in galactosemic patients (178, 194). 
Additionally, many patients are single and live with their parents, as only a minority is 
able to build up strong partnerships outside the core family (77, 142, 195). In fact, in a study by 
Hoffmann et al., approximately 40% of the patients recognized that classic galactosemia did 
impair their company with other people (195). 
In 2004, a study by Bosch et al., aiming to evaluate patients’ health-related quality of life 
(HRQoL) and specific concerns related to this disorder in patients and parents, reported 
galactosemia was seen as a burden by many patients (39%) (179). Actually, many felt different 
because of having galactosemia (34%), and believed their disease was not well understood by 
others (22%) (179). Furthermore, many parents believed the disorder influenced their contact 
with the child (73%) and that it was a burden to take care of a child with galactosemia (60%) – 
despite reporting treating and raising their child with galactosemia the same way as their healthy 
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children (69% and 77%, respectively) (179). This was the first study ever reporting the HRQoL 
of patients with classic galactosemia by using well-developed and validated instruments in 
different age groups, and the results were quite astonishing: galactosemia negatively influences 
the HRQoL, most strikingly on the cognitive domain, but also on the domain of communication 
and social function (179). 
The underlying cause(s) behind the neurological and psychoneurological outcome in 
classic galactosemia is still an enigma. It most likely results from assaults from multiple fronts 
(123). In effect, all attempts to correlate the occurrence of neurological and psychoneurological 
outcome of classic galactosemia with differences in the course of the disease, such as age at 
diagnosis, severity of the acute clinical manifestations, age of galactose-restricted diet 
implementation, diet compliance, biochemical parameters or genotype, have failed (178, 183). 
 
1.2.10.5. Growth and bone density 
Several studies have reported growth delay and decreased bone mineral density in 
patients with classic galactosemia under dietary treatment. 
The first report of decreased height in childhood and early adolescence in treated 
galactosemic patients was done by Waggoner et al., who evaluated 350 patients aged from 2 
weeks to 37 years, and found that, despite being severely delayed during childhood and early 
adolescence in many cases, growth often continued through the late teens so that final heights 
were normal (145). 
In a more recent study, Panis et al. evaluated 40 children and adolescents (13 males and 
27 females, aged 3–17 years) and reported decreased height (corrected for target height) in both 
genders and decreased height velocity in girls (196). Furthermore, predicted final height was 
lower than target height in most patients; however, as the authors emphasized, target height could 
be reached for the children who grow beyond the age of 18 (196). 
In addition, treated galactosemic children, adolescents and adults are also at risk for a 
diminished bone mineral density (BMD) (197-200). Panis et al. reported a decreased BMD in the 
same group of galactosemic patients, in whom they had found no evidence of nutritional 
deficiencies. The authors did find, however, decreased levels of bone formation markers and 
bone resorption markers, namely decreased carboxylated osteocalcin (199). In another study with 
the same patients, Panis et al. evaluated, for the first time, body composition in galactosemic 
patients, and found decreased insulin-like growth factor-I (IGF-I), which, due to important role of 
hormones in height and body composition, the authors hypothesized could play a role in the 
decreased growth (201).  
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In another study, Panis et al. (2006) studied the effect of calcium, vitamins K1 and D3 
supplementation on bone, since they had found a decreased carboxylated osteocalcin 
concentration, a marker for the vitamin K nutritional status (199, 202). Since vitamin K works 
best if given in combination with calcium and vitamin D, these authors developed a 2-year 
randomized clinical trial to investigate whether vitamin K could play a role in the 
pathophysiology of this complication. In fact, they found a statistically significant increase in 
osteocalcin carboxylation in both prepubertal and pubertal children receiving supplementation 
(202). 
In another study, Gajewska et al., aiming to assess bone formation and resorption 
processes in children and adolescents with galactosemia, reported similar mean values of bone 
turnover markers in both groups of patients, contrarily to healthy adolescents, who, in 
comparison to healthy children, presented significantly lower physiological values of the 
investigated markers (203). The higher concentration of the bone turnover markers of the 
galactosemic adolescents comparatively to age-matched controls suggested a higher rate of bone 
turnover with predominance of the bone formation process, which the authors hypothesized could 
be a reflection of an adaptive mechanism ensuring proper bone mass after disturbances of bone 
metabolism in early childhood (203).  
A recent study evaluating 32 adult patients (17 males and 15 females) showed that bone 
density in galactosemic adults is low, thereby conferring a potential for increased fracture risk 
(200). These authors suggested early interventions, starting on childhood, in order to promote 
optimal bone accrual and thereby improve lifetime bone health for this high-risk group 
galactosemics represent (200). 
The pathophysiological mechanism of the bone-related complications in classic 
galactosemia is not completely understood. Several mechanisms have been proposed, including 
nutritional deficiencies, alterations in the endocrine axis, and intrinsic factors related to bone 
metabolism (200). Because of their galactose-restricted diet, patients are at risk for nutritional 
deficiencies, particularly for calcium, since milk products are rich in casein-bound calcium – 
important for a good bioavailability of calcium – and are, therefore, considered the best source of 
dietary calcium (202). However, several studies have excluded major nutritional deficiencies, and 
concluded that other disease intrinsic factors must be involved (197, 200-202). In fact, Kaufman 
et al. found calcium intake to be correlated with BMD in adult galactosemia patients but not in 
prepubertal patients, implying that other than dietary factors must be involved (197, 202). 
Nevertheless, inadequate calcium and vitamin D intake by galactosemic patients has been 
reported, as well as a decreased carboxylated osteocalcin concentration in the serum and, when 
considering strategies to improve bone mineralization and diminish morbidity, supplements like 
calcium, vitamins K1 and D3 may be taken into consideration (197, 200, 202). In fact, 90% of the 
32 adult patients studied by Batey et al. reported they were not being followed by a nutritionist, 
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which suggests the frequency of visits with a nutritionist may decrease as the patients enter 
adulthood, highlighting the importance of providing appropriate nutritional counseling for 
maintenance of an ideal body weight and potentially as a strategy to optimize bone accrual during 
adolescence and to maintain bone mass during the adult years (200). 
 
1.2.10.6. Gonadal function 
The most common long-term complication reported for girls and women with classic 
galactosemia is primary ovarian insufficiency (POI), with an incidence between 80% to more 
than 90% (1, 125, 145, 204, 205). According to female patients and their parents, this 
complication represents the greatest psychological burden of classic galactosemia (179, 206, 
207). 
POI is a spectrum disorder of ovarian insufficiency, with clinical manifestations that may 
range from absent or delayed pubertal development to primary amenorrhea, secondary 
amenorrhea or oligomenorrhea and decreased fertility (1, 204, 206, 208). POI can be detected by 
measuring follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol and anti-
Mullerian hormone (AMH) in blood, but given the inactivity of the hypothalamic-pituitary-
ovarian (HPO) axis in childhood, these levels may not be sensitive enough to identify ovarian 
dysfunction in a presymptomatic state (208). Elevated FSH level, an indirect measure of ovarian 
function, has been found elevated very early in life (4 months to 4 years) and also between early 
childhood and onset of puberty (5–12 years), while serum AMH level, an indirect marker for 
follicular function and ovarian reserve, is abnormally low in galactosemic girls relative to age-
matched controls, even in girls younger than 2 years (125, 204, 205, 209).  
All female patients should be followed by an endocrinologist during late childhood and 
puberty (1, 149). Hormone replacement therapy (HRT) with estrogen and progesterone is 
currently the recommended therapeutic approach; the age at which HRT should begin is, 
however, debatable (1, 149, 208). 
The etiology underlying POI in classic galactosemia is not yet fully understood, and 
several mechanisms have been postulated, namely direct toxicity of metabolites – Gal-1-P and 
galactitol – and UDP-Gal deficiency (205, 206, 210). Gal-1-P may inhibit key enzymes that 
normally metabolize Glc-1-P, thereby impairing cellular metabolism and/or lead to increased cell 
stress, whereas galactitol causes osmotic stress and swelling of the ovarian cells, which would 
eventually lead to cell dysfunction (204). On the other hand, UDP-Gal deficiency can lead to 
apoptosis of oocytes and ovarian stromal cells or cause aberrant glycosylation of glycoproteins 
and galactolipids involved in ovarian function, especially since FSH contains galactose-rich 
oligosaccharide side chains (1, 204, 205, 211). FSH malfunction due to hypoglycosylation, 
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however, has been made less probable by the fact that FSH bioactivity was found normal in 
galactosemic girls (205, 209). However, a functionally altered FSH receptor due to 
hypoglycosylation remains a possibility that has not yet been studied (205). It is also conceivable 
that not one, but the different mechanisms acting in unison are responsible for this clinical picture 
(204, 205) 
Moreover, determining the point in development at which POI begins has been difficult. 
It is still uncertain whether this ovarian insufficient is initiated in early development, perhaps 
even prenatally, or whether it represents a degenerative process compounded by ongoing 
galactose exposure (204, 205). Undoubtedly, fertility issues in female patients with classic 
galactosemia are complex and multifactorial (208). However, spontaneous pregnancies may 
occur, and a predicting factor for the possibility to conceive is spontaneous menarche (208). 
Regarding the male gonadal function, there is a manifest paucity of data vis-à-vis to the 
female counterpart. Indeed, only few studies have examined the male reproductive system and, 
until recently, male fertility was believed not to be impaired by galactosemia (205, 212). 
In 2006, Rubio-Gozalbo et al. described a high frequency of cryptorchidism in 
galactosemic individuals, presenting a prevalence of 25% (3 of the 12 males) in opposition to 
≤1% in the healthy age-matched population (213). This study was, however, somewhat limited 
due to small sample size. A more recent investigation on the male reproductive system of 26 
galactosemic patients demonstrated an increased prevalence of cryptorchidism (11.6%), with low 
semen volume, and lower testosterone, inhibin B and sperm concentration than in control 
subjects – although within the normal range on average – which might indicate mild defects in 
Sertoli and Leydig cell function (212). 
With the exception of cryptorchidism, the clinical significance of these abnormalities 
should have little impact on fertility (212, 213). Again, there is a remarkable scarcity of fertility 
studies concerning galactosemic male patients, with only 3 fathered pregnancies in the literature 
(142, 212). The lack of documented paternity in men with galactosemia may be related to a 
publication bias and difficulty documenting paternity or to the known social interaction problems 
and delayed psychosocial development documented in these men (212).  
In fact, in the study on the adult galactosemic phenotype, out of the 12 men involved, 
only 2 were fathers (142). This same study also reported depression and anxiety in 39% and 67%, 
respectively, of the patients, which may be a reflection of the impact of the long-term 
complications of classic galactosemia in the adult patients (142). Indeed, despite having a normal 
life expectancy, galactosemic patients do develop long-term complications that cannot yet be 
prevented, and greater support to psychosocial issues – depression, anxiety, and social 
relationships – as well as medical issues should be provided, in order to relieve the impact of this 
disorder in adulthood (142, 179, 190).  
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Classic galactosemia unexpected long-term outcome constitute one of the main enigmas 
of this metabolic disorder and set the basis for the development of new therapeutic approaches 
(further explained below). 
 
1.2.10.7. Classic galactosemia: dietary dilemmas (175) 
In the 1950’s, different strategies to feed infants a diet without galactose were discussed 
in the literature. Nowadays, initiating the diet is much easier, as infant formulas with a very 
limited amount of galactose are widely available. Still, there are dilemmas in the treatment of 
galactosemia, and the dietary treatment varies widely around the world (175). 
Both semi-elemental formulas and soy-based formulas contain very small amounts of 
galactose, and recent studies suggest that completely eliminating galactose from the diet by 
prescribing an elemental formula allows a significantly faster decrease of the high RBC Gal-1-P 
levels (175). Zlatunich and Packman have described the case of a classic galactosemic baby, 
diagnosed by newborn screening at the age of 6 days, and put on a soy-based formula containing 
14 mg of bound galactose per liter (1.4 mg/100 mL).  Galactose daily intake was estimated to be 
13 mg. By the age of 5 months, erythrocyte Gal-1-P levels were still above 4 mg/dL, so an 
elemental formula was initiated. This formula resulted in a rapid decrease in Gal-1-P levels, 
which stayed at the low end of the treatment range (214). Two other patients, described by 
Ficicioglu et al., with a similar clinical history, were also put on an elemental formula at age of 5 
months, and they too presented statistically significant decreased levels of Gal-1-P in RBC (215).  
Nevertheless, the possibility that patients’ metabolite levels would eventually decrease on 
soy formula should not be ruled out (214). Soy protein-based formulas are safe and cost-
effective, and are the first-line therapy in many countries, namely in The Netherlands and 
Australia (170, 176, 216). It remains to be elucidated whether a potential faster decrease by the 
use of elemental formulas, would positively affect long-term outcome. In fact, prospective 
studies need to be performed to clarify this issue, before routinely putting these infants on this 
expensive and unpalatable formula (175, 176). 
Upon introduction of solids foods, some galactose is inevitably introduced into the diet 
(14, 176). Despite lactose continue being the primary source, there are other sources of galactose 
– either in the free or bound form – that are found naturally and widely distributed in foods (176). 
Though in much smaller quantities than in milk-containing foods, galactose is also present in 
cereals, offal meats, pulses, fruits and vegetables (11, 149, 176, 217). 
A thorough study by Gross and Acosta quantified the free galactose content of 45 fruits 
and vegetables, which ranged from less than 0.1mg/100g in artichoke, mushroom, olive, and 
peanut to 35.4mg/100g in persimmon (217). In addition, galactose can also be found in its 
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complex form, namely galactans and galactolipids, which have the potential to be hydrolyzed in 
the gut by β-galactosidase or pancreatic lipase, respectively, and, therefore, to release galactose, 
rendering it available for absorption (217). The actual bioavailability of these complex galactose 
substances is, however, unknown (176, 218). 
The significance of non-dairy foods to total intake of galactose in galactosemia outcome 
has long been questioned (176, 218-220). Several studies have shown that fruits and vegetables 
contribute with only small amounts of galactose compared to lactose rich foods (176). Berry et 
al. demonstrated that a lactose-free diet highly enriched in fruits and vegetables resulted in a 
mean galactose intake of 54 mg per day, and further demonstrated that the daily ingestion of 200 
mg of fruit-derived galactose (50 mg of pure galactose in fruit juice 4 times per day) for 3 weeks 
had no impact on RBC Gal-1-P values and relatively little effect on urinary galactitol levels 
(220). In another study, Bosch et al. demonstrated that supplementation of galactose during a 
period of 6 weeks up to a maximum of 600 mg per day – corresponding to the amount of 
galactose in 7 kg of apples, 2.5 kg of tomatoes, or 12 kg of peas – did not result in any physical, 
ophthalmological, or biochemical abnormalities (219). 
These data strongly suggest that the reduction of the daily dietary galactose intake by 
restricting fruit and vegetables is negligible and, in the short-term, appears to involve no 
significant clinical impact (219). Moreover, the realization that galactosemic patients 
endogenously synthesize galactose, and to an extent that far exceeds that from non-dairy foods, 
has minimized this concern (126, 149, 176, 219, 220). Therefore, some European countries – 
Denmark, Norway and United Kingdom – have liberalized the therapy, advising now a lactose-
free diet (170, 219). 
In Portugal, the diet shows slight variations according to the metabolic center. After 
management of the acute neonatal syndrome, the infant is kept on a soy formula. Upon 
introduction of solid foods, a galactose-restricted diet is implemented, with restriction of lactose-
containing foods and of some fruits and vegetables of high galactose content, namely watermelon 
and beans. Some fully cured cheeses, such as Emmental and Gruyere, are allowed, as they have 
been described to contain undetectable amounts of lactose and galactose (221). 
 
1.2.11. Current alternative therapeutic approaches in classic galactosemia  
Inborn errors of metabolism comprise a large group of disorders, commonly caused by 
inactivity of specific enzymatic steps, leading to compromised flux of molecules in evolutionarily 
conserved metabolic pathways. Traditionally, IMD are categorized as those involved in i) 
synthesis or catabolism of complex molecules (e.g., congenital glycosylation disorders); ii) 
intermediate metabolism, (e.g., amino acidopathies, organic acidemias, urea cycle defects, and 
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disorders of carbohydrate metabolism including classic galactosemia); and iii) energy 
metabolism, (e.g., disorders of gluconeogenesis, lactic acidemias, fatty acid oxidation defects, 
and Krebs cycle and mitochondrial respiratory chain disorders) (222-224). The great majority of 
pathophysiological mechanisms of IMD are related to: i) accumulation of precursor(s); ii) 
alternative metabolites normally not encountered; or iii) absence (or deficiency) of metabolites 
past the enzymatic block. Any, or a combination of these possibilities, could be responsible for 
the phenotypes associated with an enzymatic blockage (222). 
The pathophysiology of IMD varies greatly between disorders, and so will management 
and therapeutic approaches. The various therapeutic approaches of IMD can be categorized 
according to the level of management (Figure 1.7) (222). 
 
 
Figure 1.7. Overview of the current therapeutic approaches in IMD at several levels of intervention. (ADA – 
adenosine deaminase). Adapted from Tang et al., 2011 (222). 
 
In what regards classic galactosemia, its pathogenic mechanism(s), as well as its timing, 
are still inexplicable and puzzling (33, 222).  
Several hypothesis have been put forward concerning timing of the cellular 
pathophysiology: i) the long-term complications of classic galactosemia are entirely due to 
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prenatal disease; ii) the complications are due to postnatal disease, owing to the exposure to 
relatively massive concentrations of lactose in the newborn period and/or the chronic exposure to 
exogenous and endogenously synthesized galactose; iii) the complications are both prenatal and 
postnatal in origin (13, 225).  
Concerning the pathogenic mechanism(s), the hypothetical causative agents of cell and 
tissue dysfunction regard:  
i) an abnormal GALT gene per se; 
ii) an abnormal GALT protein; 
iii) pleiotropic abnormalities, dependent on an elevation of cellular Gal-1-P; 
iv) abnormal intracellular concentrations of galactitol; 
v) a combination of the above (225).  
Indeed, it is apparent that galactose and Gal-1-P accumulate in patients, with galactose 
being further metabolized through two alternative pathways to form galactitol and galactonate. 
Among all the metabolites formed, Gal-1-P and galactitol have received most attention; however, 
their potential toxicity targets and their exact pathogenic mechanism(s) are still largely unknown 
(222). 
Despite its limited efficacy in preventing long-term complications, the current standard of 
care for classic galactosemia remains dietary restriction of galactose, a therapeutic approach at 
the substrate reduction level (1, 222). 
An alternative therapeutic intervention that has been investigated is at the product 
supplementation level, with UDP-Gal. In light of the possible role of UDP-Gal deficiency in the 
pathogenesis of classic galactosemia put forward by Shin et al. in 1985, Ng et al. studied UDP-
Gal levels in hepatocytes, erythrocytes and skin fibroblasts from galactosemic patients, thereby 
confirming its deficit in GALT-deficiency cells. Accordingly, the authors suggested uridine 
administration could be of therapeutic value by raising the intracellular concentrations of UDP-
Gal (182, 226). Subsequently, Manis et al. began a 5-year study in which oral uridine was 
administered to two cohorts of galactosemic patients, whose results, however, did not support the 
hypothesis that oral uridine improved cognitive functioning in afflicted subjects (182). It is, 
however, unclear whether UDP-Gal would reach the cytosolic compartment in GALT-deficient 
cells; and thus there is still much controversy regarding this therapeutic intervention at the 
product supplementation level (222). 
Another therapeutic strategy at the enzyme level involves inhibition of GALK, the first 
enzyme of the Leloir pathway. This approach was proposed more than 10 years ago by Bosch et 
al., as a way of reducing the build-up of Gal-1-P, long known to play a key role in the 
pathophysiology of classic galactosemia, thereby converting this severe form of 
hypergalactosemia into the milder form of type II galactosemia (12, 227). Indeed, patients with 
galactokinase deficiency do not experience the long-term complications of classic galactosemia, 
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and a medically induced galactokinase deficiency could provide protection from the conversion 
of galactose to Gal-1-P. Therefore, Lai’s research group has been searching for small-molecule 
inhibitors of galactokinase over the last years (25, 228). Another therapeutic option is the 
administration of an aldose reductase inhibitor to block galactitol synthesis, and, hopefully, 
perhaps both inhibitors could be given simultaneously (33, 229). 
A more recent study regarding five GALT variants reported the pathogenic mechanism 
underlying impaired enzymatic activity is GALT misfolding and suggested this could be 
transversal to many GALT variants, and thus proposed chaperone-based therapy to classic 
galactosemia (110). 
Despite decades of intensive research, the pathophysiology of classic galactosemia 
remains largely unknown, with limited and partly ineffective therapeutic options (222). Indeed, 
so many years have gone by since the first description of this disease and, aside from dietary 
lactose restriction in infancy, few therapeutic advances have been achieved (229). 
Classic galactosemia does indeed constitute an enigma that, for now, continues to be 
unsolved. 
 
1.3. Mutation-specific therapeutic approaches  
Molecular studies in a number of genetic disorders have led to the realization that only a 
minor part of the mutations directly disrupt functional sites of the proteins. Rather, most sequence 
variations disturb either the folding of the newly synthesized variant proteins or the synthesis of 
the protein by affecting pre-mRNA processing (230-233). 
Missense and small in-frame deletions and insertions may lead to aberrant proteins, 
depending on the residual function of the specific protein, and on the cellular and environmental 
conditions; whereas splicing variations and out-of-frame deletions and insertions result in total 
loss-of-function, often due to the introduction of a premature termination codon into the mRNA, 
typically resulting in its degradation by the mRNA surveillance mechanism (234, 235). 
 
1.3.1. Pathogenic molecular mechanisms of genetic disorders – folding spoilers 
The successful execution of cellular processes in the human body depends on the 
coordinated interactions of roughly 20,000 to 25,000 different proteins, which are responsible for 
most aspects of biological function (235, 236). 
Approximately 20% to 30% of all proteins in the cell seem to be intrinsically devoid of 
any ordered three-dimensional structure and adopt folded conformations only after interaction 
with binding partners (237). However, the great majority of the proteins must be folded into their 
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native state, an ensemble of a few closely related three-dimensional structures, in order to achieve 
their function (237). How cells ensure the conformational integrity of their proteome constitutes 
one of the most important and relevant issues in biology, and provides a rational basis for 
tackling many genetic disorders in which protein (mis)folding plays a major role (237-239). 
 
1.3.1.1. Protein folding – the challenge 
Proper folding into the correct secondary structure and conformation is indispensable for 
the biological function of proteins and is achieved during, or immediately following protein 
synthesis (240). When the nascent polypeptide emerges from the ribosome, it must fold and 
assemble properly, in order for the protein to achieve its three-dimensional conformation (241). 
The native structure of a protein is mainly determined by its amino acid side chains, and is 
predominantly driven by the need to bury the hydrophobic residues within the protein core, 
hidden from the surrounding aqueous milieu (237, 241-243). Indeed, prior to folding, polypeptide 
hydrophobic domains are exposed to a complex and very crowded environment – estimated to 
reach protein concentrations as high as 300 mg/ml – that promotes inter- and intramolecular 
interactions, which could reduce the efficiency of the cellular protein folding (231, 235, 241). To 
prevent the undesired interactions and to provide a more favorable environment, folding is 
assisted and monitored by a class of proteins known as molecular chaperones. Molecular 
chaperones do not increase the rate of folding, but rather increase the probability of desirable 
interactions and prevent misguided interactions, thereby allowing proteins to fold efficiently and 
on a biologically relevant timescale (237, 241). 
To picture protein folding, a topological landscape representing different energy levels 
has been suggested. In this model the process of folding is described as a constant strive towards 
minimal free energy with the native structure of the protein being the functional conformation 
with the lowest energy level, the global minimum of the landscape (Figure 1.8). Chaperones 
iteratively bind and release their substrates, each time raising the free energy and enabling 
evasion from wrong folding pathways. Eliminating protein by degradation can, in principle, take 
place from any location in the landscape, but occurs predominantly in areas with trapped 
misfolding or on pathways toward aggregated structures. Because the free energy of a protein is a 
function of its conformation defined by the interactions between the amino acid residues, even 
small alterations in the amino acid chain may change the surface of the landscape, leading to the 
possible formation of new local free-energy minima or, in the extreme case, formation of a new 
global free-energy minimum resulting in a different stable structure of the protein, which may be 
prone to aggregation. This implies that the native state of a protein is not always the global 
energy minimum. To refine the concept of energy folding landscapes to include the aggregation 
tendency, this model can be pictured with two deep valleys (Figure 1.8) (244).  
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Figure 1.8. Free-energy folding landscape for chaperone-mediated protein folding. The landscape is drawn as a 
rugged funnel shape in a three-dimensional system with the free energy on the y axis and the conformational space or 
entropy as a two-dimensional projection on the x and z axes. Chaperones iteratively bind and release their substrates, 
each time raising the free energy and enabling escapes from wrong folding pathways, indicated by the “Unfolding” 
arrow. Eliminating protein by degradation can, in principle, take place from any location in the landscape, but occurs 
predominantly in areas with trapped misfolding or on pathways toward aggregated structures, as indicated in the 
aggregation funnel. Reproduced from Gregersen et at., 2006 (244). 
 
Given that proteins have an intrinsic tendency to misfold, cells must be able to refold 
misfolded proteins or to remove them by degradation. This sorting process is executed by the so-
called protein quality control (PQC) system, whose main components are molecular chaperones – 
which supervise folding and protect folding intermediates from nonproductive interactions that 
could result in aggregation – and proteases – which assist in the elimination of aberrant folding 
intermediates and unstable proteins that would overload the chaperone systems and potentially 
damage the cell (Figure 1.9) (235). 
Molecular chaperones are present in all types of cells and cellular compartments. Some 
chaperones interact with nascent chains as they emerge from the ribosome, whereas others are 
involved in guiding later stages of the folding process; and molecular chaperones often work in 
tandem to ensure that the various folding stages are all completed efficiently (245). Several 
classes of molecular chaperones can be distinguished, namely: the Hsp70 family, a paradigmatic 
group of molecular chaperones that control binding and release of folding intermediates; the 
chaperonins, which form a characteristic barrel structure whose interior cavity serves as a 
‘folding cage’ where proteins can fold undisturbed; small heat-shock proteins (sHsps), which 
bind unfolded proteins, thus acting as ‘holding chaperones’ for folding intermediates; the lectin 
chaperones calnexin and calreticulin, chaperones of the endoplasmic reticulum (ER) that work in 
collaboration with glycosidases and the UDP-glucose:glycoprotein glucosyltransferase (UGGT), 
recognizing incompletely folded proteins with N-glucosyl chains carrying one glucose residue 
and not allowing them to move further ahead to the Golgi compartment; and the AAA-domain-
containing chaperones, which represent a large superfamily involved in the disassembly of 
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minimum of the landscape (24). The land-
scape is drawn as a rugged funnel shape in
a three-dimensional system with the free en-
ergy on the y axis and the conformational
space or entropy as a two-dimensional projec-
tion on the x and z axes. Indeed, a computer
simulation based on experimental structural
information of the acylphosphatase protein
has demonstrated the usability of the model
(25).
Because the free energy of a protein is a
function of its conformation defined by the
interactions between the amino acid residues,
even small alterations in the amino acid chain
may change the surface of the landscape, lead-
ing to the possible formation of new local free-
energy minima or, in the extreme case, for-
mation of a new global free-energy minimum
resulting in a different stable structure of the
protein, which may be prone to aggregation.
This implies that the native state of a protein is
not always the global energyminimum.To re-
fine the concept of energy folding landscapes
to include the aggregation tende cy, which
may be aggravated by extrinsic factors, such as
high protein concentration and elevated tem-
perature, in the living cell, one can imagine a
landscape with two deep valleys (23). The idea
is visualized in Figure 1.
Protein aggregates canbe extremely stable,
even more stable than the native protein, sug-
gesting that the aggregated states are trapped
in the kinetically deepest valleys of the land-
scape. It is therefore rationalized that the deci-
sion of folding toward an aggregated or native
state is a battle between conformations sta-
bilized by intermolecular and intramolecular
interactions, respectively (23).
Furthermore, amino acid substitutions in
the protein tend to raise the local minimum
around its native state, rendering the stabi-
lization more cumbersome and increasing the
risk of assuming misfolded conformers with
enhanced aggregation tendency. Molecular
chapero es play a vital role in this battle by re-
arranging structures forming interactions to
other proteins or by exposing hydrophobic
regions and thereby lifting them to a higher
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Chaperone holding
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Figure 1
Free-energy folding landscape for chaperone-mediated protein folding:
hypothetical landscape of all possible protein conformations pictured with
higher altitude in the airspace symbolizing higher f ee energy and entropy.
Chaperones iteratively bind and release their substrates, each time raising
the free energy and enabling escapes from wrong folding pathways,
indicated by the “Unfolding” arrow. Eliminating protein by degradation
can, in principle, take place from any location in the landscape, but occurs
predominantly in areas with trapped misfolding or on pathways toward
aggregated structures, as indicated in the aggregation funnel.
Folding landscape:
a model describing
the concept that the
folding path for a
given protein strive
t ward l wer energy
and entropy
Protein aggregate:
structured or
amorphous
collections of protein
molecules bound
tog ther
by—primarily—
hydrophobic
forces
level of free energy and entropy, from which
a new folding path can start. Some chaper-
ones are even able to unfold proteins or res-
cue aggregated proteins, thereby lifting them
to a higher energy level for a second round of
folding (59).
In human genetic diseases, missense vari-
ations account for approximately half of the
known gene lesions (89). A pertinent ques-
tion, therefore, is: Will a given variant lead to
misfolding of the protein? Because of a lack
of knowledge about the folding pathway of
proteins, there is not yet a satisfactory answer
to this question. However, a number of re-
sources are available through the Internet, al-
lowing the user to test different protein vari-
ants to produce an “educated guess” related
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proteins and unfolding of misfolded proteins to present them to the degradative system (231). 
On the other hand, proteases selectively eliminate misfolded proteins, and thus require 
sorting or labeling of the polypeptide and unfolding before their processive peptidase activity 
executes peptide bond cleavage. The best-studied protease is the cytosolic proteasome, which is 
composed by a regulatory particle and a core proteolytic particle (231). Proteasome substrates are 
usually tagged by a system that recognizes proteins with a low folding capacity or structurally 
instable proteins and adds ubiquitin molecules to lysine residues in the polypeptide chain, after 
which the proteasome regulatory particle recognizes and binds the ubiquitinylated polypeptides, 
removes the ubiquitin tags, unfolds the chains and transports them into the proteolytic chamber of 
the core particle to be degraded (231). The mitochondria also contain a set of proteases with a 
similar architecture to the proteasome – proteolytic chamber and regulatory components – which 
recognize and unfold misfolded proteins, directing them to their proteolytic chamber (231). In 
contrast to the proteasome, the mitochondrial proteases substrates are not tagged with ubiquitin 
molecules; rather, they are recognized by regulatory domains or subunits of these proteases based 
on structural properties like folding status (231). 
 
 
Figure 1.9. The PQC system. The PQC system manages the pool of unfolded and partially folded conformations 
(center). Molecular chaperones promote folding, protect folding intermediates and disaggregate aggregates or unfold 
misfolded proteins, whereas proteases eliminate misfolded proteins. Reproduced from Gregersen et al., 2006 (244). 
 
The PQC system regulates the interplay between molecular chaperones and intracellular 
proteases, being of prime importance in the regulation of protein levels and functions within the 
cell. Indeed, the PQC system constitutes the hub for the protein homeostasis network (or 
proteostasis), which, together with its other components, is in place to achieve proteome 
maintenance with alternative pathways to degradation (Figure 1.10) (246).!
!
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Figure 2
Functioning of prot in quality control (PQC) systems. PQC systems manage the pool of unfolded and
partially folded conformations (center). Folding chaperones promote folding, holding chaperones
maintain solubility, and unfolding chaperones disaggregate aggregates or unfold misfolded proteins and
inject them into proteolytic chamb rs of PQC proteases.
The production and maintenance of func-
tional proteins, their turnover, and the
removal of damaged and aberrant proteins are
central tasks of PQC systems. Therefore, it is
not surprising that interferencewith these cel-
lular functions can lead to disease. Under nor-
mal conditions the PQC system can eliminate
defective ribosomal products due to errors
in translation or post-translational processes
(81), as well as aberrant proteins originating
from the load of gene variations present in the
respective individu l or from damage by cova-
lent protein modifications like those elicited
by reactive oxygen species (ROS) (27). Dis-
turbances of the PQC by overload with mis-
folding variant proteins, environmental chal-
lenges, or gene variations in PQC compo-
nents may thus trigger disease processes.
PQC systems are highly dynamic, consist
of components with often redundant func-
ROS: reactive
oxygen species
Hsc: heat-shock
cognate
tion, and react sensitively to the demands
by increasing or decreasing the transcrip-
tion and translation of their various com-
ponents. A number of PQC genes are con-
stitutively expressed at high level, e.g., the
Hsc70 and Hsp60 chaperones and protea-
some subunits; others are only expressed at
a very low level under physiological condi-
tions, but are strongly induced upon stresses
of the folding system. Furthermore, it is in-
creasingly recognized that additional factors
link the folding and degradation machiner-
ies together and help in tuning PQC to the
diverse demands (61). There may be tissue-
specific differences in the ability to elicit
the stress response and tune PQC, which
may explain the fact that variations in pro-
teins that are expressed in all tissues only
give rise to cellular dysfunction in certain
tissues.
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Figure 1.10. The several pathways of the protein homeostasis network. The PQC system constitutes the hub for the 
protein homeostasis network, managing the pool of unfolded and partially folded conformations, refolding misfolded 
proteins or removing them by degradation. Imbalances in proteostasis often lead to disease and, therefore, small-
molecule-based therapy (magenta and green circles) that manipulate the proteostasis pathways can ameliorate both 
loss- and gain-of-function diseases (explained below). (ribonuclease A is shown; Protein Data Bank ID, 2BLP). 
Adapted from Balch et al., 2008 (246). 
 
However, despite the multiple regulatory systems and the intrinsic ability of evolved 
protein sequences to avoid pathogenic pathways, many genetic disorders are a consequence of 
protein misfolding, aggregation and degradation (242, 244, 247). 
 
1.3.1.2. Protein misfolding underlies disease 
As previously mentioned, in order for a protein to carry out its specific function, it must 
fold and adopt its three-dimensional conformation (240, 241, 248). A missense mutation 
affecting a protein structure, stability and/or binding affinity may cause significant functional 
perturbations (248, 249). 
Protein stability is determined by many different factors, and the formation of hydrogen 
bonds is among the most important ones, as they are vital to many biological phenomena (248, 
250). Indeed, hydrogen bonds contribute to protein structural integrity and participate in the 
function of many macromolecules, such as molecular recognition and catalytic reactions (248, 
250). In fact, a mutation resulting in the removal or addition of a hydrogen donor or acceptor is 
Adapting Proteostasis for
Disease Intervention
William E. Balch,1 Richard I. Morimoto,2 Andrew Dillin,3 Jeffery W. Kelly4*
The protein components of eukaryotic cells face acute and chronic challenges to their integrity.
Eukaryotic protein homeostasis, or proteostasis, enables healthy cell and organismal development
and aging and protects against disease. Here, we describe the proteostasis network, a set of
interacting activities that maintain the health of proteome and the organism. Deficiencies in
proteostasis lead to many metabolic, oncological, neurodegenerative, and cardiovascular disorders.
Small-molecule or biological proteostasis regulators that manipulate the concentration,
conformation, quaternary structure, and/or the location of protein(s) have the potential to
ameliorate some of the most challenging diseases of our era.
Proteostasis refers to controlling the con-centration, conformation, binding interac-tions (quaternary structure), and location
of individual proteins making up the proteome
by readapting the innate biology of the cell, often
through transcriptional and translational changes
(Fig. 1). Proteostasis thus influences specific cel-
lular functions and enables differentiated cells to
change their physiology for successful organis-
mal development and aging in the face of con-
stant intrinsic and environmental challenges to
prevent disease onset. Proteostasis is influenced
by the chemistry of protein folding/misfolding
and by numerous regulated networks of interact-
ing and competing biological pathways (Fig. 1)
that influence protein synthesis, folding, traffick-
ing, disaggregation, and degradation (1–8). Here-
in, we examine a growing body of evidence
suggesting that adapting the cellular proteo-
stasis network by using “proteostasis regula-
tors” (Fig. 1) can partially correct proteostatic
deficiencies that contribute to a broad range of
human diseases, some that present at birth, but
most upon aging.
Proteostasis Maintenance During
Development and Aging
The competition between cellular protein fold-
ing and degradation, often referred to as protein
quality control, is one of many processes in-
fluencing proteostasis. The additional compo-
nents of the proteostasis network (Fig. 1) are in
place to achieve proteome maintenance with
alternatives in addition to degradation. Protein
folding in vivo is accomplished through inter-
actions between the folding polypeptide chain
and macromolecular cellular components, in-
cluding multiple classes of chaperones and
folding enzymes—interactions that minimize
aggregation (Fig. 2) (3). Metabolic enzymes
also influence cellular protein folding efficiency
because the organic and inorganic solutes
produced by a given compartment affect poly-
peptide chain solvation through noncovalent
forces, including the hydrophobic effect, that
influences the physical chemistry of folding.
Metabolic pathways also produce small-molecule
ligands that can bind to and stabilize the folded
state of a specific protein(s), enhancing folding
by shifting folding equilibria (9, 10). Whether a
given protein folds in a certain cell type depends
on the distribution, concentration, and subcel-
lular localization of chaperones, folding en-
zymes, metabolites, and the like (3).
Temporal cellular proteostasis adaptation is
necessary as a result of the presence of an ever-
changing proteome during development and the
presence of new proteins and the accumulation
of misfolded proteins upon aging. Because the
fidelity of the proteome is challenged during
development and aging, and by exposure to path-
ogens that demand high protein folding and
trafficking capacity, cells use stress sensors and
inducible pathways to respond to a loss of pro-
teostatic control. These include the heat shock
response (HSR) (11) that regulates cytoplasmic
proteostasis and the unfolded protein response
(UPR) (2, 12) that helps maintain exocytic
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expected to have a significant impact on the structural integrity, particularly if the affected 
residue is important for the active site structural and/or functional integrity (248). Furthermore, 
by disrupting native hydrogen bonds, many missense mutations destabilize the local structure and 
thus expose the hydrophobic core of the protein to the water phase, which often triggers 
aggregation (248). The majority of missense mutations destabilize the corresponding protein, 
such as in PKU, in which phenylalanine hydroxylase (PAH) destabilization due to missense 
mutations has been considered the major determinant of disease (248, 251). 
Despite being fundamental for a protein biological process, protein stability is, however, 
not sufficient to ensure functional integrity of a particular protein. In fact, proteins are not 
necessarily optimized to maximize their stability, and their functional regions may be 
energetically unfavorable. It is widely accepted that active site construction is thermodynamically 
unfavorable, and, accordingly, many active site mutations – particularly the removal of key 
catalytic residues – dramatically stabilize enzymes at the expense of activity (248, 252). 
Mutations of functionally important residues often result in more stable structures, especially 
when the substitutions occur in polar and charged residues, whereas mutations occurring at the 
protein surface display less effects on stability (248, 252). 
Furthermore, proteins are dynamic molecules in constant motion that can adopt different 
conformations along the pathway of the corresponding biochemical reaction. The intrinsic 
flexibility that proteins exhibit provides the ability to sample alternative conformations, and is 
thus crucial for proteins biological processes (248, 253). Missense mutations can affect the 
structural flexibility of the entire protein or just a small region, and can either shift the 
equilibrium between different conformations or can affect the entire conformational dynamics of 
the molecule (248). 
Several factors influence the impact of a mutation, namely the type of substituted amino 
acid and its location, structural environment of the affected site, and protein structural class and 
flexibility; all these factors should be considered when evaluating the effect of a mutation (248). 
Many efforts have been made to develop in silico tools that can accurately predict the 
effect of a mutation on a particular protein (248). According to the approach used, three groups of 
bioinformatics tools can be distinguished: 
i) programs that are based on different types of data relevant to protein stability and, in 
some cases, take into account experimental conditions such as temperature, salt 
concentration and pH values, which are important parameters for assessing the free-
energy changes upon mutations at near physiological conditions; 
ii) programs that are based on the evolutionary conservation data, and consider that changes 
occurring at conserved positions tend to be deleterious – despite not directly predicting 
the effect of a mutation on protein stability, these programs are typically used in 
conjunction with the first group to achieve consensus predictions; 
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iii) programs that are based on structural information and assume the ability of a protein to 
function properly depends on the fundamental physicochemical properties derived 
exclusively from structures (248). 
Bioinformatics tools belonging to the first category of servers include programs that 
incorporate different physicochemical properties of amino acids and structural preferences of 
different sites and are trained on the experimental differences of folding free energy caused by 
mutations; I-Mutant2.0, which uses support vector machines (SVMs) and makes predictions 
based on either structure or sequence alone and predict actual values of the free energy change 
(ΔΔG); MuPro, which uses SVMs leveraging both sequence and structural information; MuStab, 
which predicts only the deleterious effects of mutations and ΔΔG values; PoPMuSiC-2.0, which 
uses a combination of statistical potential and neural networks to estimate the changes in 
stability, and exploits statistical potentials that take into account the coupling between four 
protein sequence and structure descriptors and the amino acid volume variation upon mutation 
(248, 254-258). 
Bioinformatic tools belonging to the second category of servers include programs such as 
SIFT (Sorting Intolerant From Tolerant), which scores the normalized probabilities for all 
possible substitutions for a site and calculates the conditional probability that an amino acid is 
tolerated compared to the most frequent tolerated amino acid; PolyPhen (polymorphism 
phenotyping), which predicts damaging amino acid substitutions using sequence-based and 
structure-based features such as sequence conservation, structure and a position-specific 
independent count matrix derived from the multiple sequence alignment; PolyPhen-2, which uses 
8 sequence-based predictive features, 3 structure-based predictive features and a Naive Bayes 
classifier to predict the functional significance of the mutation (248, 259-261). 
Bioinformatic tools belonging to the third category include CUPSAT (Cologne 
University Protein Stability Analysis Tool), which uses structural environment-specific atom 
potentials and torsion angle potentials to predict ΔΔG; SDM (Site-Directed Mutator), which uses 
a statistical potential energy function; FoldX, which uses empirically derived energy functions 
that are quite accurate since they are based on experimental data (248, 262-265). 
Due to the high frequency of missense mutations, a comprehensive understanding of their 
pathogenic mechanisms elucidates the physicochemical features of protein folding, sheds light on 
the molecular and biochemical basis of several disorders, and thus constitutes the starting point 
for the development of therapeutic strategies (239, 248).  
 
1.3.1.3. Conformational disorders 
The term ‘conformational disorders’ was originally coined to describe diseases 
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characterized by the appearance of alternatively folded forms that produced toxic aggregates 
(231, 266). However, the term has evolved and has been broadened to include all protein 
misfolding diseases (230, 231, 244). 
Conformational disorders are typically caused by mutations that result either in a loss-of-
function – in which the protein is prematurely eliminated by proteases, leading to a reduction in 
its level and/or activity – or in a gain-of-function – in which the protein is not eliminated, but 
rather accumulated, leading to an increase in its level and/or activity, along with the introduction 
of a novel pathological function often associated with activation of a pathway (Figure 1.11) (244, 
267). While the second type of disorders is usually seen in dominantly inherited disorders, such 
as late-onset neurodegenerative diseases, the first one is typical of recessively inherited disorders, 
such as early-onset inborn errors of metabolism (230-233, 244, 267, 268). 
The hallmarks of protein folding deficiencies are prolonged interaction with chaperones, 
decreased steady-state amounts of the affected protein and the occurrence of aggregates (231). 
On this basis, the therapeutic strategy for these disorders must be to stabilize, in the soluble state, 
the folding intermediates and target them for further folding instead of degradation and/or 
aggregation, notwithstanding their pathogenic mechanism (Figure 1.11) (235). Indeed, the 
conception framework of protein misfolding diseases comprising loss-of-function and gain-of-
function pathogenic mechanisms is a practical one in the process of understanding the 
biochemistry and cell biology as well as in developing strategies for treating these diseases (244). 
 
 
Figure 1.11. Protein misfolding in conformational disorders. Conformational disorders are typically caused by 
mutations that result either in loss-of-function, characterized by absence biological activity of the folded protein, or in 
gain-of-function, characterized by a gain of toxic activity by the misfolded protein. Reproduced from Soto, 2001 (268). 
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1.3.1.4. Therapeutic strategies in loss-of-function diseases 
Many examples of conformational disorders in IMD have been described in which the 
main effect of the mutation is loss-of-function. The pathogenic effect of the mutant variant 
usually results from insufficiency of a metabolic or transport reaction and from the toxic effects 
of an accumulated substrate (231, 244). 
Many IMD have been described as conformational disorders, as they major pathogenic 
mechanism is protein misfolding (231). PKU is considered a paradigm of misfolding metabolic 
diseases, since several reports substantiate that mutations in the PAH gene lead to PAH 
misfolding, increased degradation turnover and to a loss of enzymatic function; and, accordingly, 
it is believed that PKU presents a high potential for the development of therapeutic approaches 
using chaperone-based strategy (242, 251). 
Over the last few years, molecular medicine has been exploring the usage of chemical 
and pharmacological chaperones – so-called small-molecules – in conformational disorders as a 
mean to improve the folding process, thereby ameliorating the clinical picture of these disorders 
(231, 242). 
Chemical chaperones refer to small molecules that act unspecifically – do not bind 
directly to proteins – and instead act by increasing the fraction of the correctly folded variant 
(242). Chemical chaperones include osmolytes and protein stabilizers (e.g., glycerol, trehalose, 
gama-aminobutyric acid) (242, 269). In turn, the term pharmacological chaperone is used to refer 
small molecules that bind reversibly and weakly to a specific protein, thereby promoting its 
folding and function. This group is more heterogeneous as it comprises protein cofactors, ligands 
and competitive inhibitors, among others (242). 
In the context of disease-related protein misfolding, the term “chemical chaperone” can 
be used to refer to the generality of these compounds. Actually, when a pharmacological 
chaperone – e.g., ligand or cofactor – binds to the protein and favors its native conformation, in 
practice, it is exerting a chemical chaperoning effect (242). 
Chemical chaperones bind to and stabilize the folded functional form of a mutant protein, 
thereby shifting the folding equilibria away from degradation and aggregation (246). Indeed, 
chemical chaperones intervene in different cell compartments, at different stages of the protein 
folding process: i) by directing the folding pathways avoiding dead-end intermediate states; ii) by 
acting directly over the native conformation, stabilizing it and preventing aggregation; or iii) by 
promoting refolding of misfolded or destabilized variants (Figure 1.10) (242, 246). Chemical 
chaperoning increases the concentration and proper localization of the protein by coupling more 
of the folded state to the trafficking pathway, a pathway that strongly influences proteostasis 
(246). 
Since the fate of the variant proteins is primarily guided by their physicochemical 
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properties, such as hydrophobicity and amino acid charges, a comprehensive characterization of 
mutational effects on protein stability and dynamics, and their role in enzyme loss-of-function in 
conformational diseases is crucial for the development of new therapeutic strategies (235, 270). 
 
1.3.2. Pathogenic molecular mechanisms of genetic disorders – splicing spoilers 
Splicing constitutes a critical process in the regulation of gene expression, and is a major 
contributor to proteomic diversity, as most genes express more than one mRNA by alternative 
splicing (234, 271-273). Actually, it is now estimated that more than 90% of the human genes 
with multiple exons have alternatively spliced mRNA isoforms, and that nearly 86% undergo 
alternative splicing to generate appreciable levels of two or more mRNA isoforms (274). 
Pre-mRNA splicing must, therefore, be a tightly regulated process, so that it can occur 
with high efficiency and fidelity in order to maximize gene expression and to avoid the 
production of aberrant proteins (275). Indeed, any splicing errors will result in a disconnection 
between the coding gene and its encoded protein product, and can lead to a wide range of 
diseases (272, 273, 275, 276). 
 
1.3.2.1. Pre-mRNA splicing reaction 
Accurate pre-mRNA splicing requires exon–intron boundaries to be correctly recognized 
by the splicing machinery, for the introns to be correctly excised, and for the exons to be 
precisely joined so as to generate functional mature mRNA (271, 277). Paradoxically, the 
requirement for accurate splicing depends on several degenerate splicing signals weakly 
conserved intronic cis-elements: the 5’ and 3’ splice sites – almost invariant GT and AG 
dinucleotides, respectively – the branch site (YNYURAY; underlined A represents the branch 
point) located approximately 15-35 bases upstream the 3’ splice site, and the polypyrimidine tract 
(Figure 1.12) (274, 277). Nevertheless, these elements are necessary but are by no means 
sufficient to define exon–intron boundaries (273). Additionally, there are auxiliary cis-elements 
known as splicing-regulatory elements (SREs) that recruit proteins and complexes that can either 
enhance or silence splicing and have been named descriptively: exonic and intronic splicing 
enhancers (ESEs and ISEs), and exonic and intronic splicing silencers (ESSs and ISSs) (273, 
278).  
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Figure 1.12. Splicing reaction and essential splicing signals. There are several weakly conserved intronic cis-
elements that constitute essential splicing signals, namely the 5’ splice site (GT or GU), the 3’ splice site (AG), the 
branch site comprising the branch point (A), and the polypyrimidine tract (Pyn). Splicing takes places in two 
transesterification steps. In the first step, the 2'-hydroxyl group of the A nucleotide at the branch site attacks the 
phosphate at the donor splice site, which leads to cleavage of the 5′ exon from the intron and to the formation of a lariat 
intermediate. In the second step, the phosphate group (p) at the acceptor splice site and the 3′-hydroxyl group of the 
detached exon ligates the two exons, thus releasing the intron, still in the form of a lariat. Reproduced from Pagani and 
Baralle, 2004 (279). 
 
The best characterized SREs are ESEs, which are required for definition and/or efficient 
splicing of the exons in which they reside, and, in fact, appear to be extremely frequent both in 
alternative and in constitutive exons (273, 278, 280). ESEs elements stimulate splicing and 
increase exon inclusion, by serving as binding sites for splicing factors, mainly serine/arginine-
rich proteins – SR proteins. SR proteins are a family of non-small nuclear ribonucleoproteins 
(non-snRNPs) essential for splicing that act at multiple steps of spliceosome assembly and 
function in both constitutive and regulated splicing (Figure 1.13.A) (278, 281). The sequence 
characteristics that define SR proteins are the presence of an arginine/serine (RS) domain – 
composed of at least 50 amino acids with >40% of arginine and serine; and one or more RNA-
binding domains of the RNA recognition motif (RRM) type (278). 
On the other hand, ESSs suppress the removal of adjacent introns and/or lead to exon 
skipping, and their silencer activities are usually mediated through binding of members from the 
heterogeneous nuclear ribonucleoprotein (hnRNP) family (273, 281-285). 
Unlike SR proteins, the mechanism whereby hnRNPs interfere with splicing is known 
only for a small number of cases. These include repressing assembly of components of the 
splicing machinery through multimerization along exons, blocking the recruitment of small 
nuclear ribonucleoprotein (snRNPs), or by looping out entire exons (Figure 1.13.B) (278). 
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Figure 1.13. ESEs and ESSs elements. A. The ESEs elements stimulate splicing and increase exon inclusion, by 
serving as binding sites for mainly SR proteins. SR proteins interact with components of the general splicing 
machinery, such as U1 and U2 snRNPs (small nuclear ribonucleoproteins), which interact with the 5’ splice site (GT or 
GU) and the 3’ splice site (AG), respectively, thus promoting their recognition (further explained below). B. The ESSs 
elements repress splicing by serving as binding sites for mainly hnRNPs, whose mechanisms of action include 
repressing assembly of components of the splicing machinery and blocking the recruitment of snRNPs. Reproduced 
from Busch and Hertel, 2012 (278). 
  
The splicing reaction is carried out by the spliceosome, which performs the two primary 
functions of splicing: recognition of the intron-exon boundaries and catalysis of the cut-and-paste 
reactions that remove introns and join exons (234). 
Spliceosomes do not form a preassembled complex as most ribonucleoprotein (RNP) 
machines. Rather, their assembly onto pre-mRNA is an ordered process with several distinct 
intermediates (271, 286). The spliceosome is made up of snRNPs, comprising five small nuclear 
RNAs (snRNAs) – U1, U2, U4, U5, or U6 snRNA – and more than 300 proteins (234, 278, 287, 
288). The U1 and U2 snRNPs form separate particles that bind, respectively, the 5’ splice site 
and the 3’ splice site, whereas the U4, U5 and U6 components join together in the U4/U6.U5 tri-
snRNP (234, 287, 289). Spliceosome assembly initiates with the binding of the U1 snRNP to the 
5’ splice site and of the branch point bridging protein (BBP) to the branch site. In an ATP-
dependent reaction, U2 snRNP subsequently displaces BBP and binds to the branch site, forming 
a complex that serves as a platform for the assembly of U4/U6.U5 tri-snRNP; the subsequent 
release of U1 and U4 results in the formation of the catalytically active complex, and the splicing 
reaction takes place (Figure 1.14) (287, 289). 
 
WIREs RNA Evolution of SR protein and hnRNP
The Function of SR Proteins in Regulating
Pre-mRNA Splicing
SR proteins are involved in recruiting the splicing
machinery to splice sites.11,41 It has been proposed
that the RS domain of an ESE bound SR protein
interacts directly with the RS domain of other splic-
ing factors, thereby facilitating the recruitment of
spliceosomal components such as U1 snRNP to the
5′ splice site or U2AF to the 3′ splice site.41 Thus,
SR proteins bound to ESEs function as general activa-
tors of exon definition42 (Figure 2). Interestingly, SR
protein-binding sites are present not only within alter-
natively spliced exons, but also within constitutively
spliced exons.43 It is therefore likely that SR proteins
bind to sequences found in most exons. In sum-
mary, SR proteins bound to ESEs activate constitutive
and alternative splice sites by recruiting spliceoso-
mal components to the pre-mRNA to enhance exon
recognition.
Typically, SR protein and hnRNP binding sites
are present within the vicinity of exon/intron junc-
tions, suggesting that the interplay between activation
and repression modulates the probability of exon
inclusion. In vitro studies showed that the location
and frequency of SR proteins or hnRNPs along the
pre-mRNA alter their effectiveness. For example, as
the distance between enhancer complexes and the
splice site increased, the probability of exon inclusion
decreased.44 Increasing the number of SR protein-
binding sites lessened this effect, supporting the notion
that their activity depends on their context within the
pre-mRNA molecule.45,46
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FIGURE 2 | Exon-dependent splicing activation by serine/arginine
(SR) proteins. Exon bound SR proteins interact with components of the
general splicing machinery via arginine/serine (RS)/RS domain
interactions. SR protein interactions with U2 snRNP auxiliary factor
(U2AF) 35 (yellow) and U1 snRNP (blue) are indicated to facilitate 3′
splice site (U2AF) or 5′ splice site (U1 snRNP) recognition. The splice
junctions are indicated by AG and GU.
The Frequency of SR Proteins in Eukaryotes
The intron density among eukaryotic genomes varies
dramatically. For example, most human genes are
interrupted by intervening sequences with an average
of more than eight introns/gene.47 By contrast, only
∼4% of Schizosaccharomyces cerevisiae genes har-
bor introns, most of which are single intron genes.
While the origin of ‘split genes’ is still debated, it
is well accepted that the complexity of alternative
splicing increased with multicellular complexity.47,48
Because SR proteins have functionally been associ-
ated with the regulation of alternative splicing, it may
be anticipated that the number of SR protein fam-
ily members increases with more complex alternative
splicing. As illustrated in Table 1, this is exactly the
case. While only two SR proteins are found in the fun-
gus Schizosaccharomyces pombe, multiple SR proteins
are expressed in plants and metazoans. Interestingly,
the largest number of SR proteins is identified in the
plant Arabidopsis thaliana, which is known to sup-
port extensive alternative splicing. However, classical
SR proteins are missing from S. cerevisiae, which also
lacks alternative splicing. Instead, three SR-like pro-
teins have been identified in S. cerevisiae, one of which,
Npl3, has been shown to modulate the efficiency of
pre-mRNA splicing.49 In general, the species-specific
presence of SR family proteins correlates with the
presence of RS domains within other components of
the general splicing machinery allowing interaction
between them.
To demonstrate the significance of the observed
expansion within the family of SR proteins, it is useful
to compare the conservation of splicing factors asso-
ciated with the general splicing machinery. The five
snRNPs U1, U2, U4, U5, and U6 make up the core of
the spliceosome. Each snRNP is assembledwith a com-
mon set of Sm proteins and additional proteins unique
to each snRNP.Homologs of the vast majority of these
spliceosomal core proteins are present throughout all
eukaryotes (Table 2), demonstrating that the splicing
machinery itself is highly conserved and that the pres-
ence of the snRNPs and their associated components
is essential to support intron removal.
The Evolutionary Origin of SR Proteins
A phylogenetic tree analysis of the 12 human SR
proteins indicates the presence of 6 families, 1 of
which consists of 3 closely related SR protein members
(Figure 3). These families are largely conserved among
higher eukaryotes as illustrated by a species-specific
tree comparison (Figure 4). Based on amino acid
sequence alignments among several eukaryotic species
it was suggested that successive gene duplications
Volume 3, January/February 2012 © 2011 John Wiley & Sons, Ltd. 3
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The Function of hnRNP Proteins
in Regulating Pre-mRNA Splicing
Like SR proteins, hnRNP proteins direct their influ-
ence on pre-mRNA splicing through site-specific bind-
ing with the target RNA. This binding is supported by
the RRM or the KH domains present in hnRNP pro-
teins. After binding, the business end of hnRNPs (RGG
boxes, glycine-rich, acidic or, proline-rich domains)
then promotes protein/protein interactions that ulti-
mately mediate splicing decisions. Unlike SR pro-
teins, the mechanism through which hnRNPs interfere
with splicing is known only for a small number of
cases. These include repressing spliceosomal assem-
bly through multimerization long xons,67 blocking
the recruitment of snRNPs,68,69 or by looping out
entire exons70 (Figure 5). Clouding our mechanistic
understanding of hnRNP action is the fact that some
hnRNPs can repress or activate exon recognition
depending on their location relative to the regu-
lated splice site. Clearly, additional functional work
needs to b carried out to derive the common mecha-
nisms employed by hnRNPs in modulating alternative
splicing.
Over the last years it has become increasingly
clear that exon selection is influenced by a num-
ber of activating and inhibitory elements. Given the
divergent sequences a d archit cture of eukaryotic
gene , every exon is exp cted to have a specific set
of identity elements that permit its recognition by the
spliceosome. Each exon is flanked by a unique pair
of splice site signals and contains a unique group of
SR and hnRNP protein-binding sites. The sum of con-
tributions from these SR and hnRNP pr tein-binding
sit s ultimately defi es the overall recog ition poten-
tial of an exon or the overall binding affinity for the
spliceosome.24
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FIGURE 5 | Exon-dependent splicing repression by heterogeneous
nuclear ribonucleoprotein (hnRNP) proteins. Exon bou d hnRNP
proteins interfere ith the association of the general splicing machinery
with the pre-mRNA. AG and GU indicate the splice junctions.
The Frequency and Evolution of hnRNP
Proteins in Eukaryotes
The difference in hnRNP abundance between
unicellular and multicellular organisms is more
striking than that observed for SR proteins as the
number of families and family members is higher in
multicellular organisms (Table 3). These observations
suggest that hnRNP genes were either subjected to
more duplication events, or that different selective
pressures existed for duplicated hnRNP genes.
Ultimately this results in a higher degree of functional
hnRNP diversification. As was observed for SR
proteins, only one clear hnRNP homolog is detected
in S. pombe (Musashi). This hnRNP is conserved
across most eukaryotes (Table 3); however, it is
apparently missing in A. thaliana. Another interesting
difference between the nature of hnRNP and SR
protein expansion is the fact that A. thaliana hosts
the most plentiful SR protein ensemble while only
a limited number of hnRNPs are detected (compare
Tables 1 and 3). It is possible that these differences
may reflect properties of how alternative pre-mRNA
splicing is achieved in each species. Clear homologs of
the hnRNP family are missing in S. cerevisiae. Instead,
S. cerevisiae expresses Hrp1, an hnRNP-like protein
involved in 3′ end processing that correlates with the
expression of the SR-like Npl3.71 Thus, a distantly
related gene exists in S. cerevisiae. However, it is
unclear whether it originated from the ancestral gene
that gave birth to the hnRNP protein family.
The phylogenetic tree analysis of the human
hnRNP proteins indicates the presence of 13 fam-
ilies consisting of multiple closely related hnRNP
members (Figure 6). The members of each family are
most closely related among higher eukaryotes as illus-
trated by a species-specific tree comparison (Figure 7).
hnRNP family diversity appears to have derived from
successive gene duplication events. For example, it
was shown that the intron/exon architecture of the
hnRNP A2 gene is near identical to that of hnRNP
A1, in agreement with the ‘common origin by gene
duplication’ model.72 Similar arguments can be made
for the other hnRNP families. If Hpr1 in S. cerevisiae
is considered a relative of the hnRNP family, it can be
argued that hnRNPs are ancestral to eukaryotes just
like SR proteins are. As pre-mRNA splicing diversi-
fied in multicellular organisms to include more and
more complex alternative splicing patterns, a striking
expansion of hnRNPswas promoted. By contrast, sim-
plification of pre-mRNA splicing may have resulted in
the loss of hnRNP diversity.
Why are there significantly more hnRNP mem-
bers in humans compared to the number of human SR
protein members? As mentioned above, the human
Volume 3, January/February 2012 © 2011 John Wiley & Sons, Ltd. 7
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Figure 1.14. Spliceosome assembly. The spliceosome assembles onto pre-mRNA in an ordered process with several 
distinct intermediates. Spliceosome assembly initiates with the binding of the U1 snRNP to the 5’ splice site and of the 
branch point bridging protein (BBP) to the branch site; U2 snRNP subsequently displaces BBP and binds to the branch 
site, forming a complex that serves as a platform for the assembly of the U4/U6.U5 tri-snRNP. The subsequent release 
of U1 and U4 results in the formation of the catalytically active complex, and the splicing reaction takes place. 
Reproduced from Kornblihtt et al., 2013 (290). 
 
The spliceosome plays an extremely important role in the splicing process, as it must 
identify bona fide exons, ignore pseudoexons (sequences that resemble an exon, both in size and 
in the presence of flanking splice-site sequences, but that should never be recognized as an exon 
by the splicing machinery), join contiguous exons without inadvertent skipping and appropriately 
regulate alternative splicing to meet the physiological requirements of cells and tissues (273, 
291). These challenges are met by combinations of cis-regulatory elements and trans-acting 
factors that constitute what is now recognized as the splicing code (291-293). 
Extensive efforts have been made to decipher the splicing code (291-293). Whereas the 
consensus splice sites were relatively easy to identify from alignments of exon–intron boundary 
sequences, the remainder of the code – particularly exon definition – remains to be fully 
elucidated (291). Nevertheless, at present, it is well-known that exon definition is accomplished 
by the accumulated recognition of multiple weak signals, as each exon has a specific set of 
identity elements – a unique pair of splice site signals and a unique group of SR proteins and 
hnRNPs binding sites – that ultimately define its overall recognition potential and the overall 
binding affinity for the spliceosome (234, 278). 
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Deciphering the splicing code is of paramount importance, as it would allow predicting 
the splicing pattern(s) in a developmental and cell-type-specific way uniquely from sequence 
inspection, and would, therefore, enable the reliable prediction of the effect(s) of a mutation (272, 
291-293).  
 
1.3.2.2. Splicing as a primary cause of disease 
Until recently, the effect of a mutation on gene expression was based exclusively on its 
location and it was assumed to affect only the coding potential: point mutations in coding regions 
were usually scored as missense, nonsense or translationally silent mutations, whereas mutations 
in non-coding regions would have to affect the classical consensus splice-site signals to be 
considered splicing mutations (234, 273). Furthermore, knowing that the primary effect of an 
exonic mutation is a splicing defect, rather than the predicted protein-coding mutation, is crucial 
for understanding the detailed pathogenic mechanism of a disease, since it is important to 
distinguish if, for instance, a mutation results in loss of expression due to aberrant splicing and/or 
degradation, or instead results in expression of a protein containing a missense mutation (291). In 
fact, until recently, mutation detection was accomplished primarily by genomic DNA analysis, in 
which deep intronic sequences were not scanned, and transcript analysis was rarely performed 
(294). 
In the recent years, however, there has been increasing evidence that both exonic and 
deep intronic mutations may affect splicing, which entails that many mutations might have been 
misclassified (273, 277, 294, 295). At present, splicing mutations represent 10% to 30% of the 
mutations reported to the Human Gene Mutation Database (HGMD® Professional 2013.1). 
These numbers are, however, probably underestimated, due to the misclassification of many 
mutations (296). 
As explained above, splicing is a highly intricate process that shows extraordinary 
structural and compositional dynamics, both crucial features for splicing fidelity and accuracy. It 
is therefore not surprising that disruption in any of the events involved in the pre-mRNA 
processing may lead to disease (297). 
Indeed, according to the mechanism whereby splicing defects result in a primary cause of 
disease, splicing mutations can be divided into two broad categories: i) mutations that disrupt a 
cis-acting element, in which a single gene is affected and in which the mutation can either lead to 
aberrant splicing or to aberrant regulation of splicing; ii) mutations that disrupt a trans-acting 
factor, in which multiple genes are affected, since the mutation will interfere with either a 
component of the splicing machinery or with the splicing regulatory complex (Figure 1.15) (234).  
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Figure 1.15. Molecular mechanisms whereby splicing defects lead to disease. Splicing mutations can be divided 
into two broad categories: cis- and trans-acting mutations. The first category includes cis-acting mutations, which alter 
the splicing of either a constitutive (A) or an alternative exon (B); this class constitutes the great majority of the 
splicing mutations. The second category includes trans-acting mutations, which can interfere with a component of the 
splicing machinery (C) or with the splicing regulatory complex (D). The distinction between cis- and trans- acting 
effects has important mechanistic implications, as effects in cis have a direct impact on the expression of only one 
gene, whereas effects in trans have the potential to affect the expression of multiple genes. Adapted from Faustino and 
Cooper, 2003 (234). 
 
The majority of splicing mutations are single nucleotide substitutions that affect cis-
acting elements. These mutations can result in exon skipping, retention of the mutated intron, 
usage of a cryptic 5’ or 3’ splice site, introduction of a new splice site within an exon or intron, or 
more rarely activation of a pre-existing cryptic splice site distal from the mutation. These 
mutations often cause a shift in the opening reading frame (ORF), which, in case of introduction 
of a premature termination codon (PTC) into the mRNA, usually triggers nonsense-mediated 
mRNA decay (NMD). The NMD is a post-transcriptional mechanism that, by eliminating 
abnormal transcripts that prematurely terminate translation, prevents the production of truncated 
proteins that could function in dominant-negative or other deleterious mechanisms (298). 
According to the established rule, transcripts with a PTC located more than 50-55 nucleotides 
upstream the next exon-exon junction are generally recognized as premature and elicit NMD 
(298, 299). This pathway, also known as mRNA surveillance mechanism, is an mRNA quality 
control system, particularly important in alternative splicing, as one-third of the resulting variant 
transcripts introduce PTCs and are degraded through NMD (291, 300). 
Effectively, it is estimated that one-third of disease-causing mutations may induce 
aberrant splicing of pre-mRNA transcripts and a partially overlapping third to PTCs and NMD; 
and, in some diseases, the estimates even go up to 50% and >70% for aberrant splicing and 
NMD, respectively (300).  
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1.3.2.3. The deleterious effect of point mutations on pre-mRNA splicing in IMD 
Several examples of cis-acting splicing mutations have been described for IMD, namely 
for organic acidemias, lysosomal disorders, congenital disorders of glycosylation, 
tetrahydrobiopterin deficiencies and fatty acid oxidation disorders (291, 294). Interestingly, in the 
fatty acid oxidation disorder resultant from deficiency in medium-chain acyl-CoA dehydrogenase 
(MCAD), one of the described missense mutations in the MCAD gene affects an ESE, which is 
inactivated, causing exon skipping, thus leading to disease (291). Additionally, a silent A→C 
polymorphism in the same exon located 11 nucleotides upstream from that ESE mutation 
modulates the severity of exon skipping, since the C variant inactivates an adjacent ESS, thereby 
lessening the skipping of the exon (291). This particular example reiterates the importance of 
exonic mutations in splicing defects, as it illustrates the complexity of the splicing code and the 
difficulties we currently have in deciphering it, and thus reinforce the importance of decoding it 
(291).  
Indeed, in order to design a therapeutic strategy, it is crucial to know the molecular 
mechanism whereby a genetic variation affects splicing. Given the impossibility to do so directly 
from the genomic sequence, several methodologies were developed to aid in the elucidation of 
the role of a genetic variation in the pre-mRNA processing. 
The most direct approach to determine how a genetic variation is affecting splicing is to 
perform a reverse transcription PCR (RT-PCR) analysis from the relevant tissue(s) of affected 
individuals (301). However, obtaining RNA from the disease-relevant tissues is frequently a 
major limitation; and, even if an RNA sample from the affected tissue is available, the detection 
of a particular splicing product is not straightforward, as aberrant transcripts are often degraded 
by NMD, thereby precluding their detection by normal RNA analysis (291). This problem of 
degradation can be solved by establishing stable cell lines from the patient lymphoblasts and 
treating them with NMD inhibitors, such as puromycin and cycloheximide, and then evaluate the 
transcription profile (294, 302, 303). 
An alternative approach is to use minigene-based technologies (276, 301). Initially 
described 20 years ago, minigenes constitute a relatively fast approach to identify splicing 
spoilers and to study their underlying functional mechanisms (276). In this methodology, the 
relevant genomic segment is cloned into a plasmid between an upstream ubiquitous 
transcriptional promoter and a downstream gene segment necessary for mRNA 3’ end formation. 
The plasmid is transfected into mammalian cells, and the transcription pattern is analyzed by RT-
PCR with primers specifically designed to amplify processed transcripts derived from the 
minigene, to distinguish them from the cell endogenous transcripts (279, 280, 301). In addition to 
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their utility for analyzing the effects of mutations and allelic variants on splicing efficiency, 
minigenes have been a mainstay of investigations to identify the cis-acting elements and trans-
acting factors that regulate tissue-specific alternative splicing (301). 
A third method is the in vitro splicing assay. In this procedure, labelled pre-formed RNA 
molecules that are transcribed with bacterial polymerases are incubated in the presence of nuclear 
extracts and the resulting spliced products are resolved on polyacrylamide denaturing gel. With 
this assay, the intermediates of the splicing reactions, such as the lariat, can be evaluated and 
more molecular mechanistic studies can be performed. However, in contrast to the minigene 
procedure, the in vitro assay only allows relatively short sequences to be studied, does not 
reproduce nuclear organization and architecture and, most importantly, does not take into account 
the fact that transcription and splicing are intimately connected in the cell (274, 279).  
A great boost for predicting the impact of nucleotide variations on splicing has been the 
development of in silico tools, which evaluate the many possible influences of a mutation on pre-
mRNA splicing (304, 305). Bioinformatic tools include programs such as Splice-Site Prediction 
by Neural Network (NNSplice) and Cryptic Splice Finder (CSF), which predict splice sites; 
ESEfinder and Relative Enhancer and Silencer Classification by Unanimous Enrichment 
(RESCUE-ESE), which predict ESEs; PESX, which detects Putative ESEs and ESSs; Human 
Splicing Finder (HSF), which predicts splicing enhancer and silencer motifs by different sets of 
algorithms; mfold, which predicts all possible optimal and suboptimal secondary structures of a 
particular mRNA sequence, and sfold, which predicts only the best mRNA secondary structure; 
and SpliceAid 2, which, besides the 5’ splice site, 3’ splice site, polypyrimidine tract and branch 
point, also evaluates tissue-specific and cell-specific expression of SREs and trans-acting factors 
(304, 306-318). The main problem that remains for any algorithm is the degree of certainty of the 
predictions in the identification of splicing defects (302). Indeed, bioinformatic tools per se lack 
of reliability, and none of the aforementioned programs is 100% conclusive or predictive. 
Nevertheless, in silico approaches can and should be used in predicting the effect of a genetic 
variation on the splicing process, but as an integrated part of the experimental approach (276, 
284, 302, 317, 319). 
Unraveling the pathogenic mechanism of a mis-splicing mutation is, indeed, the starting 
point for further research and for the development of therapeutic interventions, in which directly 
targeting RNA is an increasingly compelling therapeutic strategy (302, 320). 
 
1.3.2.4. Molecular approaches to splicing therapeutics  
The screening of mutations in individuals at the genome and transcriptome scales allows 
the design of different therapeutic strategies for mutation-specific, personalized medicine based 
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on how the mutations take their toll (300). 
Since the recognition of splicing as a primary cause of disease, several therapeutic 
strategies directed toward correcting or circumventing splicing abnormalities have arisen (234, 
320). Approaches include overexpression of proteins that alter splicing of the affected exon, use 
of oligonucleotides to block use of aberrant splice sites and force use of beneficial splice sites, 
use of small molecules that indirectly modulate splicing (e.g., by altering phosphorylation of 
splicing factors or by stabilizing putative secondary structures, high-throughput screens to 
identify compounds that influence splicing efficiencies of target pre-mRNAs, and a trans-splicing 
approach to replace mutated exons with wild-type exons (Figure 1.16) (234). 
 
 
Figure 1.16. Molecular approaches to splicing therapeutics. Therapeutic approaches can either alter the splicing 
patterns of target genes (panels a–d) or target specific splice variants at the RNA or protein level to achieve a 
therapeutic affect (panel e). a) Small-molecule-based therapy, in which small-molecules modulate the splicing patterns 
by, e.g., altering the SR proteins phosphorylation state. b,c) Antisense therapy, in which antisense oligonucleotides are 
used to block the access of splicing factors to either the splice sites or to other components of the splicing code (panel 
b), or to enhance splicing of the targeted exon (panel c). d) Trans-splicing or SmaRT (spliceosome-mediated RNA 
trans-splicing) approach is used to reprogram the mRNA expressed from mutated genes, by tethering exogenous RNA 
into the endogenous mutated pre-mRNA. e) Isoform-specific targeting, in which alternative or aberrant splicing is 
targeted through the recognition of specific mRNA or protein, by specific RNA interference- or antibodies-mediated 
degradation, respectively. As with all therapies, splicing-based approaches have issues with off-target effects, toxicity, 
efficiency and delivery. The potential applications are diverse; however, most applications are gene-specific and are 
therefore limited to specific diseases so they must be optimized for individual genes. Reproduced from Wang and 
Cooper, 2007 (291). 
 
Currently, the most widely used therapy toward correcting aberrant splicing is pre-
mRNA targeting anti-sense oligonucleotides (ASOs). ASOs are short synthetic, modified nucleic 
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(panel e). a | The use of small-molecule drug therapy is a particularly attr ctive approach to modifying splicing patterns 
because of th  relative ease of delivery and dosage con rol. Many chemical compounds have been found to affect the 
splicing of numerous genes67,98. Although the mechanisms by which splicing patterns are altered are unknown for most of 
these compounds, several of them affect splicing by altering the steady-state levels, phosphorylation state or intracellular 
distribution of SR proteins98. Molecules that alter the SR phosphorylation state are shown here as an example. SR proteins 
are phosphorylated by SR protein kinases (SRPKs) 1 and 2, DNA topoisomerase I (TOPO I), and a family of CDC2-like 
kinases (CLKs) and are dephosphorylated by protein phosphatase-1 (PP1)98. The phosphorylation status of SR proteins 
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that affect the ac iviti s f these enzym s can be used to alter splicing atterns. The lack o  sp cificity in this approach 
foreshadows a high potential for off-target effects; however, the recent development of splicing reporters with 
fluorogenic readouts allows for high-throughput screening for compounds with highly specific effects101,102.  
b,c | Antisense oligonucleotides that are modified to enhance stability and prevent RNase H-mediated degradation of the 
target RNA provide a gene-specific approach to altering splicing patterns using loss- or gain-of-function approaches103. 
In loss-of-function approaches (panel b), an oligonucleotide is used to block access of splicing factors to either the splice 
sites or other components of the splicing code, such as intronic and exonic splicing enhancer (ISE and ESE) and suppressor 
(ESS and ISS) elements. For example, a systematic analysis of overlapping antisense oligonucleotides that are 
complementary to the survival of motor neuron 2, centromeric (SMN2) gene exon identified oligonucleotides with 
dramatic positive or negative effects on exon inclusion, presumably by blocking ESE and ESS elements and/or secondary 
structures that are important for controlling the amount of exon inclusion104 . Oligonucleotides have been used to 
circumvent the inclusion of mutated exons to restore production of a truncated but functional protein. In an interesting 
twist to this approach, oligonucleotides have been used for a gain of splicing function (panel c). Bifunctional 
oligonucleotides that contain targeting (complementary) and effector domains can be created to enhance splicing of the 
targeted exon. In one case, a chimeric peptide nucleic acid molecule was made that contained arginine-serine (RS) 
peptides to mimic the functional domain of SR proteins bound to an ESE105. A different approach utilized an 
oligonucleotide that contained an ESE to serve as a binding site for SR proteins106. d | Trans-splicing is used to 
reprogramme the mRNA that is expressed from mutated genes. The most common approach is to express an exogenous 
pre-mRNA that contains a replacement wild-type sequence that is flanked upstream by a strong 3a splice site and a 
segment that is complementary to an intron located upstream of the mutation (indicated by a red cross) in the target  
pre-mRNA. The exogenous RNA is tethered to the endogenous pre-mRNA from the mutated allele, which positions the 
wild-type segment of the mRNA to be spliced in place of the mutant segment. This approach, dubbed SmaRT 
(spliceosome-mediated RNA trans-splicing) has been used successfully in cell culture and in mouse models of disease103. 
Non-spliceosomal trans-splicing approaches using group I ribozymes and a tRNA-splicing endonuclease from the 
archeon Methanococcus jannaschii have also been demonstrated in cell culture103. e | Alternative or aberrant splicing 
produces mRNAs that contain unique sequences and proteins with unique epitopes that can be targeted using RNAi-
mediated degradation or antibodies, respectively. These features can be utilized in cases in which removing one isoform is 
of benefit. As with all therapies, splicing-based approaches have issues with off-target effects, toxicity, efficiency and 
delivery. The potential applications are diverse; however, most applications are gene-specific and are therefore limited to 
specific diseases so they must be optimized for individual genes.
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acids that hybridize with the target mRNA and/or pre-mRNA through Watson-Crick base pairing 
and modulate its function (313, 321-323). 
ASO binding to the mRNA and/or pre-mRNA result in decreased levels of translation of 
the target transcript by various mechanisms, depending on the chemistry properties of the ASO 
and on the location of hybridization (313, 322). These mechanisms can be broadly categorized as 
i) degradative, in which the ASO promotes degradation of the RNA either through endogenous 
enzymes, such as RNase H, or through cleavage mechanisms designed into the oligonucleotide; 
and as ii) non-degradative, in which the ASO binding to the mRNA or pre-mRNA modulates 
RNA function without promoting its degradation, rather ASO binding either sterically hinders 
translation of the mRNA or modulates pre-mRNA processing (320-322, 324). Actually, masking 
a regulatory sequence in the pre-mRNA is possible by designing an ASO complementary to the 
pre-mRNA area of interest, in a way that the trans-splicing regulatory factors are unable to bind 
and changes in splicing occur (325, 326). The application of oligonucleotide-based methods to 
redirect and modulate pre-mRNA splicing was first demonstrated for β-thalassemia and now 
shows promise for both spinal muscular atrophy and Duchenne muscular dystrophy (267, 327). 
In order to be effective as therapeutics, ASOs must reach and selectively hybridize to the 
target RNA. This requires appropriate biodistribution of the ASO, efficient uptake, and a 
sufficient half-life within tissues (321). 
Unmodified ASOs are rapidly degraded in vivo by the endogenous nucleases and their 
overall charge prevent them from penetrating the plasmatic membrane, which confers them poor 
potency (313, 321). Accordingly, in order to obtain efficacious activity, it would be necessary to 
administer high doses of unmodified ASOs, which would increase the possibility of pernicious 
off-target effects, both through hybridization to non-targeted RNAs and through interactions with 
proteins (321). Therefore, various chemical modifications have been developed, aiming to 
enhance nuclease resistance, prolong tissue half-life, increase affinity and potency, and reduce 
non-sequence-specific toxicity (Figure 1.17) (313). 
The earliest and best characterized modified ASOs are the phosphorothioate (PS)-ASO, 
whose mechanism of action involves RNase H-mediated cleavage of target mRNA. The PS-
backbone modification, in which one of the non-bridging oxygen atoms in the phosphodiester 
bond is replaced by a sulphur atom, confers higher resistance to the ASOs against nuclease 
degradation, thereby improving their bioavailability (Figure 1.17) (313, 321). Indeed, the 
antisense effect of the PS-ASOs can be observed for over 48 hours after a single application to 
tissue culture cells (328). However, PS modification may slightly reduce the affinity of the ASOs 
for the mRNA target due to the fact that the melting temperature of the heteroduplex decreases by 
approximately 0.5 ºC per nucleotide. In addition, PS-ASOs have also been reported to produce 
non-sequence-specific toxicities because of their affinity to bind to proteins, e.g., serum albumin 
(313, 321, 322, 329). 
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Figure 1.17. Three generations of ASOs. Modifications to the sugar and/or the backbone of the nucleotide provide 
ASOs with different biophysical, biochemical and biological properties: phosphorothioate (PS) – first generation; 2’-
O-Methyl (2’-OMe) and 2’-O-(2’-methoxy)ethyl (2’-MOE) – second generation; peptide nucleic acid (PNA), 
phosphoroamidate morpholino oligomer (PMO) and locked nucleic acid (LNA) – third generation. Adapted from 
Kunze et al., 2010 (322). 
 
To further increase the binding affinity for target mRNA, second-generation ASOs with 
2’-alkyl modifications of the ribose were developed, of which 2’-O-Methyl (2’-OMe) and 2’-O-
(2’-methoxy)ethyl (2’-MOE) modifications of PS-ASOs are the two most widely studied (Figure 
1.17) (313, 322). Chemical modification of the 2’ position of the sugar moiety primarily 
increases binding affinity to target RNA, and so these ASOs show a slightly enhanced target 
affinity (321). Furthermore, 2’-OMe- or 2’-MOE-ASOs are less toxic than PS-ASOs, show an 
increased tissue half-life due to improved nuclease resistance, and present the potential for oral 
administration. Unexpectedly, 2’-OMe and 2’-MOE substitutions do not support RNase H-
mediated cleavage of target mRNA, which implies they can only exert antisense activity via 
inhibition of translation, thereby dampening their efficacy (313, 322, 329). To circumvent this 
shortcoming, a chimeric ASO was developed in which the central “gap” region consists of 
approximately ten PS-modified 2’-deoxynucleotides and in which each flank consists of 
approximately five 2’-OMe or 2’-MOE PS-modified nucleotides. This chimeric ‘gapmer’ ASO 
allows RNase H to sit in the central gap to execute target-specific mRNA degradation, while the 
flanks resist to nuclease cleavage due to the 2’-alkyl modifications (313, 321, 322). 
In the third generation of ASOs, further chemical modifications of the furanose ring were 
performed, conferring them enhanced target affinity and nuclease resistance. Of these ASOs, 
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peptide nucleic acid (PNA), phosphoroamidate morpholino oligomer (PMO) and locked nucleic 
acid (LNA) are the three most studied (Figure 1.17) (313). 
PNA is a non-charged nucleotide analogue, in which the phosphodiester backbone is 
replaced with a flexible pseudopeptide polymer (N-(2-aminoethyl)glycine) and nucleobases are 
attached to the backbone via methylene carbonyl linkage. PNA-ASOs hybridize complementary 
RNA with high affinity and specificity and exert the antisense effect by forming a sequence-
specific duplex with the target mRNA, causing steric hindrance of the translational machinery, 
thereby leading to protein knockdown (313). 
PMO chemistry involves the replacement of the ribose sugar with a six-membered 
morpholino ring and the charged phosphodiester intersubunit linkage is replaced by an uncharged 
phosphorodiamidate linkage. PMO does not allow RNase H-mediated cleavage, and so its 
antisense effect is primarily mediated by steric interference either at the splicing level or at the 
translational level (330). Regarding splicing modulation, binding of a PMO-ASO to a 5’ and/or 
3’ splice site in the pre-mRNA can cause the splicing machinery to effectively skip an entire 
exon, in order to induce removal of in-frame exons containing a missense, nonsense or frameshift 
mutation, thereby rescuing, at least partly, the protein function; or to skip a pseudoexon, by 
sterically blocking the access of the splicing machinery to the pseudoexonic regions, in order to 
force the usage of the natural splice sites, recovering normally spliced transcripts that encode the 
functional protein (294, 330-332). Regarding translational modulation, PMO-ASO binding to 
mRNA sterically hinders ribosomal assembly, thereby leading to translational arrest and thus to 
gene silencing (313). 
Both PNA and PMO chemical modifications confer them excellent resistance to 
nucleases and proteases, and, since their backbones are uncharged, their ASOs are unlikely to 
form unwanted interactions with nucleic acid-binding proteins (329, 333-336). 
LNA is a conformationally restricted nucleotide containing a methylene group linking the 
2’-O and 4’ position of the ribose. This chemistry serves to lock the furanose ring into the N-type 
sugar conformation (2’-O,4’-C-methylene-β-D-ribofuranosyl), thereby presenting a high 
hybridization affinity with RNA (337, 338). 
LNA-ASOs present a high hybridization affinity towards target RNA and the resultant 
duplexes are not substrates for RNase H (313, 334, 337, 339). Notwithstanding, LNA is 
compatible with PS linkages and with other monomers, e.g., DNA and RNA, whose chimeric 
ASOs can elicit RNase H-mediated mRNA cleavage (313, 337). There are, however, 
contradictory reports regarding the properties the chimeric sequence must exhibit in order to 
elicit RNase H activity, namely in the length of the sequence and in the modification pattern of 
the ASO (337). Nevertheless, the overall conclusion is that LNA-ASOs can indeed be designed to 
present a degradative mechanism of action through RNase H, and with the advantage of 
improved binding and target accessibility conferred by the LNA monomers (337, 339). 
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Moreover, LNA presents various properties that make it a promising molecule in the field 
of nucleic acid research, namely good aqueous solubility, high biological stability, low toxicity 
and, more importantly, outstanding mismatch discrimination (339). LNA charged phosphate 
backbone allows ready delivery into cells using standard cationic transfection agents; and studies 
in a mouse model for splicing modulation activity demonstrated that LNA-ASOs are nontoxic 
and that the sequence-specific antisense effects of a single-dose regimen of a LNA-ASO persists 
for more than 3 weeks (336). Furthermore, oral delivery of the unformulated LNA-ASO induced 
minimal but clearly detectable splice modulation in a sequence-specific manner in targeted pre-
mRNA (340). Moreover, in another study, LNA-ASOs were shown to be delivered to both liver 
and kidney of mice and non-human primates with remarkable efficacy following parenteral 
administration (341, 342). 
The recent developments in oligonucleotides chemistry have provided ASOs with 
different biophysical, biochemical and biological properties based on various modifications to the 
sugar or the backbone of the nucleotides, which greatly enhanced the drug-like properties of 
ASOs, allowing rational design of diverse and powerful antisense therapeutic tools with 
extensive clinical applications (321, 343). Nevertheless, there are still some challenges for ASOs 
to overcome in order to constitute an effective antisense therapeutic strategy: i) the efficiency 
with which the treatment corrects the splicing defect; ii) the off-target effects, i.e., the side-effects 
on splicing of pre-mRNAs other than the target; and iii) the effectiveness and long-lasting 
delivery to the target cells (267, 313, 320, 323). 
With the recent clinical success of several antisense-therapies, and establishment of 
proof-of-concept efficacy in several disease models, ASOs have established themselves as a 
promising and rapidly-developing therapeutic strategy covering a wide range of genetic 
disorders. With such dramatic improvements in antisense technology in a relatively short time 
frame, and with the current frenzied pace of antisense research, new and enhanced ASOs designs 
will likely be forthcoming and will facilitate their widespread application in the clinical realm 
(344).  
 
1.3.3. The future is now for rare genetic disorders (345) 
More than a decade after the first draft of the human genome sequence, the remarkable 
wealth of knowledge has profoundly affected our understanding of the human pathophysiology at 
a molecular level (345). Indeed, the growing knowledge of the human genome, epigenome, 
transcriptome, proteome and metabolome has led to development of many therapeutic strategies, 
in which not only clinical but especially molecular data are applied in the design of the 
appropriate drug for a particular person (346). In fact, treatment of genetic diseases is no longer 
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just disease-oriented, it is now stratified to fit the patient, the allele, and the process underlying 
the phenotype (347). 
Undoubtedly, the post-genomic era has begun, and with it the promise of tailoring the 
practice of medicine to the individual (348). 
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1.4. Objectives 
After more than 100 years since the first description of galactosemia, there are still many 
“clouds gathering over galactosemia”. Indeed, despite early diagnosis and lifelong dietary 
restriction of galactose resolving the potentially lethal symptoms of classic galactosemia, the 
long-term outcome is often disappointing with most patients developing complications in the 
long run.  
Advances in human genome research in the past decade have shifted the medicine’s 
paradigm of disease-oriented care into the new paradigm of patient-focused care. Indeed, with the 
post-genomic era, has arisen the concept of personalized medicine, in which functional genomic 
analyses provide important insights into the molecular pathogenesis of genetic disorders, thus 
identifying new treatment targets that guide in the design and development of new therapeutic 
approaches.  
Molecular studies in inherited metabolic disorders have led to the realization that only a 
minor part of the mutations directly disrupt functional sites of the proteins, as most genetic 
defects disturb the protein at its structural level, and/or disturb its synthesis by affecting the pre-
mRNA processing, ultimately affecting the protein at its cellular level. Hence, mutation-specific 
structural and functional analyses are of paramount importance for the development of new 
therapeutic approaches, as a better understanding of their underlying molecular mechanisms of 
pathogenesis opens new avenues of research, paving the path for the development of new 
therapeutic strategies to tackling inborn errors of metabolism. 
 
Accordingly, the aims of this study were: 
 
• Genotyping all Portuguese galactosemic patients, and displaying the mutational 
spectrum of classic galactosemia in Portugal; 
• Functional characterization of the highly prevalent intronic variation 
c.820+13A>G and its correction by antisense therapy; 
• Structural-functional characterization of the most prevalent GALT missense 
mutants, and of other clinically important missense mutants; 
• Development of a prokaryotic model of galactose sensitivity to evaluate the 
ability of human GALT variants in rescuing bacteria from galactose-induced 
toxicity; 
• Development of an unicellular model and of biophysical methodologies to 
characterize human GALT mutants and ultimately to guide in the development 
of new therapeutic agents in classic galactosemia. 
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2.1. Abstract 
Classic galactosemia is an autosomal recessive disorder caused by deficient activity of 
galactose-1-phosphate uridylyltransferase (GALT). Patients develop symptoms in the neonatal 
period, which can be ameliorated by dietary restriction of galactose. Nevertheless, many patients 
develop long-term complications, with a broad range of clinical symptoms with a poorly 
understood pathophysiology. The high allelic heterogeneity that characterizes this disorder is 
thought to play a determinant role in biochemical and clinical phenotypes. 
Herein, we aimed to characterize the mutational spectrum of GALT deficiency in 
Portugal and to assess potential genotype-phenotype correlations. 
Direct sequencing of the GALT gene and in silico analyses were employed to evaluate the 
impact of uncharacterized mutations upon GALT functionality. Molecular characterization of 42 
galactosemic Portuguese patients revealed a mutational spectrum comprising 14 nucleotide 
substitutions: 10 missense, 2 nonsense and 2 putative splicing mutations. Sixteen different 
genotypic combinations were detected, half of the patients being p.Q188R homozygotes. 
Notably, the second most frequent variation is a splicing mutation. In silico predictions 
complemented by a close-up on the mutations’ locations in the protein structure suggest that the 
uncharacterized missense mutations have cumulative point effects on protein stability, oligomeric 
state, or substrate binding. One splicing mutation is predicted to cause an alternative splicing 
event. This study reinforces the difficulty in establishing a genotype-phenotype correlation in 
classic galactosemia, a monogenic disease whose pathogenesis and clinical features suggest it is 
actually a complex disease. Indeed, classic galactosemia pathophysiological mechanisms result in 
a broad range of clinical outcomes, such as ovarian insufficiency and neurological dysfunction, 
and emphasize the need to expand the knowledge on this “cloudy” disorder. 
 
2.2. Introduction 
Classic galactosemia or type I galactosemia (OMIM #230400) is an inherited disorder  
of the galactose metabolism, caused by deficient activity of galactose-1-phosphate 
uridylyltransferase (GALT; EC 2.7.7.12), the second enzyme of the Leloir pathway. This 
condition is inherited in an autosomal recessive pattern and occurs with a pan-ethnic frequency of 
approximately 1:30,000 to 1:60,000 live births (1, 2).  
Generally asymptomatic at birth, infants born with classic galactosemia become ill within 
days-to-weeks after initiating breast milk or lactose-containing formula ingestion (1, 3). Initial 
symptoms include poor feeding, vomiting and diarrhea with poor weight gain progressing with 
liver failure, renal tubular disease, Escherichia coli sepsis, coma, and death (1). Life-long dietary 
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restriction of galactose, the current gold standard therapy, partially relieves or prevents these 
acute and potentially lethal symptoms. However, many patients go on to develop severe long-
term complications (4). 
The human GALT gene (GenBank Accession NG_009029.1) is located in chromosome 
9p13 and spans about 4 kb of DNA arranged in 11 exons (5, 6). The 1295 bp-long open reading 
frame is translated into a 379 amino acid polypeptide with an estimated molecular mass of 44 
kDa, the active enzyme being an 87 kDa homodimer (1).  
GALT belongs to the histidine triad family of transferases, displaying a double-
displacement or ping-pong mechanism (7). In the first half-reaction, UDP-glucose (UDP-Glc) 
enters the active site and binds covalently to a histidine in the active site (His186), and glucose-1-
phosphate (Glc-1-P) is released. In the second half-reaction, galactose-1-phosphate (Gal-1-P) 
enters the active site, and the enzyme-bound UMP is transferred to Gal-1-P, forming and 
releasing UDP-galactose (UDP-Gal) (1). 
Classic galactosemia is characterized by high allelic heterogeneity (8), and to date 264 
different variations have been described at the GALT locus (9, 10). Although a few of these 
mutations are relatively common, most are rare (1). Approximately 60% of the described 
variations are missense mutations, a common observation in genetic disorders (11). Additionally, 
19 silent (7.2%), 17 nonsense (6.4%), 17 small deletions (6.4%), 6 insertions (2.3%), 3 indel 
(1.1%), 2 large gene deletions (0.8%), 2 no-stop changes (0.8%) and 1 frameshift (0.4%) 
mutations have also been reported. Regarding non-coding regions, 14 splice site variations 
(5.3%) have been described. The remaining 18 variations are classified either as benign (16; 
6.1%) or as uncertain (2; 0.8%) (9).  
The most frequently observed mutations are p.Q188R, p.K285N, p.S135L and p.L195P 
(1, 12). The predominant mutation in galactosemic patients of European descent is p.Q188R, 
which accounts for about 64% of all GALT mutations (1, 12). The mutation reaches its highest 
frequency in Ireland, where it occurs at a relative allele frequency of 94% (13), and shows a 
South-Eastern declining gradient throughout Europe (14, 15). Homozygous patients bearing the 
p.Q188R mutation have essentially no residual GALT activity in red blood cells (RBC) and have 
been frequently associated with a poor outcome (15, 16). The p.K285N is the second most 
common European mutation, especially in the countries of Central and Eastern Europe where it 
can account for up to 34% of classic galactosemia cases (17). In homozygous patients, this 
mutation is associated with complete absence of GALT activity in RBC, representing a severe 
clinical phenotype (15, 16). The p.S135L mutation is found almost exclusively in individuals of 
African origin, accounting for approximately 91% of African GALT mutant alleles (18, 19). 
Notably, this mutation appears to exhibit some tissue specificity: homozygous patients have 
essentially no GALT activity in RBC, but present some low residual activity in leukocytes. 
Homozygosity for this mutation is often associated with mild clinical outcomes (1, 10, 20). 
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Besides these pathogenic mutations, several variants that do not result in galactosemia 
have also been reported and are named after the place of their discovery (21). The most common 
variant, Duarte or D2, has p.N314D mutation associated with three intronic substitutions and a 4-
nucleotide promoter deletion. The promoter deletion appears to decrease promoter function in 
appropriate constructs (22) and may thus account for the lower activity of the Duarte variant. The 
Los Angeles or D1 variant has the p.N314D and the c.652C→T (p.L218L) mutations, with 
neither the intronic substitutions nor the promoter deletion found in the Duarte variant, presenting 
a GALT activity slightly higher than the wild-type one. 
An essential question regarding classic galactosemia concerns the identification of 
predictive factors to distinguish patients who will thrive in the long run from those who will 
experience complications. Therefore, GALT genotyping may be a valuable prognostic tool 
providing information about the biochemical and clinical outcome (10), contributing to a more 
personalized and effective therapy (23). Considering the wide mutational spectrum observed 
throughout the world, as well as the broad range of functional consequences of the mutations, 
there is no doubt that molecular analysis contributes to a better understanding of Portuguese 
galactosemic population prognosis. 
Most recent studies on the molecular characterization of classic galactosemia in Portugal 
proposed p.Q188R to be the only frequent mutation in Portuguese patients, as the other variations 
were found in no more than two alleles (24). The aim of this study is to characterize the 
mutational spectrum of the GALT locus in a group of 42 Portuguese galactosemic patients, 
updating the current mutational spectrum. Moreover, an in silico strategy is herein employed to 
evaluate the impact of uncharacterized mutations upon GALT functionality. Finally, comparing 
the modeling data with phenotypic parameters presented by the patients, we assess potential 
genotype-phenotype correlations. 
 
2.3. Methods 
2.3.1. Patients 
Forty-two galactosemic Portuguese patients, encompassing four pairs of siblings, were 
investigated. The nineteen females (45%) and twenty-three males (55%) integrated in the study 
originated from all regions in Portugal, including Madeira and Azores Islands, thus being 
considered representative of the whole population. Diagnosis of patients from South/Center 
regions and Madeira Island was confirmed by absent or reduced (<5% of control mean) GALT 
activity in RBC. A positive Beutler test was used to confirm diagnosis of patients from North 
region and Azores Islands. A galactose-restricted diet was started upon disease suspicion. A 
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whole blood sample was collected from every patient in order to prepare RBC lysates for 
evaluation of GALT activity and to isolate nucleic acids for mutational analysis.  
This study was approved by the local Ethics Committees and informed consents were 
obtained from the patients or their parents, who were also enrolled in the study, whenever 
possible. 
 
2.3.2. GALT activity  
Patients’ GALT activity was determined by HPLC, according to a previously described 
method (25). Briefly, GALT activity was measured in RBC lysates using 40 mM Tris–HCl pH 
7.5, 40 µM DTT, 6 mM Gal-1-P, 125 mM glycine and 1.5 mM UDP-Glc. Reaction substrate and 
product, respectively UDP-Glc and UDP-Gal, were separated using a reversed-phase Supelcosil 
(LC-18-S column, 150 mm × 4.5 mm, particle size 5 µm; Sigma-Aldrich) with UV detection at 
262 nm (Waters 2996 Photodiode Array detector). The column temperature was maintained at 
22°C. GALT activity was expressed as nmol of UDP-Gal formed per µmol of hemoglobin per 
hour. 
Otherwise, the Beutler enzyme spot test was employed, in which GALT enzyme activity 
is monitored with the aid of phosphoglucomutase and glucose-6-phosphate dehydrogenase and 
visualization of the fluorescence of reduced NADP+ under ultraviolet light (26, 27). Potential 
false positives were discarded by determination of galactose or Gal-1-P levels. 
 
2.3.3. Galactose-1-phosphate levels 
Gal-1-P levels were determined in RBC lysates by an in-house adaptation of a 
fluorometric assay (28), in a two-step reaction, using 500 mM Tris pH 8.6, 0.45 mM Mg2+, 0.34 
mM NAD+. In the first reaction, free galactose is quantified by the addition of galactose 
dehydrogenase, which catalyses the oxidation of galactose and the reduction of NAD+ to NADH, 
monitored by fluorescence spectroscopy. In the second reaction, Gal-1-P is quantified by the 
addition of alkaline phosphatase, thereby producing galactose, which is, once again, estimated by 
the fluorescence emitted by NADH. Gal-1-P is calculated by the difference between the second 
reaction, which measures total galactose (Gal-1-P plus free galactose), and the first reaction, 
which measures free galactose. Results were expressed as mg of Gal-1-P per 100 mL of RBC 
lysate. 
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2.3.4. Genotype Analysis 
Genomic DNA was isolated from peripheral blood samples using the Citogene® DNA 
Blood Kit (Citomed, Lisbon, Portugal) according to the manufacturer’s instructions. Total RNA 
was prepared from peripheral lymphocytes using the RNeasy® MiniKit (Qiagen, Hilden, 
Germany), and contamination by genomic DNA was eliminated by treatment with 
deoxyribonuclease I. One µg was reverse transcribed using the Reverse Transcription System 
A3500 kit (Promega, Madison, WI, USA) with random primers following the manufacturer´s 
instructions. 
All the individual exons and respective intron boundaries, as well as the full-length 
cDNA, were PCR amplified and scanned for mutations by direct sequence analysis, using the 
ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction Kit, and ABI PRISM 3100 
Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Additionally, in those cases 
revealing no alteration, the full introns were completely sequenced after PCR amplification. 
Table 2.1 lists the primers used for amplification of the GALT gene and cDNA. 
 
2.3.5. In silico analysis of missense variants 
GALT protein sequences from several organisms were retrieved from NCBI BLAST 
using as template the human GALT sequence (SWISS-PROT accession number: P07902.3). 
Selected sequences were aligned with ClustalX interface for Windows (29) and inspected with 
Genedoc. To predict the impact of selected missense mutations on the GALT stability and 
function, a structural model of wild-type human GALT was generated with the SWISS-PROT 
server (30, 31), using as template the structure of Escherichia coli GalT (1GUP) (32). Using the 
same approach, structural models of the p.F171C, p.G175D, p.P185S, p.S192G, p.R259W, 
p.P295T, and R333G mutants were also generated. The wild-type human GALT PDB file was 
modified to include only chain A. With the obtained model PDB, different servers were used to 
increase the robustness of the predictions of the mutations impact: PolyPhen-2 (33), SDM (34), 
PopMusic v2.1 (35, 36) and CUPSAT (37, 38). As controls of disease-causing mutations, the 
prevalent variants p.S135L, p.Q188R and p.K285N were analyzed using the same servers.  
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Table 2.1. Sequence of oligonucleotides used for the amplification of GALT gene and cDNA. 
Primer ID Sequence Location in sequence Fragment length 
 Genomic (NG_009029.1)   
Exon 1F  TGG ACG GAG AAA GTG AAA GG 5002 – 5021 
221 bp 
Exon 1R  AGG GGA CGA AAG CTT CCT AA 5205 – 5224 
Exon 2F  GGA GAG AGG GAG CTA GAG AGC 5399 – 5419 
300 bp 
Exon 2R  CTG TGG GTG GAG GAC AGT TC 5679 – 5698 
Exon 3+4F  GTA TGG GGC AGT GAG TGC TT 5814 – 5833 
300 bp 
Exon 3+4R  TCC AAC TCT GGT TTG AAA GTT GT 6091 – 6113 
Exon 5F  GTA GCA CAG CCA AGC CCT AC 6142 – 6161 
244 bp 
Exon 5R  CCC AGA ACC AAA GCT TCA TC 6368 – 6387 
Exon 6F  TCA GGA GGG AGT TGA CTT GG 6418 – 6437 
210 bp 
Exon 6R  TTT CCT CTG TCC CAT CCA TT 6608 – 6627 
Exon 7F  CCT GCC TGT TCT TCT CTG CT 1662 – 1681 
231 bp 
Exon 7R  CCT TTA CAC ACC TCT CTC ATG G 6871 – 6892 
Exon 8+9F  CAC CTT GAT GAC TTC CTA TCC A 7089 – 7110 
399 bp 
Exon 8+9R  GAA  ATG GTG TTG GGG CTA  AA 7468 – 7487 
Exon 10F  CTG GTT GGG TTT GGG AGT AG 7691 – 7710 
299 bp 
Exon 10R  TCA GGT GCC TGC ACA TAC TG 7470 – 7499 
Exon 11F  CAG AGC AAG ACC TCG TCT CA 8627 – 8646 
300 bp 
Exon 11R  TTT TAT TAA TGC TAT ATC TGC CCA  AA 8901 – 8926 
DelProm F GCT CTG GGT GAA GTA GGA TCA 4856 – 4876 
299 bp 
DelProm R GTT ACC GTT TGC CCG GAA G 5136 - 5154 
IVS1F  AGT GGA ACC GAT CCT CAG C 5077 – 5095 
435 bp 
IVS1R  GGT GAG CTG ACA CCA GCA 5494 – 5511 
IVS2+3F = 2F GGA GAG AGG GAG CTA GAG AGC 5399 – 5419 
715 bp 
IVS2+3R = 3+4R TCC AAC TCT GGT TTG AAA GTT GT 6091 – 6113 
IVS4F = 3+4F GTA TGG GGC AGT GAG TGC TT 5814 – 5833 
574 bp 
IVS4R = 5R   CCC AGA ACC AAA GCT TCA TC 6368 – 6387 
IVS5F  GGC TGT TGT TGA TGC ATG G 6261 – 6279 
347 bp 
IVS5R  AAT CCT GTT CCC ATG TCC AC 6588 – 6607 
IVS6F =  6F TCA GGA GGG AGT TGA CTT GG 6418 – 6437 
475 bp 
IVS6R = 7R CCT TTA CAC ACC TCT CTC ATG G 6871 – 6892 
IVS7+8F = 7F CCT GCC TGT TCT TCT CTG CT 6662 – 6681 
826 bp 
IVS7+8R = 8+9R GAA  ATG GTG TTG GGG CTA  AA 7468 – 7487 
IVS9F = 9+9F CAC CTT GAT GAC TTC CTA TCC A 7089 – 7110 
901 bp 
IVS9R = 10R TCA GGT GCC TGC ACA TAC TG 7470 – 7499 
IVS10.1F  ATG GTT GGC TAC GAA ATG CT 7874 – 7893 
492 bp 
IVS10.1R  GGC CGA TGG TAT GGA GTT 8348 – 8365 
IVS10.2F  TCC AGC AAA ATG TCT CCT GA 8320 – 8339 
487 bp 
IVS10.2R  GAT GGT TGC TGT CTC CCT GT 8787 – 8806 
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Primer ID Sequence Location in sequence Fragment length 
 mRNA (NM_000155.2)   
Fragment AF TGG ACG GAG AAA GTG AAA GG 2 - 21 
366 bp 
Fragment AR TGG GAA GTC GTT GTC AAA CA 348 - 367 
Fragment BF CCC TCT CAA CCC TCT GTG TC 274 - 293 
500 bp 
Fragment BR TGG TTA GGA CCA GAC GTT CC 754 - 773 
Fragment CF GTG AGG AGC GAT CTC AGC A 669 - 687 
378 bp 
Fragment CR GGA GCG GAG GGT AGT AAT GA 1027 - 1046 
Fragment DF GAC GTC CTT TCC CTA CTC CA 940 – 959 
343 bp 
Fragment DR TTC AAG GCC CTT TCT GCT TA 1263 – 1282 
 
2.3.6. In silico analysis of potential splice variants 
The intronic mutations identified in the Portuguese galactosemic population were 
analyzed by bioinformatic tools, using different algorithms, which predict their influence upon 
splicing signals and splicing regulatory sequences in the context of the sequence variation. The 
strength of authentic and cryptic splice sites was assessed by NetGene2 (39, 40) and NNSPLICE 
0.9 (41). Predictive programs RESCUE-ESE (42) and ESEfinder 3.0  (43, 44) were used for 
detection of exonic splicing enhancer (ESE) motifs. RESCUE-ESE identifies hexamers whose 
sequences are possible binding sites of several known RNA binding factors, and predicts whether 
a mutation disrupts any of these elements. ESEfinder 3.0 identifies ESE responsive to the human 
SR proteins: SRSF1, SRSF2, SRSF5 and SRSF6, formerly known as SF2/ASF, SC35, SRp40 
and SRp55, respectively, and predicts whether a mutation disrupts or enhances the binding of any 
of these proteins. Default settings for human sequences and default thresholds were used for all 
analyses. 
 
2.4. Results and Discussion 
2.4.1. Mutational spectrum and genotypes found in the Portuguese GALT deficient 
patients 
This study aimed to update characterization of the mutational spectrum of GALT 
deficiency in Portugal (24, 45), as well as to assess genotype-phenotype correlations. The 
molecular characterization of 42 galactosemic Portuguese patients was achieved, corresponding 
to 76 independent mutant alleles. The mutational spectrum encompassed 14 different mutations, 
which are distributed along the GALT gene (Table 2.2). All mutations are nucleotide 
!
!96 
substitutions, corresponding to 10 missense (~71%), 2 nonsense (~14.5%), and 2 putative 
splicing (~14.5%) mutations. Moreover, 5 of the observed mutations were so far only identified 
in Portuguese galactosemic patients (p.F171C, p.G175D, p.P185S, p.S192G and p.P295T), the 
majority being located in exon 6, the most conserved exon in the GALT gene. 
 
Table 2.2. Characterization of GALT mutations identified in 42 Portuguese galactosemic patients, corresponding 
to 76 independent mutant alleles. 
Sequence variation GALT mutation Exon/Intron Alleles 
(n) 
Allele  
frequency (%) 
In vitro  
GALT activity 
c.238C>T p.R80X E2 1 1.3 n.a. 
c.328+33G>A IVS3+33G>A I3 1 1.3 n.a. 
c.404C>T p.S135L E5 3 4.0 5% (46, 47) 
c.443G>A p.R148Q E5 2 2.6 n.a. 
c.512T>G p.F171C E6 1 1.3 n.a. 
c.524G>A p.G175D E6 3 4.0 n.a. 
c.553C>T p.P185S E6 2 2.6 14% (48) 
c.563A>G p.Q188R E6 51 67.1 0% 
c.574A>G p.S192G E7 1 1.3 n.a. 
c.610C>T p.R204X E7 1 1.3 0% (49) 
c.775C>T p.R259W E8 2 2.6 <0.2 (50) 
c.820+13A>G IVS8+13A>G I8 6 8.0 n.a. 
c.883C>A p.P295T E9 1 1.3 n.a. 
c.997C>G p.R333G E10 1 1.3 n.a. 
Total   76 100  
n.a. – not available 
 
Among the 42 patients, genotype analysis revealed the presence of 16 different genotypic 
combinations. Moreover, 26 patients were homozygotes (62%), corresponding to 46 independent 
mutant alleles, while the remaining patients were compound heterozygotes. Table 2.3 shows the 
genotypes found in the Portuguese galactosemic population, half of the patients being 
homozygous for the p.Q188R mutation. 
The p.Q188R mutation, accounting for 67.1% of all mutant alleles, was once more 
confirmed as the most prevalent mutation in Portuguese galactosemic population (24, 45), as 
reported in all  European descendant patients. Twenty-one patients have this mutation in 
homozigosity, and 14 patients in compound heterozygosity. 
Surprisingly, the intronic variation c.820+13A>G (IVS8+13A>G), described as benign in 
the ARUP database (http://www.arup.utah.edu/database/GALT/GALT_display.php) (9), was 
found in 6 independent mutant alleles, thus being the second most frequent mutation among the 
Portuguese galactosemic patients (8.0%).  This mutation was identified in a homozygous patient 
and in five compound heterozygotes, two of them being siblings. Four patients carry the p.Q188R 
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in the other allele, while one revealed the p.P295T mutation in his second allele. Interestingly, all 
these patients originate from central regions of Portugal. 
The third most frequent mutations were p.S135L and p.G175D, each accounting for 4% 
of all mutant alleles. Concerning the p.S135L mutation, it was identified in 3 independent mutant 
alleles, and always in heterozygosity. Considering the strong African immigration Portugal 
experienced in the late XX century, it is noteworthy that only three patients carry the p.S135L 
mutation. Two of them are heterozygotes for p.Q188R variant, while the other patient carries the 
p.F171C (c.512T>G; TTT>TGT) mutation in the other allele. It is interesting to note that another 
mutation in the same nucleotide (c.512T>C, TTT>TCT, p.F171S) was described as the second 
most frequent mutation in African-Americans (15, 51). Both parents of the latter patient are from 
the Democratic Republic of São Tomé and Príncipe, in line with the African origin of the 
p.S135L and p.F171S mutations.  
Up to now, the p.G175D mutation was exclusively detected in Portugal. A previous study 
from 2006 reported a patient carrying this mutation in only one allele (24, 45). Herein we report 
the identification of two additional independent mutant alleles identified in homozygous status in 
a pair of siblings from Madeira Island. 
The p.R148Q, p.P185S and p.R259W mutations were detected with a frequency of 2.6%. 
Notably, the p.R148Q mutation, previously described as a common mutation in the Iberian 
Peninsula, was only found in two mutant alleles, whereas seven alleles have been identified in the 
Spanish galactosemic population (24, 45). On the other hand, up to now, p.P185S has been found 
exclusively in the Portuguese galactosemic population, in a homozygous patient. Similarly, the 
p.R259W was detected in homozygosity in one patient. 
The remaining mutations – p.R80X, c.328+33G>A (IVS3+33G>A), p.F171C, p.S192G, 
p.R204X, p.P295T, p.R333G – occurred to a lesser extent, at a frequency of only 1.3%, 
corresponding to one allele of each mutation. 
Two additional individuals whose phenotypes were suggestive of classic galactosemia 
have been initially enrolled in this study. Their molecular characterization revealed the presence, 
in heterozygous status, of the p.N314D mutation, along with the associated promoter deletion and 
intronic variations. Nevertheless, their GALT activity showed values compatible with the Duarte 
variant carrier status, thus being excluded from this study (52).  
Moreover, we screened for the p.N314D variation among all the previously referred 
galactosemic patients and no mutant allele was identified. Accordingly, all the investigated 
patients carried only two mutant GALT alleles in trans. 
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It is noteworthy that two frequent mutations (p.K285N and p.L195P) observed in 
European populations, including the Spanish one, remain undetectable among the Portuguese 
patients. Interestingly, the Spanish GALT spectrum encompasses 21 different mutations, 7 more 
than the Portuguese one, but there are only 5 mutations in common with both populations. 
Nevertheless, these data are in accordance with what is observed for other genetic disorders, 
including phenylketonuria, which present remarkably different mutational spectra between both 
countries (53-55). 
 
2.4.2. Prediction of mutations’ impact upon GALT stability and functionality 
Most of the mutations identified in the Portuguese galactosemic population affect strictly 
conserved residues in GALT sequences from organisms of all life domains, suggesting that the 
substituted positions are structurally and functionally relevant. Only a few missense mutations 
(e.g., p.Q188R, p.S135L) were studied by expressing the recombinant mutant proteins either in 
eukaryotic or prokaryotic systems (e.g. (56, 57)). While the effect upon the enzyme structural and 
functional properties of the newly described mutations is still under investigation and out of the 
scope of the present paper, we employed bioinformatic tools to predict their structural and 
functional impact (Table 2.4). To this end, we generated a structural model of human GALT 
using as template the E. coli GalT structure (PDB code 1GUP (32)), which was strengthened by 
the high sequence identity and similarity between both primary sequences (51% and 64%, 
respectively). To increase the robustness of the mutations predictions, we employed four different 
servers, and always tested the most prevalent disease-causing missense mutations identified in 
classic galactosemia patients, namely p.Q188R, p.S135L, and p.K285N.  
Although there is a reasonable degree of consensus between prediction servers (Table 
2.4), there are relevant point discrepancies, which may be due to these servers analyzing the 
overall structural perturbations and overlooking essential details such as dimer assembly, metal 
binding, active site and other functionally relevant residues. A striking example is p.Q188R, 
which is not considered disease-causing or destabilizing by every server; however, Q188 is a key 
site for reaction intermediates stabilization and the high impact of the p.Q188R mutation cannot 
be discriminated by the servers (58). These limitations and discrepancies weaken the conclusions 
drawn from the prediction servers, which prompted us to generate structural models of the GALT 
mutants herein studied, to visually inspect local effects in the mutations in terms of proximity to 
the active site, bound reaction intermediates, dimer interface, and appearance or loss of H-bonds 
and salt bridges (results summarized in Table 2.5).  
The p.F171C mutant typifies the prediction servers’ limitations: whereas two programs 
suggest a stabilizing effect, the other two classify it as a destabilizing mutation (Table 2.4).  A 
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closer look to the mutation location (Supplementary Figure S2.2) shows that F171 is located near 
the active site and is part of a hydrophobic patch that includes W190 from the same monomer 
and Y339 from the opposing monomer. F171 has been shown to be tightly associated with Q188, 
the residue which stabilizes the bound intermediate, by establishing H bonds between both main 
chain carbonyl and amine groups. Indeed, substitutions in F171 by Ser, Leu and Tyr were shown 
to alter the position of Q188 and disturb the dimer interface and hexose binding (51). In the 
F171C model (Supplementary Figure S2.2), the H-bonds between the main chain C- and N- 
groups of C171 and Q188 are slightly shorter than in wild-type GALT, which could account for 
some distortion in the Q188 side-chain position, thus affecting hexose binding. Moreover, the 
C171 may disturb the monomer-monomer interaction by weakening the hydrophobic patch with 
W190 and Y339.    
The substitution of a glycine by an aspartate residue in the p.G175D mutant is 
consensually destabilizing according to the servers’ predictions (Table 2.4). G175 is strictly 
conserved (Supplementary Figure S2.1) and inserted in a coil region near the active site and 
bound substrate, as observed in the generated model (Supplementary Figure S2.2). The only 
striking structural perturbation resulting from the substitution of glycine by aspartate in this 
mutant is the moderately strong H-bond possibly made between the aspartate side-chain 
carboxylate and the main chain amine group of nearby M177 (D175 side-chain C=O and M177 
main chain NH at a distance of 2.73 Å; Table 2.5). This additional H-bond may create an extra 
rigidity in this coil region that is marked by strong sequence conservation and is located near the 
dimer interface. In summary, this mutation is located not far from the active site and bound 
hexose, and may also introduce structural perturbations in a coil region close to the monomer-
monomer interface (Table 2.5).   
One of the most striking mutations is the substitution of proline by serine in the p.P185S 
mutant. This mutation is located at the core of the H-P-H active site and, thus, likely to have a 
strong impact on the GALT activity of the mutated enzyme. This mutation has already been 
characterized from a functional point of view along with other substitutions in the same position 
by alanine, glycine, glutamine and glutamate, by expressing the human GALT (wild-type and 
mutants) in a yeast GALT-null system (48). In this study, p.P185S was produced in lower 
abundance than wild-type, and displayed impaired conformational stability and ~7-fold decreased 
activity as compared to wild-type. Indeed, the prediction servers concur in assigning a 
destabilizing and disease-causing effect to this mutation (Table 2.4). A closer inspection of the 
possible structural impact of this mutation (Supplementary Figure S2.2) shows that the 
substituting serine may not only disturb the active site, but also introduce some rigidity in the H-
(P)S-H tripeptide, since the S185 side-chain hydroxyl moiety is likely to form a strong H-bond 
with the main-chain C=O from valine 137 (S185 -OH at 2.48 Å from V137 main-chain C=O; 
!
!102 
Table 2.5). Overall, this mutation is predicted to have a strong impact on GALT activity, while 
causing some local structural perturbations within each monomer.  
The substitution of serine by glycine in p.S192G occurs in a position with poor sequence 
conservation, being replaced by a cysteine in the fruit fly GALT, a leucine in yeast GALT and 
asparagine in bacterial GalT proteins (Supplementary Figure S2.1). This position is, however, 
located near the active site, a region of strong sequence conservation. As observed in Table 2.4, 
the servers’ predictions for this mutation are contradictory, since it is either considered to be 
benign/neutral, or destabilizing. It must, however, be taken into account that prediction servers 
focus solely on local contact and global impact concerning the structural model of the monomeric 
GALT. Indeed, a closer inspection of the mutated site shows that the substituted serine is likely to 
yield a weak H-bond between its side-chain -OH moiety and the -OH moiety of tyrosine 339 
from the opposing monomer, Y339(B) in Supplementary Figure S2.2 (Ser192 side-chain -OH at 
3.45 Å from side-chain -OH of Y339(B)). It is thus likely that, despite the fact that S192 is not 
close to the active site or bound substrate, the substitution to a glycine will prevent the formation 
of a H-bond with the neighbouring Y339(B) and thus disturb the dimer interface (Table 2.5). 
Notably, this tyrosine residue – Y339(B) – is strictly conserved, and is the same residue 
responsible for dimer  interface perturbation caused by the p.F171C mutation.  
The p.R259W mutation affects a position with no sequence conservation, although 
located amidst a highly conserved motif. Prediction servers diverged in ranking this mutation 
(Table 2.4).  A closer inspection shows the mutated R259 is located at the GALT surface, with its 
side chain guanidinium moiety protruding into the solvent (Supplementary Figure S2.2). This 
residue is located far from the active site or dimer interface. The most striking perturbation 
resulting from substituting tryptophan side chain concerns the movement of an adjacent 
glutamate residue (E271) side chain. The tryptophan bulky indole moiety induces a 3.24 Å 
displacement of the E271 side chain carboxylate which enables the formation of two moderately 
strong H-bonds (2.98 Å and 3.01 Å) with the side chain -OH and main chain NH group of T268. 
These extra H-bonds will likely cause rigidity between the helix where E271 is located and the 
coil region of T268. This mutation highlights how even subtle structural perturbations in the 
GALT surface may propagate into functionally and structurally relevant sites and affect the 
overall GALT activity.  
The substitution of proline by threonine in the p.P295T mutant occurs in a strictly 
conserved sequence motif (Supplementary Figure S2.1) in a coil region. In line with the structural 
perturbations arising from proline substitutions, the prediction servers align in scoring this as a 
probably destabilizing and disease-causing mutation (Table 2.4). Proline substitutions by 
threonine have been shown to induce disease-causing structural and functional perturbations in 
proteins related to other pathologies (59, 60). A closer look into the localization of the p.P295T 
mutation (Supplementary Figure S2.2) shows that the T295 side chain -OH moiety is within H-
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bonding distance with the M177 side chain sulfur atom (3.70 Å; sulfur H-bonds may display 
longer distances (61, 62)). As mentioned for the p.G175D mutation, this M177 is located in a coil 
region near the dimer interface, and the rigidity derived from an extra H-bond may disturb the 
monomer-monomer interaction (Table 2.5).  
The p.R333G mutation occurs in a strictly conserved position amidst a motif of high 
sequence conservation (Supplementary Figure S2.1). This substitution of arginine by glycine is 
ranked by the four prediction servers as a destabilizing mutation (Table 2.4). R333 is located in a 
coil region distant from the H-P-H active site or the bound substrate (Supplementary Figure 
S2.2). A closer inspection of this position reveals that the R333 side chain guanidinium moiety is 
located at the monomer surface close to the dimer interface, although no interaction with the 
other monomer can be envisaged. However, the R333 guanidinium moiety appears to be involved 
in a H-bond network with the main chain carbonyl groups of M177 and K334. The substitution of 
R333 by a glycine leads to the loss of these three H-bonds and is, thus, likely to disturb this 
whole region located at the monomer-monomer interface (Table 2.5).  
In summary, the predicted structural and functional effects of the described mutations 
reveal that apparently innocuous substitutions may cause a number of point disturbances in the 
active site, substrate binding moieties, putative metal binding sites, and monomer-monomer 
interface. Altogether, these subtle perturbations may account for impaired conformational 
stability and/or increased proneness to aggregate, prompting the misfolded mutant GALT for 
degradation by the cell protein quality control systems, resulting in lower levels of a less active 
GALT protein, and ultimately leading to low GALT activity in patients. The inspection of local 
effects of the mutations, together with the knowledge on the wild-type structure and function, 
provide a more valuable tool than prediction servers which overlook relevant information about 
the analyzed proteins. Moreover, these predictions should be carefully considered, since they rely 
upon the observation of structural models based on the crystallographic structure of the E. coli 
enzyme.  
 
2.4.3. GALT variations putatively affecting splice events 
Bioinformatic programs were used to evaluate a possible missplicing effect of the two 
intronic variations identified in the Portuguese patients, c.820+13A>G (IVS8+13A>G) and 
c.328+33G>A (IVS3+33G>A). It is noteworthy that none of these nucleotide transitions was 
identified in 100 control alleles (24, 45), which strongly suggests they are indeed disease-causing 
mutations. 
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In order to predict if the c.820+13A>G mutation directly affects the pre-mRNA splicing 
of the GALT gene or if it is just a marker linked to another causative mutation, and to understand 
the possible mechanism underlying it, wild-type and mutant gene sequences comprising exon 8, 
intron 8 and exon 9 (320 bp) were scanned by two different programs for splice site prediction 
and the relevant scores were compared.  
Although both programs calculate scores according to different algorithms, the analyses 
gave similar results. The authentic 5’ splice donor site of intron 8 presents the same or similar 
scores in both wild-type and mutant sequences in each program (0.64 and 0.86 in NNSplice and 
NetGene2, respectively) and these results are indicative that this is not a weak splicing donor site. 
Both programs also predict a new GT donor site (c.820+14_15) in the presence of the mutation. 
In the NNSplice program, this cryptic donor site is only recognized in the mutant sequence, in 
which it scores 0.95, whereas in the NetGene2 program it scores 0.68 and 0.99 in the wild-type 
and mutant sequences, respectively. This cryptic splice site is located immediately downstream of 
the variant nucleotide site and, in the presence of the mutation, both programs assign it a higher 
strength comparatively to the canonical 5’ splice site. These results suggest that, in vivo, the 
c.820+14_15 splice site prevails over the canonical 5’ splice site, being used by the spliceosome 
machinery and leading to the inclusion of the first 13 nucleotides of intron 8 in the coding 
sequence. 
The authentic 3’ splice acceptor site of intron 8 shows very low scores in both programs, 
0.45 in NNSplice and 0.04 in NetGene 2, revealing its intrinsic weakness. Moreover, both 
programs reveal that the mutation seems to create a new splice acceptor site in intron 8, 
immediately upstream the activated cryptic donor site (c.820+12_13) which, despite being also 
extremely weak, shows higher scores than the canonical one (0.51 and 0.09 in NNSplice and 
NetGene2, respectively).  
The evaluation of possible modifications on ESE patterns caused by this nucleotide 
variation, was then assessed by two different programs which displayed contradictory results. 
The ESEfinder 3.0 program scores the same or very similar values for three of the SR proteins 
analyzed (SRSF2, SRSF5, SRSF6) in both wild-type and mutant sequences. However, when 
analyzing the results for the SRSF1 protein, we observe that its binding score increases from 
1.986666 in the wild-type sequence, which is close to the threshold value (1.956), to a much 
higher score of 3.906278 in the mutant sequence (CCCAGGT, positions 9–15 of intron 8). On the 
other hand, the RESCUE-ESE program identifies in the same region a binding sequence 
(CAAGTA, positions 11–16 of intron 8) in the wild-type sequence, but not in the mutant one. 
Concerning the c.328+33G>A, wild-type and mutant gene sequences encompassing exon 
3, intron 3 and exon 4 (213 bp) were also scanned by the previously referred predictive servers. 
NNSplice and NetGene2 programs attribute similar scores, in the presence and absence of this 
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variation, to the natural donor (0.90 and 0.96) and acceptor (0.95 and 0.73) splice sites, 
respectively, and recognized no cryptic splice sites in either sequence. 
The ESEfinder software shows this intronic change presents the same binding scores to 
all motifs covered by this software, with the exception of those for SRSF1. In effect, the wild-
type sequence presents a motif (AGGAGGG, positions 28-34 of intron 3) scoring 2.05955 which 
is however no longer recognized in the presence of the mutation (AGGAGAG). On the contrary, 
the RESCUE-ESE program only identifies a new ESE motif for this same SR protein in the 
presence of the mutation (AGGAGA, positions 28-33 of intron 3). 
Altogether, these data strongly suggest that the c.820+13A>G variation is most probably 
a splicing mutation, whereas the effect of the c.328+33G>A variation remained elusive. 
Unfortunately, aberrant splicing resulting from these mutations could not be investigated since no 
material other than genomic DNA was available from these patients or their parents. Efforts are 
underway to study these mutations in greater detail. 
 
2.4.4. Assessing potential genotype-phenotype correlations in classic galactosemia  
In order to evaluate the functional significance of GALT mutations, we searched for 
correlations between genotypes and several phenotypic manifestations of classic galactosemia, 
namely cataracts, anomalies in motor function, intellectual and learning disabilities, ovarian 
dysfunction, speech impairment and white matter anomalies. 
Genotype-phenotype correlations are difficult to establish since most patients are 
compound heterozygotes and, for that reason, the resulting phenotype depends on the interactions 
between products of two different alleles. Moreover, genotype-phenotype correlations usually 
rely on the knowledge of the residual enzymatic activity of each mutation, determined by 
heterologous expression of recombinant proteins. Concerning GALT mutations, few have already 
been characterized (47, 49, 64-66) and, accordingly, herein we employed an in silico approach to 
predict the effect of the mutations on GALT functional properties. 
The p.Q188R mutation is by far the most common in European populations, and one of 
the best characterized mutations (10). Homozygous patients for this mutation have undetectable 
RBC activity, which is consistent with the in vitro functional assays that show a complete loss of 
enzymatic activity in the homodimeric state. Indeed, half of the Portuguese GALT deficient 
patients are homozygous for the p.Q188R mutation and, as expected, their RBC Gal-1-P values 
are always in the upper levels of the advocated therapeutic range, and present a severe clinical 
phenotype with several negative outcomes (Table 2.3). On the other hand, the 14 heterozygous 
patients for p.Q188R present biochemical and clinical phenotypes strongly dependent on the 
second mutation. Severe or null mutations, such as p.R80X, p.R148Q, p.S192G and p.R204X, 
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confirm the severe phenotype; whereas milder mutations, such as p.S135L, alleviate the 
phenotype and strongly reduce the negative outcomes.   
Indeed, some missense mutations appear to partially retain enzymatic activity, being 
associated with a milder biochemical phenotype, which is evidenced by in vitro functional 
analysis (10). Heterologous expression of p.S135L using a yeast expression system demonstrated 
~5% of wild-type activity (47) and all the three patients carrying this mutation present a mild 
phenotype. Additionally, the p.P185S mutation presents 14% of residual activity when expressed 
in a yeast system (48); however, all prediction servers estimate a strong impact on GALT 
activity, due to the local structural perturbations within each monomer that this mutation causes. 
Actually, the homozygous patient for p.P185S seems to confirm the former data, since he 
presents some residual activity in RBC and his RBC Gal-1-P values tend to be close to the lower 
limit of the therapeutic range; and, in addition, this patient presents only slight speech and 
learning disabilities, which, overall, confers a mild phenotype. 
The p.R259W mutation was also identified in a homozygous patient; however, in 
opposition to p.P185S, biochemical and clinical phenotypes are in agreement with the majority of 
prediction servers, which propose p.R259W as a destabilizing mutation whose structural 
perturbations affect GALT activity, thereby causing a severe phenotype. 
The p.F171C mutation was identified exclusively in a Portuguese patient, carrying the 
p.S135L mutation in the other allele. In fact, the rarity of this mutation and the fact that it is in 
trans with a mild mutation make it difficult to estimate if the mild phenotype presented by this 
patient is due to p.S135L or if p.F171C itself alleviates the phenotype. Moreover, this mutation 
has never been expressed in vitro, and prediction servers estimate an ambiguous effect for this 
mutation (Table 2.4). Closer inspection of its location, however, suggests it may affect hexose 
binding and/or disturb the monomer-monomer interaction; additionally, this patient presents a 
similar phenotype to both patients who present the severe mutation, p.Q188R, in trans with the 
mild mutation p.S135L, which reinforces the idea that p.F171C mutation could be a severe 
mutation. 
The predicted destabilizing effect of p.G175D is contrasted by the variability of the 
observed phenotypes. Although both homozygous siblings for p.G175D have a normal school 
career, the sister presents white matter anomalies, while the brother displays no negative 
outcomes. On the other hand, the patient who carries this mutation in heterozygous state with the 
p.Q188R mutation presents a severe phenotype, thereby confirming our prediction that the 
phenotype of heterozygous patients for p.Q188R strongly depends on the second mutation. 
Indeed, a potential severe mutation such as p.G175D is not capable of alleviating the phenotype 
and, as a result, emphasizes the severe phenotype conferred by the p.Q188R mutation.  
A genotype-phenotype correlation was also attempted on the patients carrying the 
potential splicing mutations. The effect of the c.328+33G>A variation remained elusive. 
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Nevertheless, the patient harboring it in heterozygosity with the severe p.Q188R shows a mild 
clinical phenotype with no negative outcomes, and the control blood Gal-1-P values are always 
only slightly above the normal range. These data suggest that this intronic mutation should be a 
mild mutation.  
Concerning the c.820+13A>G transition, all bioinformatic tools predict a severe splicing 
mutation, that induces a frameshift leading to a premature stop codon. Accordingly, it is 
anticipated that the resulting mRNA should be directed to the nonsense mediated decay system, 
with no detected enzymatic activity in biological samples. However, despite displaying null 
GALT activity in RBC, the patient who carries this mutation in homozygous state presents a mild 
clinical phenotype. No negative outcomes other than moderate learning disabilities were 
observed, which nevertheless have not hampered the patient in completing a secondary education 
level. On the other hand, patients carrying this mutation in heterozygosity with the p.Q188R 
mutation also display mild phenotypes but some negative outcomes, such as speech impediments 
and learning disabilities. Finally, the patient who carries the c.820+13A>G mutation in 
heterozygous state with the p.P295T mutation also reveals a mild phenotype. Altogether, these 
results suggest that c.820+13A>G transition, despite its potential severe disease effect, may 
alleviate the severe negative outcomes caused by highly deleterious mutations, such as p.Q188R. 
The mild phenotype afforded by this mutation could be due to tissue availability of specific 
spliceosomal factors, which may prevent the full expression of the alternative splicing effect. 
 
2.5. Conclusion 
The present work expands the knowledge on the mutational spectrum of classic 
galactosemia in Portugal, and also predicts the impact on the structural and functional effects of 
mutations identified in Portuguese patients that were not yet characterized. The establishment of 
potential correlations between genotype and phenotype is not trivial due to several factors. 
Firstly, in silico analysis servers and softwares are rather limited since they evaluate overall 
structural perturbations, overlooking relevant functional information, such as oligomeric 
arrangements, cofactor and ligand binding. These limitations were tentatively overcome by 
closely inspecting the local effects of the mutations and attempting to envisage structural-
functional impairments. Secondly, despite being a monogenic disorder, the phenotype of classic 
galactosemia is not straightforward. There is a paucity of structural information on the Leloir 
pathway enzymes. It has been hypothesized they could form supra-molecular complexes, which 
would imply that a change in the GALT protein could affect the entire metabolic pathway (67). 
Moreover, galactose metabolites are implicated in several physiological pathways, including the 
intricate glycosylation reactions, which are reflected on many distinct levels. Finally, the 
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influence of other genetic modifiers, epigenetic alterations, and environmental factors must be 
considered (68).  
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Human 1: M S R S G T D P Q Q R Q Q A S E A D A A A A T F R A N D H Q H I R Y N P L Q D E W V L V S A H R M K R P W Q G Q V E P Q :60
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Drosophila 1: - - - - - - - - - - - - - - - - - - - - - M Q F V A S E H P H R R L N P L N G Q W V L V C P H R T Q R P W S G Q Q E K A :39
E_coli 1: - - - - - - - - - - - - - - - - - - - - M T Q F N P V D H P H R R Y N P L T G Q W I L V S P H R A K R P W Q G A Q E T P :40
Salmonella 1: - - - - - - - - - - - - - - - - - - - - M T P F N P I D H P H R R Y N P L T G Q W V L V S P H R A K R P W Q G A Q E T P :40
Klebsiella 1: - - - - - - - - - - - - - - - - - - - - M S V F N P V D H P H R R Y N P L T G Q W I L V S P H R A K R P W Q G A Q E T P :40
Erwinia 1: - - - - - - - - - - - - - - - - - - - - M Q K F N P V D H P H R R Y N P L S D Q W I L V S P H R A K R P W Q G A Q E T A :40
H_influenzae 1: - - - - - - - - - - - - - - - - - - - M T A L F E P T E H P H R R Y N P L I D Q W V L V S P H R A K R P W Q G Q Q E K V :41
H_haemolyticus 1: - - - - - - - - - - - - - - - - - - - M S D I F E P T E H P H R R Y N P L I D Q W V L V S P H R A K R P W Q G Q Q E K V :41
Saccharomyces 1: - - - - - - - - - - - - - - - - - - M T A E E F D F S S H S H R R Y N P L T D S W I L V S P H R A K R P W L G Q Q E A A :42
* . * * * * * * . . * : * * . . * * : * * * * *
Human 61: L L K T V P R H D P L N P L C P G A I R A N G E V N P Q Y D S T F L F D N D F P A L Q P D A P S P P S D H P - - - - - :115
Rat 61: L L K T V P R H D P L N P L C P G A T R A N G E V N P P Y D G T F L F D N D F P A L Q P D A P D P G P S D H P - - - - - :115
Drosophila 40: Q K N E L P E F D P T N P L C P G V T R P N G I Q T P E Y E S T Y V F E N D F P A L V E V V P V P P N N D D P - - - - - :94
E_coli 41: A K Q V L P A H D P D C F L C A G N V R V T G D K N P D Y T G T Y V F T N D F A A L M S D T P D A P E S H D P - - - - - :95
Salmonella 41: S Q Q M L P A H D P D C F L C A G N T R V T G D K N P D Y K G T Y V F T N D F A A L M A D T P N A P D S H D P - - - - - :95
Klebsiella 41: A K Q T L P A H D P D C F L C P G N T R V T G D T N P N Y T G T Y V F T N D F A A L M T D T P D A P E S D D P - - - - - :95
Erwinia 41: S Q E K L P A H D P D C F L C P G N T R V T G D K N P D Y S S T Y V F T N D F A A L M T D T P D A P E S E D M - - - - - :95
H_influenzae 42: N E E Q K P S Y D P T C Y L C P S N K R I T G E L N P D Y R K P Y V F K N D F S A L L E D T P A P E K S S D P - - - - - :96
H_haemolyticus 42: N E E Q K P S Y D P T C Y L C P S N K R I T G E L N P D Y R K P Y V F K N D F S A L L E D T P A P E K S S D P - - - - - :96
Saccharomyces 43: Y K P T A P L Y D P K C Y L C P G N K R A T G N L N P R Y E S T Y I F P N D Y A A V S D Q P I L P Q N D S N E D N L K N :102
* . * * * * . . * . * . * * . : : * * * : . * : . . .
Human 116: - L F Q A K S A R G V C K V M C F H P W S D V T L P L M S V P E I R A V V D A W A S V T E E L G - - - - - - - A Q Y P W :167
Rat 116: - L F R V E A A R G V C K V M C F H P W S D V T L P L M S V P E I R A V I D A W A S V T E E L G - - - - - - - A Q Y P W :167
Drosophila 95: - L F Q I A P A R G N C R V M C F H P K S N L T L P T M S A A E I V V V I D E W I S Q F N E L S - - - - - - - A K Y A W :146
E_coli 96: - L M R C Q S A R G T S R V I C F S P D H S K T L P E L S V A A L T E I V K T W Q E Q T A E L G - - - - - - - K T Y P W :147
Salmonella 96: - L M R C Q S A R G T S R V I C F S P D H S K T L P E L S L P A L T E I V R T W Q T Q T A E L G - - - - - - - K T Y P W :147
Klebsiella 96: - L M R C Q S A R G T S R V I C F S P D H S K T L P E L S L E A L E D V V K T W Q E Q T A D L G - - - - - - - K S Y P W :147
Erwinia 96: - L M R C E S A R G T S R V I C F S P D H S K T L P E L T V A G I E Q V V R T W Q E Q T A D L G - - - - - - - Q H Y P W :147
H_influenzae 97: - L F Q S S Q A R G E S R V I C F S P D H S K T L P L L T A L E I E E V I K V W Q E Q L R E L G - - - - - - - A K Y Q W :148
H_haemolyticus 97: - L F Q S S Q A R G E S R V I C F S P D H S K T L P L L T A L E I E E V I K V W Q E Q L R E L G - - - - - - - A K Y Q W :148
Saccharomyces 103: R L L K V Q S V R G N C F V I C F S P N H N L T I P Q M K Q S D L V H I V N S W Q A L T D D L S R E A R E N H K P F K Y :162
* : : . * * . * : * * * . * : * : . : : : * : * . : :
Human 168: V Q I F E N K G A M M G C S N P H P H C Q V W A S S F L P D I A Q R E E R S Q Q A Y K S Q H G E P L L M E Y S R Q E L L :227
Rat 168: V Q I F E N K G A M M G C S N P H P H C Q V W A S N F L P D I A Q R E E R S Q Q T Y H N Q H G K P L L L E Y G H Q E L L :227
Drosophila 147: V Q I F E N K G A A M G C S N P H P H C Q I W S C S F L P T E P Q L K Q E R L R A Y Y A T N E R P M L A D Y V E R E L Q :206
E_coli 148: V Q V F E N K G A A M G C S N P H P H G Q I W A N S F L P N E A E R E D R L Q K E Y F A E Q K S P M L V D Y V Q R E L A :207
Salmonella 148: V Q V F E N K G A A M G C S N P H P H G Q V W A N S F L P N E A E R E D R L Q K A Y F A E Q R S P M L V D Y V Q R E L A :207
Klebsiella 148: V Q V F E N K G A A M G C S N P H P H G Q V W A N S F L P N E A E R E D R L Q K E Y Y A A Q G Q P M L L D Y V Q R E L A :207
Erwinia 148: V Q V F E N K G A A M G C S N P H P H G Q V W A N S F L P N E V K R E D D L Q R A Y F E Q H G S P M L V D Y S A R E L K :207
H_influenzae 149: V Q I F E N K G A A M G C S N P H P H G Q I W A N S F L P N E V A R E D R T Q R D Y L L K H G S V M L V D Y V K R E L A :208
H_haemolyticus 149: V Q I F E N K G A A M G C S N P H P H G Q I W A N S F L P N E V A R E D R T Q R D Y L L K H G S V M L V D Y V K R E L E :208
Saccharomyces 163: V Q I F E N K G T A M G C S N L H P H G Q A W C L E S I P S E V S Q E L K S F D K Y K R E H N T D L F A D Y V K L E S R :222
* * : * * * * * : * * * * * * * * * * . . : * : * : : : : * *
Human 228: R K E R L V L T S E H W L V L V P F W A T W P Y Q T L L L P R R H V R R L P E L T P A E R D D L A S I M K K L L T K Y D :287
Rat 228: R K E R L V L T S E Y W I V L V P F W A V W P F Q T L L L P R R H V Q R L P E L T P A E R D D L A S T M K K L L T K Y D :287
Drosophila 207: R Q E R I V I E N R D W L V V V P F W A T W P F E T M L I S R N N N K R I N D L T A E Q R Y N L A L T I K E L T T K Y D :266
E_coli 208: D G S R T V V E T E H W L A V V P Y W A A W P F E T L L L P K A H V L R I T D L T D A Q R S D L A L A L K K L T S R Y D :267
Salmonella 208: D G S R T V V E T E H W L A V V P Y W A A W P F E T L L L P K T H V L R I T D L S D E Q R D S L A L A L K K L T S R Y D :267
Klebsiella 208: D G S R T V V D T E H W L A V V P Y W A A W P F E T L L L P K A H V Q R I T D L T D A Q R S D L A L A L K K L T S R Y D :267
Erwinia 208: D G S R T V V E T E H W L A V V P W W A A W P F E T L L L P K A H I K R L V D L T D A Q R T D L A L A L K K L T S R Y D :267
H_influenzae 209: L K E R I V V E T E H W I A L V P Y W A I W P F E T L L L P K T H V K R L T E L S D E Q S K D L A V I L K K L T T K Y D :268
H_haemolyticus 209: L K E R I V V E T E H W V A L V P Y W A V W P F E T L L L P K T H V K R L T E L S D E Q S K D L A V I L K K L T T K Y D :268
Saccharomyces 223: E K S R V V V E N E S F I V V V P Y W A I W P F E T L V I S K K K L A S I S Q F N Q M A K E D L A S I L K Q L T I K Y D :282
. * * : . . : : . : * * : * * * * : : * : : : . : : : : : . . * * : * : * : * *
Human 288: N L F E T S F P Y S M G W H G A P T G S E A G - A N W N H W Q L H A H Y Y P P L L R S A T V R K F M V G Y E M L A Q A Q :346
Rat 288: N L F E T S F P Y S M G W H G A P M G L K T G - A T C D H W Q L H A H Y Y P P L L R S A T V R K F M V G Y E M L A Q A Q :346
Drosophila 267: N L F Q C S F P Y S M G W H G A P T G P E H A H A S S A H W T L H A I Y Y P P L L R S A S V R K F M V G F E L L A M A Q :326
E_coli 268: N L F Q C S F P Y S M G W H G A P F N G E E N - - - - Q H W Q L H A H F Y P P L L R S A T V R K F M V G Y E M L A E T Q :323
Salmonella 268: N L F Q C S F P Y S M G W H G A P F N G E E N - - - - A H W Q L H A H F Y P P L L R S A T V R K F M V G Y E M L A E T Q :323
Klebsiella 268: N L F Q C S F P Y S M G W H G A P F N D E D H - - - - N H W Q L H A H F Y P P L L R S A T V R K F M V G Y E M L A E T Q :323
Erwinia 268: N L F Q C S F P Y S M G W H A A P F N G E A N - - - - D H W Q L H A H F Y P P L L R S A T V R K F M V G Y E M L A E T Q :323
H_influenzae 269: N L F E T S F P Y S M G F H A A P F N G E D N - - - - E H W Q L H A H F Y P P L L R S A T V R K F M V G Y E M L G E N Q :324
H_haemolyticus 269: N L F E T S F P Y S M G F H A A P F N G E D N - - - - E H W Q L H A H F Y P P L L R S A T V R K F M V G Y E M L G E S Q :324
Saccharomyces 283: N L F E T S F P Y S M G I H Q A P L N A T G D - - E L S N S W F H M H F Y P P L L R S A T V R K F L V G F E L L G E P Q :340
* * * : * * * * * * * * * * . : : * : * * * * * * * * : * * * * : * * : * : * . *
Human 347: R D L T P E Q A A E R L R A L P E V H Y H L G Q K D R E T A T I A :379
Rat 347: R D L T P E Q A A E R L R V L P E V H Y C L T Q K D K E T A A T A :379
Drosophila 327: R D L T P E Q A A Q R L R E V D G K C H Y L E K - - - - - - - - - :350
E_coli 324: R D L T A E Q A A E R L R A V S D I H F R E S G V - - - - - - - - :348
Salmonella 324: R D L T A E Q A A E R L R A V S D I H F R E S G V - - - - - - - - :348
Klebsiella 324: R D L T A E Q A A E R L R A V S D V H F S E S G V - - - - - - - - :348
Erwinia 324: R D L T A E Q A A E R L R S V S D I H F R E T G A - - - - - - - - :348
H_influenzae 325: R D L T A E Q A A E R L R A L S E V H Y K E R T K - - - - - - - - :349
H_haemolyticus 325: R D L T A E Q A A E R L R A L S E I H Y K L K - - - - - - - - - - :347
Saccharomyces 341: R D L I S E Q A A E K L R N L D G Q I H Y L Q R L - - - - - - - - :365
* * * . * * * * : : * * : .  
Supplementary Figure 2.1. Sequence alignment of GALT proteins. Protein sequences retrieved from NCBI BLAST 
and aligned with Clustal X for Windows. GALT protein sequence accession numbers: Human (SwissProt P079023); 
Rat, Rattus norvegicus (SwissProt Q03249.3); Drosophila, Drosophila melanogaster (SwissProt Q9VMA2.2); E_coli, 
Escherichia coli str. K12 substr. MG1655 (SwissProt P09148); Salmonella, Salmonella enterica subsp. enterica (NCBI 
ZP_03217106.1); Klebsiella, Klebsiella pneumoniae subsp. pneumoniae NTUH-K2044 (NCBI YP_006637266.1); 
Erwinia, Erwinia billingiae Eb661 (NCBI YP_003740707.1); H_influenziae, Haemophilus influenziae Rd KW20 
(SwissProt P31764.2); H_haemolyticus; Haemophilus haemolyticus M19107 (GenBank EGT77758.1); 
Saccharomyces, Saccharomyces cerevisiae (GenBank AAA34627.1). Yellow boxes highlight the active site residues 
His184-Pro185-His186 and the substrate stabilizing residue Q188; red boxes highlight the mutations herein analyzed in 
detail. 
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Supplementary Figure 2.2. Structural model of human GALT with highlighted mutations. Structural model of 
human GALT (green cartoon) and a monomer of E. coli GalT (orange ribbon, PDB code 1GUP, B chain). Red sticks, 
GALT mutations herein studied. Green sticks, His184-Pro185-His186 active site and Q188 residue (human GALT 
numbering), which stabilizes bound UDP-glucose (yellow sticks). Inset panels highlight structural effects of studied 
mutations. Figure generated with PyMOL. 
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3.1. Abstract 
In recent years, antisense therapy has emerged as an increasingly important therapeutic 
approach to tackle several genetic disorders, particularly inherited metabolic disorders. Intronic 
mutations activating cryptic splice sites are particularly amenable to antisense therapy, since the 
canonical splice sites remain intact, thus retaining the potential for restoring constitutive splicing. 
Mutational analysis of Portuguese galactosemic patients revealed the intronic variation 
c.IVS8+13A>G as the second most prevalent mutation, strongly suggesting its pathogenicity. 
The aim of this study was to functionally characterize this intronic variation, to elucidate its 
pathogenic molecular mechanism(s) and, ultimately, to correct it by antisense therapy. Minigene 
splicing assays in two distinct cell lines and patients transcript analyses showed that the mutation 
activates a cryptic donor splice site, inducing an aberrant splicing of the GALT pre-mRNA, which 
in turn leads to a frameshift with inclusion of a premature stop codon (p.D274GfsX291). 
Functional-structural studies of the recombinant wild-type and truncated GALT showed that the 
latter is devoid of enzymatic activity and prone to aggregation. Finally, two LNA 
oligonucleotides, designed to specifically recognize the mutation, successfully restored the 
constitutive splicing, thus establishing a proof-of-concept for the application of antisense therapy 
as an alternative strategy for the clearly insufficient dietary treatment in classic galactosemia. 
 
3.2. Introduction 
During the last years, splicing mutations have emerged as an important pathogenic 
mechanism, underlying 10-30% of genetic diseases (HGMD® Professional 2013.1) (1). Splicing 
accuracy depends on the recognition of exon–intron junctions, which are defined by intronic cis-
elements: 5′ splice site, 3′ splice site, branch site and poly-pyrimidine tract (2-4). Even though 
these are essential elements, splicing also requires more discrete elements, entitled splicing 
regulatory elements (SRE). Indeed, several cis-regulatory sequences direct the splicing 
machinery to use the correct splice sites, which include exonic/intronic splicing enhancers 
(ESE/ISE) and silencer elements (ESS/ISS). Exonic splicing enhancers (ESE) and intronic 
splicing enhancers (ISE) stimulate splicing and serve as binding sites mainly for serine/arginine-
rich proteins (SR proteins). Exonic splicing silencers (ESS) and intronic splicing silencers (ISS) 
repress splicing, and often function by binding of proteins from the heterogenous nuclear 
ribonucleoprotein (hnRNP) family (2, 4-6). Although most reported splicing mutations directly 
abolish an authentic splice site or create a novel one, an increasing number of disease-associated 
mutations that alter splicing enhancers or silencers have been reported (2, 7-9). Indeed, each 
nucleotide modification should be considered a potential candidate for splicing alterations since 
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not only intronic but also nonsense, missense and silent modifications may impact splicing (10). 
Accordingly, constitutive and regulated splicing reactions are considered potential therapeutic 
targets and novel strategies for their correction are evolving. Among these novel approaches, 
antisense oligonucleotides must be highlighted, since many are in phase II/III of clinical trials, 
namely AVI4658 (Eteplirsen®), a morpholino oligonucleotide for Duchenne muscular dystrophy 
(11). Furthermore, one of the hallmarks of antisense oligonucleotides is their exquisite 
specificity, being capable of distinguishing a single nucleotide mismatch (12). 
Classic galactosemia (OMIM #230400), which affects about 1/47,000 live-births, results 
from deficient activity of galactose-1-phosphate urydylyltransferase (GALT, EC 2.7.7.12). This 
is a key enzyme in galactose metabolism, constituting an essential route for nursing infants, as 
lactose represents their primary carbohydrate source (13, 14). The present gold standard of care 
of galactosemia patients is a lifelong dietary galactose restriction which, however, has proven to 
be inadequate to prevent the long-term sequelae (13-17). The disorder is caused by mutations in 
the GALT gene, which profoundly impair GALT enzymatic activity (14, 18, 19). The GALT gene 
is located in chromosome 9p13, is arranged into 11 exons spanning about 4.0 kb of genomic 
sequence, and encodes a 379 amino acid protein, which is assembled as a ~87 kDa homodimer 
(19-22). 
As many other autosomal recessive metabolic disorders, classic galactosemia displays 
great allelic heterogeneity with more than 260 variations described (available at: 
http://www.arup.utah.edu/database/GALT/GALT_display.php, last surveyed November 2013) 
(23). Although most are missense mutations, other variations have been reported, namely silent, 
nonsense and noncoding changes (18, 24, 25). Moreover, several intronic mutations have been 
identified in the GALT gene, approximately half of which are known to affect splicing (23). 
Mutational analysis of 42 Portuguese patients confirmed p.Q188R as the prevalent molecular 
defect (67.1%), and surprisingly revealed an intronic variation, IVS8+13A>G (c.820+13A>G), as 
the second most frequent mutation, accounting for 8.0% of the mutant alleles (26). Although 
IVS8+13A>G transition is currently classified as benign, complete GALT sequence of a 
galactosemic patient homozygous for this variation revealed no other alteration in his genomic 
DNA (23). Furthermore, this variation has never been identified in controls and was found in 
Portuguese patients either in homozygous or compound heterozygous state (26). 
The aim of this study is to confirm that the IVS8+13A>G transition is indeed a disease-
causing mutation, to elucidate its pathogenic mechanism, by in vitro, ex vivo and in vivo 
approaches, to functionally characterize the resulting protein and, finally, to use antisense 
oligonucleotides, namely locked nucleic acids (LNA), to modulate the deleterious effect of the 
mutation. 
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3.3. Materials and Methods 
3.3.1. Patients 
This study was approved by the local Ethics Committees and written informed consents 
were obtained from patients and family members enrolled in this study. The IVS8+13A>G 
variation was identified in six galactosemic patients: one homozygous for this variation and five 
compound heterozygotes, four bearing the p.Q188R mutation, and one the p.P295T mutation  
(26).  
The clinical presentation was common to all patients, and included poor feeding, 
vomiting, weight loss, jaundice and hepatomegaly. Only the younger brother of one of the 
patients was diagnosed pre-symptomatically and put on a galactose-restricted diet immediately 
after birth. At present, all patients are under dietary treatment, with calcium and vitamin D 
supplementation. 
 
3.3.2. In vivo splicing analysis  
Total RNA was isolated from lymphocytes of homozygous and compound heterozygous 
patients, and of control wild-type GALT homozygous individuals using the TRIZOL reagent 
(Invitrogen Corporation, Carlsbad, CA, USA). RNA was reverse transcribed using the NZY 
First-Strand cDNA Synthesis Kit (NZYTech, Lisbon, Portugal) and PCR analysis was performed 
using the CF and CR primers (Table 3.1) with the following cycle conditions: 5 min at 94 °C, 1 
min at 60 °C, 2 min at 72 °C, 30 cycles of 40 sec at 94 °C, 40 sec at 60 °C, 90 sec at 72 °C, 
followed by 7 min at 72 °C. After separation by 2 % NuSieve GTG agarose gel electrophoresis, 
PCR products were purified (Isolate PCR and Gel Kit, Bioline, London, UK), and further 
analyzed by direct sequencing analysis using the ABI Prism BigDye Terminator Cycle 
Sequencing Ready Reaction Kits, in an ABI PRISM 310 Genetic Analyzer (Applied Biosystems, 
Foster City, CA, USA).  
 
3.3.3. Minigenes construction   
Genomic fragments encompassing the region of the GALT gene containing the 
IVS8+13A>G variation were PCR-amplified from one heterozygous patient carrying this 
mutation, using the primers 7F and 9R (Table 3.1). The fragment includes the last portion of 
intron 7, exon 8, intron 8, exon 9, and the initial portion of intron 9, and is 399 bp long. Both 
wild-type and mutant fragments were cloned into the pCR®2.1TOPO vector (Invitrogen 
Corporation, Carlsbad, CA, USA), and positively selected by blue/white screening. Fragments 
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were then subcloned into the exon-trapping vector pSPL3, kindly provided by Prof. Bélen Pérez 
(Centro de Biologia Molecular Severo Ochoa, Universidad Autónoma de Madrid, Madrid, 
Spain). Clones bearing the wild-type and mutant inserts were analyzed by direct sequencing for 
confirmation of fragment insertion and evaluation of their correct orientation. 
 
Table 3.1. Sequence of DNA oligonucleotides used in this study. 
Oligonucleotides Sequence (5’ → 3’) 
CF GTG AGG AGC GAT CTC AGC A 
CR GGA GCG GAG GGT AGT AAT GA 
7F CAC CTT GAT GAC TTC CTA TCC 
9R GAA ATG GTG TTG GGG CTA AA 
SD6 TCT GAG TCA CCT GGA CAA CC 
SA2 GCT CAC AAA TAC CAC TGA GAT 
6His-F a CCA GCG GAT CCC CCT CAA AAA TGC ATC ATC ACC ATC ACC ACA TGT 
CGC GCA GTG GAA CCG ATC 
6His-R a GAT CGG TTC CAC TGC GCG ACA TGT GGT GAT GGT GAT GAT GCA TTT 
TTG AGG GGG ATC CGC TGG 
IVS8-Mut-F b CCC CTG CTG AGC GTG ATG GTC AGT CTC CCA GAT CTA GCC TCC ATC 
ATG 
IVS8-Mut-R b CAT GAT GGA GGC TAG ATC TGG GAG ACT GAC CAT CAC GCT CAG CAG 
GGG 
a underlined residues encode the hexa-histidyl tag 
b underlined residues represent the first 13 nucleotides of intron 8 
 
3.3.4. Ex vivo splicing analysis  
Empty pSPL3 vector and minigene constructs containing wild-type (pSPL3.wt) and 
mutant sequences (pSPL3.mut) were transfected into eukaryotic cell lines (HeLa and COS-7) 
using Lipofectamine 2000 (Invitrogen Corporation, Carlsbad, CA, USA), according to the 
manufacturer’s instructions. Twenty-four hours after transfection, total RNA was extracted using 
the TRIZOL reagent (Invitrogen Corporation, Carlsbad, CA, USA), reverse transcribed using the 
NZY First-Strand cDNA Synthesis Kit (NZYTech) and PCR reaction was performed using the 
pSPL3-specific primers SD6 and SA2 (Table 3.1) with the following cycle conditions: 40 sec at 
95 °C, 40 sec at 55 °C, 90 sec at 72 °C and a final extension for 10 min at 72 °C. PCR products 
were separated by 2 % Nusieve GTG agarose gel electrophoresis, purified and analyzed by direct 
sequencing analysis. 
 
3.3.5. Correction of alternative splicing with LNA oligonucleotides 
Two locked nucleic acid (LNA) oligonucleotides were designed and synthesized and 
purified by Exiqon (Vedbaek, Denmark). Antisense oligonucleotide IVS8-LNA1 is a 
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15-mer (5’-CCAGGATCCTACCTG-3’), whereas IVS8-LNA2 is a 16-mer 
(5’-GATCCTACCTGGGAGA/3Phos); the mutant nucleotide is underlined.  
Cell cultures and minigene transfection followed the previously referred protocol for ex 
vivo splicing analysis. Five hours after minigene transfection, the antisense oligonucleotides 
IVS8-LNA1, IVS8-LNA2 or saline solution (as control) were transfected using Lipofectamine 
2000, as previously mentioned. We used two different concentration ranges, namely low 
concentrations (5-150 nM) and high concentrations (0.5-1.0 µM). Conventional RT-PCR for 
splicing analysis was performed after 24 hours, using the pSPL3-specific primers SD6 and SA2 
(Table 3.1), as described above. PCR products were analyzed by agarose gel electrophoresis and 
further sequenced. 
 
3.3.6. Production of recombinant wild-type and mutant GALT 
GALT cDNA, a generous gift of Prof. Judith Fridovich-Keil (Department of Human 
Genetics, Emory University, USA) was cloned into the pET24b(+) plasmid. The T7 tag was 
deleted using the NdeI and EcoRI enzymes; subsequently, GALT cDNA was cloned using the 
enzymes HindIII and SalI. By site-directed mutagenesis (QuikChange® II XL Mutagenesis kit, 
Stratagene) using the primers 6His-F and 6His-R (Table 3.1), a hexa-histidyl tag was introduced 
at the N-terminus. All introduced changes were confirmed by direct sequencing in both forward 
and reverse orientations, using the universal primers T7 promoter (#69348-3) and T7 terminator 
(#69337-3). The resultant recombinant vector was named pET24.6His.GALT. 
The IVS8+13A>G mutation was generated by site directed mutagenesis (NZY 
mutagenesis kit, NZYTech) using the IVS8-Mut-F and IVS8-Mut-R primers (Table 3.1), and 
confirmed by direct sequencing in both forward and reverse orientations. The resultant 
recombinant vector was named pET24.6His.GALT.p.IVS8. The vectors bearing the wild-type or 
mutant GALT were transformed into E. coli BL21(DE3) Rosetta cells, which were grown in M9 
minimal medium (27), containing kanamycin (25 µg/mL) and chloramphenicol (34 µg/mL). At 
an O.D.600 of 0.3, isopropyl-D-thiogalactoside (IPTG) was added to a final concentration of 400 
µM to induce GALT expression, and, simultaneously, medium was supplemented with 100 µM 
ferrous ammonium sulfate and 100 µM zinc sulfate. Culture was incubated for an additional 4 
hours, at 21 °C, 120 rpm, at which point, cells were collected by centrifugation at 8,000 xg for 5 
min, at 4 °C.  
The bacterial pellets were resuspended in buffer A (50 mM Tris pH 7.5, 300 mM KCl, 
and 10 % glycerol) containing 1 mM phenylmethanesulfonyl fluoride (PMSF) and 1 mg/mL 
lysozyme. After a 30-min incubation at 4 °C, cells were disrupted by sonication (three 60 sec 
pulses, 50% efficiency, with 30 sec gaps in between for cooling). The fusion proteins expressed 
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in E. coli were purified by immobilized metal affinity chromatography (IMAC) using a HisTrap 
FF column (Amersham, GE Healthcare). After cell disruption and centrifugation at 13,000 xg, for 
5 min, at 4 °C, imidazole was added at a final concentration of 20 mM to the supernatant cell 
lysates, which was loaded into a HisTrap FF column pre-equilibrated with five column volumes 
(Vc) of buffer A with 20 mM imidazole. The column was then washed with ten Vc of buffer A 
containing 20 mM imidazole, and with five Vc of buffer A with 50 mM imidazole. Pure proteins 
were eluted with 2.5 mL of buffer A containing 500 mM imidazole, which was subsequently 
eliminated with a PD-10 desalting column (Amersham, GE Healthcare). Protein solutions were 
concentrated by ultrafiltration using Vivaspin 15R (Sartorius Stedim, Germany) 30 kDa-cutoff 
filters, at 3,000 xg and 4 °C in a swinging-bucket centrifuge. Immunoblotting and GALT 
enzymatic activity determination were performed on the same day as purification; the remaining 
samples were aliquoted, flash-frozen in liquid nitrogen and stored at -80 °C. 
 
3.3.7. Immunoblotting 
The purified proteins were run on a 12.5 % SDS-PAGE and transferred into 
nitrocellulose membrane (Hybond ECL, Amersham, GE Healthcare). After a 2-hour blocking 
with 5 % milk in PBS-T buffer, the membrane was incubated for 1 hour at room temperature with 
the primary mouse monoclonal anti-GALT antibody (sc-365577, Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) at a 1:1000 dilution. After three washes with PBS-T buffer, the membrane 
was incubated for 1 hour at room temperature with the secondary peroxidase-conjugated 
Affinipure goat anti-mouse IgG (H + L) antibody (Jackson ImmunoResearch Laboratories, West 
Grove, PA, USA) at a 1:1000 dilution. The ECL Prime Western Blotting Detection Reagent was 
used for protein detection (Amersham, GE Healthcare). 
 
3.3.8. GALT enzymatic activity 
GALT enzymatic activity was measured as previously described (28). All assays were 
carried out at 37 °C, in a reaction mixture containing 40 mM Tris–HCl, pH 7.5, 2 mM Gal-1-P, 
0.5 mM UDP-Glc, 40 µM dithiothreitol (DTT) and 125 mM glycine. UDP-Glc and UDP-Gal 
were separated by HPLC and analyzed by UV detection at 262 nm (26, 28). 
 
3.3.9. Far-UV circular dichroism 
Far-UV circular dichroism (far-UV CD) spectra and thermal denaturation profiles were 
recorded in a Jasco J-710 spectropolarimeter, coupled to a Jasco PTC-348WI Peltier temperature 
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controller and a Haake G/D8 water bath. GALT protein samples were at 0.15 mg/mL (wild-type) 
or 0.25 mg/mL (p.IVS8), each spectrum being the result of six accumulations at a 50 nm/min 
scan rate. Thermal denaturation profiles were monitored at 222 nm in a 0.1 cm light path cuvette, 
in the 20-90 °C temperature range (1 °C /min slope; data pitch: 1°C; delay time: 0 sec). 
Temperature scan curves were fit according to a two-state model. 
 
3.3.10. Differential scanning fluorimetry 
Differential scanning fluorimetry (DSF) was performed in a C1000 Touch thermal cycler 
equipped with a CFX96 optical reaction module (Bio-Rad, Hercules, CA, USA).  
All fluorescence measurements were performed at a final protein concentration of 0.1 
mg/mL in buffer A, and SYPRO orange (Invitrogen Corporation, Carlsbad, CA, USA) at a 5x 
working concentration, in a 50 µL total volume. The PCR plate was sealed with Optical-Quality 
Sealing Tape (Bio-Rad) and centrifuged at 400 xg  for 1 min. DSF assays were carried out with a 
10-min incubation step at 20 °C followed by ramping the temperature from 20 °C to 90 °C at 
1 °C /min, with a 1 sec hold time every 0.2 °C and fluorescence acquisition using the HEX 
channel. Data were processed using CFX Manager software V3.0 (Bio-Rad). Temperature scan 
curves were fitted to a biphasic sigmoidal function and the Tm values were obtained from the 
midpoint of the first and second transitions. 
 
3.3.11. Dynamic light scattering 
Dynamic light scattering (DLS) analysis was performed on a ZetaSizer Nano-S (Malvern 
Instrument, UK) particle size analyzer, coupled to a precision Peltier temperature control unit; a 
He-Ne laser was used as the light source (633 nm). Prior to analysis, samples were centrifuged at 
20,000 xg for 30 min at 4 °C, diluted in buffer A to a final concentration of 0.15 mg/mL, and 
filtered with a 0.22 µm membrane in order to remove larger aggregates. Data were processed 
using Zetasizer Nano DTS software v7.01 (Malvern Instrument). Temperature was ramped from 
20 °C to 70 °C at 0.5 °C/min, with the particle size average, distribution and total scattering 
intensity being collected. The melting temperature (Tagg), at which both size and intensity start to 
increase significantly, was determined by fitting the obtained data to a plateau followed by one 
phase association equation. The kinetics of thermal aggregation was monitored at 37 °C and 
42 °C for 60 min. 
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3.4. Results 
3.4.1. Ex vivo analysis revealed the intronic mutation IVS8+13A>G is sufficient to 
cause aberrant splicing of the GALT transcript 
Since RNA samples from the patients were initially not available, the mutation 
characterization started by minigene analysis. To investigate if the intronic mutation 
IVS8+13A>G was sufficient to cause aberrant splicing, we cloned the previously referred 399 bp 
fragment containing the wild-type or the mutant regions of the GALT gene into the pSPL3 exon-
trapping vector. Minigene constructs, pSPL3.wt and pSPL3.mut, differed exclusively in the 13th 
nucleotide of intron 8 (Figure 3.1A). Eukaryotic HeLa and COS-7 cell lines were transiently 
transfected with each construct and with empty vector, and the resulting splicing products were 
analyzed by direct sequencing. Transfection with the empty vector pSPL3 showed a single 263 bp 
fragment resulting from the vector canonical splicing sites. Concerning the wild-type and mutant 
constructs, both cell lines revealed a different splicing pattern: whereas the COS-7 cell line 
exhibited a complex transcript profile, the HeLa cell line displayed a much simpler splicing 
profile.  
Transfection of HeLa cells with the wild-type minigene pSPL3.wt showed a single 396 
bp fragment, resulting from the inclusion of exon 8 and exclusion of exon 9; and transfection 
with the mutant minigene pSPL3.mut originated a single 409 bp fragment, also resulting from the 
inclusion of exon 8 and exclusion of exon 9, including however the first 13 nucleotides of intron 
8 (Figure 3.1B).  
Transfection of COS-7 cells with the wild-type and mutant minigenes revealed several 
fragments, corresponding to the usage of all available splicing sites, including a cryptic donor site 
in the vector sequence (data not shown). Nevertheless, comparing with the wild-type minigene, 
transcript profiles of the mutant minigene construct were clearly different, since all transcripts 
presented the additional first 13 nucleotides of intron 8 and the canonical donor splice site was 
never used in any of the splicing events. 
Results obtained in two different eukaryotic cell lines showed that the IVS8+13A>G 
mutation per se activates a cryptic donor splice site (c.820+14_15), which leads to the inclusion 
of the first 13 nucleotides of intron 8 in the resulting mature mRNA, being thus responsible for 
inducing an aberrant splicing of the GALT transcript.  
 
3.4.2. In vivo analysis confirmed that IVS8+13A>G is a disease-causing mutation  
Classic galactosemic patients carrying the IVS8+13A>G mutation were selected for 
transcript analysis. Lymphocytes were isolated from two patients, one homozygous and one 
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heterozygous, as well as from controls, and total RNA was extracted. RT-PCR analysis of the 
GALT cDNA revealed the presence of two fragments when analyzing either control individuals 
or the homozygous patient, and the presence of four fragments when analyzing the heterozygous 
patient.  
Direct sequencing analysis of the expected fragment – 378 bp – of the control individuals 
revealed a splicing reaction using the canonical splice sites and thus including the end of exon 7, 
entire exons 8 and 9 and the beginning of exon 10 (Figure 3.2). However, the smallest fragment – 
294 bp – resulted from an alternative splicing event, with skipping of exon 9, most likely derived 
from the weakness of the 3’ acceptor site in intron 8. When analyzing the homozygous patient’ 
fragments (391 and 307 bp), we confirmed they only differ from those of control individuals by 
the additional 13 bp corresponding to the first nucleotides of intron 8, and resulting from 
transcription of the allele carrying the IVS8+13A>G transition (Figure 3.2).  
 
 
Figure 3.1. Minigene constructs and transcript analysis of transfected HeLa cells. Panel A, schematic 
representation depicting the minigene constructs. The PCR fragment comprising the last portion of intron 7, exon 8, 
intron 8, exon 9 and the first portion of intron 9 was cloned in the pSPL3 vector: pSPL3.wt minigene presents the 
genomic wild-type fragment; pSPL3.mut minigene presents the genomic mutant fragment (IVS8+13A>G mutation 
underlined); Panel B, RT-PCR pattern and sequence analysis of the corresponding fragment: pSPL3.wt fragment (396 
bp) resulted from the inclusion of exon 8 and skipping of exon 9; pSPL3.mut fragment (409 bp) resulted from the 
inclusion of exon 8 and the first 13 nucleotides of intron 8, and skipping of exon 9. 
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Concerning the analysis of the heterozygous patient, we observed the presence of the four 
previously mentioned fragments corresponding to both alleles, either not carrying or carrying the 
splicing mutation (data not shown). Moreover, we determined that IVS8+13A>G mutation is not 
responsible for the alternative splicing causing exon 9 skipping. 
 
 
Figure 3.2. Transcript analysis of control and patient’s lymphocytes confirm different splicing patterns. Total 
RNA was isolated from lymphocytes of control and a homozygous patient with the IVS8+13A>G mutation. RT-PCR 
analysis of GALT mRNA revealed the presence of two fragments: control showed the expected fragment (378 bp) and 
a smaller fragment (294 bp) that resulted from an alternative splicing event with skipping of exon 9; homozygous 
patient also showed the two fragments, although both presented the first 13 nucleotides of intron 8 (391 bp and 307 
bp). 
 
3.4.2. The use of antisense therapy allowed the ex vivo reversion of the alternative 
splicing caused by IVS8+13A>G mutation 
To investigate the possibility of restoring correct splicing by antisense therapy, two LNA 
oligonucleotides were designed. Both oligonucleotides were targeted to the cryptic splice site, 
sterically blocking the access of the spliceosome machinery to this site, and thus forcing the 
usage of the canonical donor splice site in the vicinity. HeLa and COS-7 cell lines were 
transfected with both minigene constructs and LNAs at two different concentration ranges. 
Transcript analysis of the wild-type minigene was not affected by any of the antisense 
oligonucleotides, at both concentration ranges (data not shown). Transcript analysis of the mutant 
minigene revealed that both antisense oligonucleotides at low doses were not able to hamper the 
binding of the spliceosomal machinery to the cryptic splice site (data not shown). When the 
LNAs were raised to the higher concentration range, the aberrant splicing was completely 
abolished and the natural splicing mechanism was recovered (Figure 3.3). This process suggests 
there is an LNA concentration threshold (0.5 µM), after which the splicing correction appears to 
be dose-independent. 
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Figure 3.3. Antisense nucleotides correct the splicing pattern of the mutant minigene. Transcript analysis of HeLa 
cells expressing the wild-type and mutant minigene constructs and further treated with antisense oligonucleotides. 
RT-PCR pattern and sequence analysis of the corresponding fragment in untreated (0 µM) and treated (0.5, 0.75 and 1 
µM IVS8-LNA1). IVS8-LNA2 showed identical transcript profile, also subsequently confirmed by direct sequencing. 
HeLa cells confirmed that both LNA oligonucleotides fully corrected the aberrant splicing (herein represented IVS8-
LNA1).  
 
3.4.2. The truncated mutant GALT is stable but inactive and prone to aggregation 
The IVS8+13A>G mutation, despite inducing a frameshift in the open reading frame and 
introducing a premature stop codon 17 amino acids downstream (p.D274GfsX291 or 
p.D274Gfs*17), does not seem to elicit the nonsense mediated decay (NMD) system, as reverse 
transcript analysis detected the aberrant mature transcript in all patients. There is thus a 
considerable possibility that the mutant protein will be translated in vivo. 
To further understand the molecular mechanism of disease, the recombinant wild-type 
and truncated mutant GALT were produced in a prokaryotic expression system and analyzed 
from a functional-structural viewpoint.  
Wild-type and mutant proteins were purified by affinity chromatography. 
Immunoblotting analysis showed two main bands with molecular masses of ~45 kDa for the 
wild-type and ~34 kDa for the truncated GALT (Supplementary Figure S3.1A). Besides the main 
band, both proteins display bands with lower molecular mass and much lower intensity. 
The impact of the mutation on the protein stability and proneness for aggregation was 
probed by different biophysical techniques. By far-UV CD spectroscopy, we observed nearly 
identical spectra for the wild-type and truncated p.IVS8 GALT, particularly two minima at 208 
and 222 nm (Figure 3.4A). Monitoring CD ellipticity at 222 nm as a function of increasing 
temperature and fitting data to a two-state model, secondary structure thermal denaturation 
profiles yielded Tm values of 53.0±1.3 °C and 54.6±2.1 °C, respectively for wild-type and p.IVS8 
GALT. Differential scanning fluorimetry assays were employed to obtain thermal denaturation 
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profiles focused on the proteins’ tertiary structure elements. Two melting transitions were 
observed (Figure 3.4B), with similar Tm values for both proteins: Tm1 43.7±0.6 °C and Tm2 
52.5±1.1 °C for wild-type, and Tm1 43.4±0.1 °C and Tm2 51.8±0.1 °C for p.IVS8 GALT. The 
propensity to aggregate in solution of both wild-type and mutant GALT was analyzed by DLS. 
Both proteins displayed quite similar Tagg (Figure 3.4C; 41.3±0.1 °C for wild-type and 41.1±0.1 
°C for p.IVS8) and overlapping aggregation kinetics profiles at 37 °C (26.6±0.0 °C for wild-type 
and 25.6±2.7 °C for p.IVS8; data not shown). However, the aggregation kinetics at 42 °C showed 
a faster aggregation of p.IVS8 GALT comparatively to wild-type (Figure 3.4D), with a t1/2 of 
5.0±0.1 min for mutant GALT and 7.0±0.2 min for wild-type.  
Recombinant wild-type GALT displayed a specific enzymatic activity of 
10.2 µmol.mg-1.h-1, whereas p.IVS8 GALT had null activity, under standard conditions. 
 
 
Figure 3.4. Mutant GALT is more prone to aggregation. Biophysical methodologies employed to analyze the 
structural impact of the mutation IVS8+13A>G on the recombinant GALT protein. Panel A, far-UV circular dichroism 
spectra and thermal denaturation profiles (Inset) for wild-type (a) and p.IVS8 (b); Panel B, thermal denaturation 
profiles obtained by DSF for wild-type (a) and p.IVS8 (b);  Panel C, thermal denaturation analyzed by DLS for wild-
type (a) and p.IVS8 (b); Panel D, aggregation kinetics analyzed by DLS at 42 °C for wild-type (a) and p.IVS8 (b). 
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3.5. Discussion  
We report the first functional characterization of an intronic mutation in the GALT gene, 
and the first description of antisense oligonucleotides as therapeutic agents in classic 
galactosemia. Previous in silico analysis of the target sequence revealed the presence of a cryptic 
donor splice site (c.820+14_15) which, in the presence of the mutation IVS8+13A>G, undergoes 
activation, leading to the exonization of the first 13 nucleotides of intron 8 (26). Since RNA 
samples were initially not available from patients, the splicing effect predicted by bioinformatic 
programs was first confirmed by minigene studies. Minigene-based technologies are widely used 
to functionally characterize mis-splicing mutations and to evaluate the efficacy of antisense 
oligonucleotides in modulating splicing in a number of genetic disorders, namely in inherited 
metabolic disorders (29, 30). 
A minigene carrying the genomic region of GALT spanning from exon 8 to exon 9 and 
respective intronic boundaries was generated, and splicing was evaluated in two eukaryotic cell 
lines, HeLa and COS-7. The transcript profiles were different between cell lines: HeLa cells 
displayed a very simple profile with one single fragment, while COS-7 cells displayed a more 
complex profile. Nevertheless, a key observation common to both cell lines is that the presence 
of the IVS8+13A>G mutation always induced the usage of the cryptic donor site instead of the 
canonical one. 
The weakness of the acceptor splice site in intron 8, also predicted by the previous in 
silico analysis (26), was also fully confirmed by the minigene functional assay, as transcript 
profiling analyses of the wild-type minigene also showed exon 9 skipping, thereby confirming 
this phenomenon is not related with the mutation herein under study. 
Pre-mRNA splicing is a process highly dependent on the availability of tissue-specific 
factors. Accordingly, the different transcript profiles of HeLa and COS-7 cell lines most likely 
reflect these differences. Indeed, recognition of splicing targets and splicing efficiency are 
modulated by auxiliary proteins that recognize and bind to cis-acting elements in the pre-mRNA, 
thereby either stimulating or inhibiting the recruitment of other splicing factors for the 
spliceosome assembly (31, 32). Moreover, the binding of these auxiliary proteins to either exonic 
or intronic sequences must be determinant for modulating the usage of weak splice sites. Each 
eukaryotic cell line presents a particular pool of splicing factors, and therefore it is expected that 
both cell lines present different splicing profiles. Specifically, the HeLa cell line, despite its wide 
usage in splicing assays, most probably lacks specific factor(s) that are crucial for exon 9 
inclusion in the mature GALT mRNA.  
Further genetic analysis of homozygous and heterozygous patients carrying the 
IVS8+13A>G mutation fully confirmed the results obtained by the minigene analyses. Indeed, a 
fragment containing the insertion of the first 13 nucleotides of intron 8 was always detected by 
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RT-PCR analysis, in contrast to controls, who presented a fragment resulting from the 
constitutive splicing event. Surprisingly, because never reported before, a second fragment was 
identified, in both patients and controls, corresponding to the skipping of exon 9, thus evidencing 
in vivo the minigene results (26). The occurrence of exon 9 skipping in homozygous wild-type 
individuals confirms this alternative splicing event is not caused by the IVS8+13A>G mutation. 
Indeed, transcripts resulting from alternative splicing have been previously described as normally 
rare transcripts that are part of the “background” noise of the splicing process (33). Accordingly, 
this alternative splicing of the GALT transcript should correspond to a physiological event, at 
least in human lymphocytes, which we herein report for the first time. 
Altogether, ex vivo and in vivo analyses demonstrated that the IVS8+13A>G variation is 
actually a disease-causing mutation. Our results reiterate that the ex vivo approach using a 
minigene splicing assay constitutes a reliable tool to unravel the molecular mechanism(s) 
whereby a mutation affects splicing (34). Nonetheless, despite being a valuable tool per se, 
whenever possible, the minigene approach should be complemented by the in vivo analysis of 
patients’ cells, as in the present study. 
Once proven the pathogenic effect of the IVS8+13A>G mutation, we investigated the 
possibility of restoring correct splicing by antisense therapy with two LNA oligonucleotides. 
Both oligonucleotides were targeted to the cryptic splice site, so that the access of this splicing 
site would be sterically blocked to the spliceosome machinery, which would, thus, be forced to 
use the canonical donor splice site in the vicinity. 
The need for two oligonucleotides stemmed from the fact that this mutation activates a 
cryptic donor splice site extremely close to the natural one and, accordingly, its steric blocking by 
antisense oligonucleotides could affect the correct splicing, by preventing the recognition and/or 
binding of the canonical GT by the spliceosome machinery. For that reason, we have chosen to 
design two oligonucleotides, IVS8-LNA1 and IVS8-LNA2, whose distance from the canonical 
GT is 10 and 5 nucleotides, respectively. Furthermore, we have chosen to design LNA 
oligonucleotides for their high mismatch discrimination ability (35). LNA is an RNA analogue 
that is conformationally locked in an N-type (C3’-endo) conformation (36-38), which confers it 
an extremely high affinity to complementary RNA and greatly improves mismatch 
discrimination. In addition, LNA oligonucleotides display high stability and low toxicity in 
biologic systems (37).  
In the first experiments, we tested LNA concentrations in the reported ranges, i.e., below 
100 nM. However, as the inhibition of the alternative splicing process was never achieved, higher 
concentrations were attempted (0.5-1 µM), which successfully restored the normal splicing 
profile. After the lowest LNA concentration at which the normal splicing profile was obtained 
(0.5 µM), no improvement in efficiency was observed at increasing doses. These results suggest 
that the effective LNA concentration may be potentially sequence-dependent and are in 
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accordance with previous pharmacological studies which provided evidence for LNA 
oligonucleotides to exhibit ‘threshold affinity’ – described as the concentration that the LNA 
must achieve in order to exhibit high potency, and beyond which further increase in affinity will 
not necessarily correlate with additional potency (39). 
The transcript displaying the additional 13 nucleotides of intron 8 induces a frameshift in 
the open reading frame and introduces a premature termination codon (PTC) 17 residues 
downstream: p.D274GfsX291 or p.D274Gfs*17. PTC-containing transcripts usually trigger the 
nonsense-mediated decay (NMD) system, an mRNA surveillance mechanism by which the cell 
controls the quality of the mRNA (2, 40). Abnormal transcripts that prematurely terminate 
translation are eliminated by the NMD pathway, thereby preventing the production of truncated 
proteins that could have deleterious gain-of-function or dominant-negative effects (40, 41). 
The NMD pathway is elicited upon recognition of a PTC located more than 50–55 
nucleotides upstream the following exon junction (40). The GALT IVS8+13A>G mutation leads 
to the inclusion of a PTC 44 nucleotides upstream of the exon 9 - exon 10 junction, which should 
prevent the NMD from recognizing and degrading this transcript, thus allowing for a truncated 
protein to be formed. Indeed, we could detect the presence of the mutant transcript in all patients 
carrying this mutation.  
The splicing mutation herein reported results in an mRNA encoding a truncated 
polypeptide with 290 amino acid residues, 89 shorter than wild-type GALT (Supplementary 
Figure S3.1B). Moreover, the 17 residues of p.IVS8 in the C-terminus differ from the wild-type 
sequence due to the frameshift caused by the aberrant splicing event. Structural models of both 
wild-type human GALT and p.IVS8 (Supplementary Figure S3.1C) were obtained based on the 
structure of bacterial GALT (PDB code: 1GUP) (42). Notably, the missing residues in p.IVS8 
include i) a helix that protrudes into the other monomer to assemble the functional dimeric form, 
and ii) three of the four ligands (the three histidines) that bind the mononuclear non-heme iron in 
the native bacterial enzyme. Native GALT is proposed to function as a homodimer, and the non-
catalytic iron center has been assigned a structural role (21, 43). These observations thus led us to 
anticipate considerable functional and structural perturbations in p.IVS8 as compared to the wild-
type enzyme. To further understand the molecular mechanism dictating the functional and 
structural impairment regarding p.IVS8, recombinant wild-type and mutant GALT were 
expressed and purified from bacterial cells. A set of biophysical methodologies were employed to 
analyze the structural impact of the mutation on p.IVS8 GALT. We observed that the wild-type 
and mutant GALT displayed nearly identical far-UV CD spectra (Figure 3.4A), consistent with a 
high content in α-helical structural elements, balanced with β-sheets and coil regions 
(Supplementary Figure S1C). Moreover, the thermal denaturation profiles obtained for both 
proteins yielded very similar Tm values, ruling out perturbations at the secondary structure level. 
DSF assays allowed analyzing the mutation’s effect on the tertiary structure and, although no 
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clear structural domains are detected in GALT, two transitions could be observed for both wild-
type and p.IVS8 GALT (Figure 3.4B). Very similar Tm values were obtained between the two 
variants for both transitions, which suggest the absence of major structural perturbations at the 
tertiary structure level. By DLS, we analyzed the propensity of wild-type and p.IVS8 GALT to 
aggregate in solution. Both proteins exhibited nearly identical thermal aggregation profiles and 
Tagg values (Figure 3.4C), and overlapping aggregation kinetics at 37 °C. However, p.IVS8 was 
shown to aggregate significantly faster at 42 °C, as compared to the wild-type GALT (Figure 
3.4D), which indicates a higher propensity for aggregation. Since soluble aggregates are 
recognized and marked for degradation by the cellular protein quality control machinery, it is 
likely that in a cellular context p.IVS8 has a significantly shorter lifetime. Whereas recombinant 
wild-type GALT displayed a specific enzymatic activity in the range of reported values, p.IVS8 
had null activity under the same conditions. This indicates that not only p.IVS8 is likely to be less 
stable in a cellular context, but it also appears to be completely inactive. Therefore, despite the 
possibility that the stable mutant mRNA is translated into p.IVS8 GALT in the patients’ cells, it 
should be completely devoid of any functional ability. These observations clearly enforce the 
potential of antisense therapy to correct splicing mutations and to restore GALT function in a 
physiological context. 
In conclusion, this study constitutes the first functional characterization of an intronic 
mutation in classic galactosemia by two distinct yet complementary approaches: minigene assays 
in two cells lines and patients’ genetic analysis. Additionally, functional-structural analyses of the 
resultant protein revealed its lack of activity and high propensity to aggregation, despite no major 
structural perturbations having been identified. Furthermore, two LNA oligonucleotides, 
specifically designed to recognize the IVS8+13A>G mutation, have successfully restored the 
splicing profile, and thus establish a proof-of-concept for the application of antisense therapy for 
mis-splicing mutations in classic galactosemia. 
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3.8. Supplementary Material 
 
Supplementary Figure S3.1. Recombinant production and in silico analysis of wild-type and truncated mutant 
GALT. Panel A, immunoblotting analysis of purified recombinant wild-type (lane 1, WT) and mutant (lane 2, p.IVS8) 
GALT proteins; Panel B, sequence alignment between wild-type and p.IVS8 mutant obtained with Clustal X; red box 
highlights the His184-Pro185-His186 active site; orange spheres highlight the conserved mononuclear iron ligands; light 
blue box highlights the missing residues in the p.IVS8 mutant; Panel C, structural models of wild-type and p.IVS8 
GALT obtained with Swiss-Modeller with the Escherichia coli GALT (PDB code 1GUP) as the structural template; 
grey cartoon depicts the overlapping structure of wild-type and p.IVS8, whereas the light blue cartoon depicts the extra 
residues in wild-type GALT; orange and purple spheres depict respectively the iron and zinc ions in the bacterial 
enzyme; orange ribbons depict the opposing monomer from the bacterial GALT PDB; figure elaborated with PyMOL 
(44). 
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4.1 Abstract 
Galactose-1-phosphate uridylyltransferase is a key enzyme in the galactose metabolism, 
particularly important in the neonatal period due to the ingestion of galactose-containing milk. 
GALT deficiency results in the life-threating genetic disorder classic galactosemia, whose 
pathophysiology, despite several decades of intensive research, is still not fully elucidated. 
Classic galactosemia is a loss-of-function disease, hypothesized to result from GALT misfolding. 
A thorough functional-structural characterization of GALT most prevalent variants is still 
lacking, hampering the development of a small-molecule based therapeutic approach. The aim of 
this study is to investigate the structural-functional effects of nine mutations in the GALT gene, 
four of which account for the vast majority of the mutations identified worldwide in galactosemic 
patients. Several methodologies were employed, from enzymatic activity and thermal inactivation 
to biophysical methods, to evaluate the mutations’ impact on the GALT protein secondary, 
tertiary and quaternary structure. The results indicate no major effects on the secondary and 
tertiary structures, and reveal that the key structural impact concerns aggregation in solution. In 
particular, p.Q188R, the most frequent allele at a worldwide scale, accounting for ~60% of 
mutant alleles, displayed a much lower Tagg than WT GALT, and aggregated much faster both at 
37 °C and upon thermal insult at 42 °C. Thus, GALT aggregation, rather than misfolding, appears 
to be the major pathogenic mechanism underlying the most prevalent missense mutations, and so 
we hypothesize that proteostasis modulators might potentially improve GALT function, opening 
new avenues for therapeutic research in classic galactosemia. 
 
4.2 Introduction 
Classic galactosemia (OMIM #230400) is an autosomal recessive disorder caused by 
mutations in the GALT gene, resulting in deficient activity of galactose-1-phosphate 
uridylyltransferase (GALT, EC 2.7.7.12), a key enzyme in galactose metabolism (1). GALT 
catalyzes the second step of the Leloir pathway, converting galactose-1-phosphate (Gal-1-P) and 
UDP-glucose (UDP-Glc) into glucose-1-phosphate and UDP-galactose (UDP-Gal) (1).  
In classic galactosemia, acute symptoms generally appear soon after birth upon exposure 
to milk, and include: vomiting, diarrhea, excessive weight loss, lethargy, hypotonia, liver 
dysfunction, and, in the absence of intervention, can escalate to cataracts, E. coli sepsis, and 
eventually to neonatal death (1-4). These symptoms generally self-resolve once the patient is 
placed on a stringent life-long dietary restriction of galactose, which is the current standard of 
care (5). However, despite resolving the acute and potentially lethal symptoms, the dietetic 
treatment does not prevent the development of serious long-term complications, namely cognitive 
!!142 
and neurologic disabilities, and premature ovarian insufficiency in females (1, 6). 
Thus far 266 variations have been described at the GALT locus (available at 
http://www.arup.utah.edu/database/GALT/GALT_display.php, last surveyed on December 
2013), of which missense mutations constitute the majority (>60%), despite the high allelic 
heterogeneity (7). In particular, the p.Q188R mutation (c.563A>G; CAG→CGG) is by far the 
most frequent, accounting for ~63% of GALT mutant alleles (8, 9). Its incidence is particularly 
high in European descendant patients, reaching >90% of mutant alleles in Ireland; it has however 
never been reported in Asian descendant patients (1, 10, 11). Other frequent mutations include 
p.S135L, p.K285N and p.N314D. The p.S135L mutation (c.404 C>T; TCG → TTG) affects 
mostly African descendant patients, ranging from approximately half of mutant alleles in African 
Americans to ~90% in South African patients (8, 9). The second most frequent GALT mutant 
allele in European descendant patients is p.K285N (c.855G>T; AAG→AAT), with a higher 
incidence in Eastern Europe, reaching 34% in Poland (8, 9, 12, 13). The p.N314D mutation 
(c.940A>G; AAC→GAC) appears to be an evolutionary remnant, since the D314 is actually the 
ancestral allele that persists nowadays at a pan-ethnic frequency of nearly 10% (12, 14). 
Notwithstanding the several studies on the molecular basis of these mutations’ pathogenicity (15-
26), a characterization of these variants focusing on different structural features is still missing. 
 To date there is no solved three-dimensional structure of the human GALT. However, 
based on the availability of the E. coli GalT structure (27) and on the high sequence identity and 
similarity among the human and the prokaryotic GALT, a three-dimensional model of the human 
GALT was constructed which provided important insights into the structural and functional 
features of this protein (Figure 4.1). GALT is a member of the transferase branch of the histidine 
triad (HIT) family of enzymes; the catalytic site sequence His-Pro-His is conserved in nature, and 
was firstly identified in the E. coli enzyme at residues 164 to 166, corresponding to residues 184 
to 186 in the human sequence (27-30). The reaction displays ping-pong kinetics and a double 
displacement mechanism, involving an uridylyl-enzyme, in which the nucleophilic histidine at 
residue 186 is transiently nucleotidylated (27, 31, 32). The active enzyme is an 86.6-kDa 
homodimer (Figure 4.1) composed of ~43.3-kDa monomers, with two active sites, each formed 
by residues contributed by both subunits (33). Whereas the E. coli GalT has two mononuclear 
metal-binding sites (one for zinc and the other for iron) with proposed structural roles, the human 
GALT lacks two of the zinc ligands, thus remaining to be established whether metal binding in 
the human protein is comparable to that of the bacterial GalT (34). 
A recent study reported that five missense mutations in the GALT gene led to misfolding 
of the GALT protein, suggesting classic galactosemia as a conformational disorder (35). 
However, little is known about the conformational impact of the most prevalent mutations, which 
hampers the design of alternative therapies for this monogenic disorder based on the use of 
stabilizing low molecular weight compounds (36). Accordingly, the aim of this study is to further 
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investigate the structural-functional effects of the most prevalent mutations in the GALT gene, 
p.Q188R, p.S135L, p.K285N and p.N314D, and of five other clinically relevant mutations, 
p.R148Q, p.G175D, p.P185S, p.R231C and p.R231H. 
 
 
Figure 4.1 - Structural model of GALT dimer. Structural model of human GALT (grey cartoon representation) 
obtained using Escherichia coli GalT crystallographic structure as template (orange ribbon representation, PDB ID: 
1GUP). Iron (orange sphere), zinc (purple sphere), and bound UDP-glucose (light blue lines) originate from 1GUP 
PDB. Mutations herein studied are represented in red sticks. Figure generated with PyMOL (37). 
 
4.3 Materials and Methods 
4.3.1 Production of recombinant human GALT variants 
Recombinant human GALT was produced by cloning the human GALT cDNA sequence 
into pET24, to yield a N-terminally hexa-histidyl-tagged protein, as previously described (38). 
Site-directed mutagenesis (NZY mutagenesis kit, NZYTech, Lisbon, Portugal) was employed to 
introduce all the mutations herein under study using the primers listed in (Supplementary Table 
S4.1). Direct sequencing in both forward and reverse orientations was used to confirm the correct 
introduction of mutations and to exclude additional mutational events.  
Vectors bearing the cDNA encoding the GALT variants were transformed into E. coli 
BL21 (DE3) Rosetta cells. For protein production, cells were grown in M9 minimal medium (39) 
supplemented with 100 µM ferrous ammonium sulfate and 100 µM zinc sulfate, at 37 °C. Protein 
expression was induced by addition of 400 µM IPTG once the OD600nm reached 0.3, the cultures 
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were placed at 21 °C, and the cells were harvested after 4 hours. Bacterial cells were resuspended 
in buffer A (50 mM Tris pH 7.5, 300 mM KCl, and 10% glycerol) with 1 mg/mL lysozyme and 
500 µM phenymethanesulfonyl fluoride, disrupted by sonication, and clarified by centrifugation 
(5 minutes at 8,000 xg).  
The fusion proteins were purified by immobilized metal affinity chromatography 
(IMAC), by loading the cellular extracts into a 1-mL FF-Crude column (Amersham, GE 
Healthcare) and eluting the proteins with buffer A containing increasing concentrations of 
imidazole (pure GALT eluted at 500 mM imidazole). After purification, imidazole was 
eliminated with a desalting column pre-equilibrated and eluted with buffer A, and protein 
solutions were concentrated by ultrafiltration, aliquoted, flash-frozen in liquid nitrogen and stored 
at −80 °C. Protein purity was assessed by SDS-PAGE, and protein concentration was determined 
by the Bradford assay (40). 
 
4.3.2 GALT activity assays and thermal inactivation profiles 
GALT enzymatic activity was measured as previously described (41), and performed on 
the same day as purification. All assays were carried out for 30 min at 37 °C, in a reaction 
mixture containing 2.0 mM Gal-1-P, 0.5 mM UDP-Glc, 40 µM dithiothreitol (DTT) and 125 mM 
glycine, in 40 mM Tris–HCl, pH 7.5. UDP-Glc and UDP-Gal were separated by HPLC and 
analyzed by UV detection at 262 nm (41, 42). The enzyme activity was expressed in µmol UDP-
Gal formed per hour per mg protein at 37 °C (µmol UDP-Gal.h−1.mg−1). Adequate controls 
lacking either substrate or the GALT protein were routinely performed. 
Wild-type (WT) GALT kinetic parameters for UDP-Glc and Gal-1P were determined in 
the same conditions as in (42) with minor modifications namely the use of nine concentrations of 
UDP-Glc (0.02-1.5 mM; [Gal-1-P] = 2.0 mM), and nine concentrations of Gal-1-P (0.05- 6.0 
mM; [UDP-Glc] = 0.5 mM). The steady-state kinetic constants were determined by nonlinear 
regression analysis using the GraphPad Prism 6 software (GraphPad, Software, Inc), the 
Michaelis-Menten equation for Gal-1-P and the modified Michaelis-Menten equation to account 
for substrate inhibition for UDP-Glc.  
Thermal inactivation profiles were obtained by analyzing enzyme activity as a function 
of temperature in the 20-65 °C range. Aliquots of protein (WT and p.N314D: 4.28 µg/mL; 
remaining mutants: 21.4 µg/mL) were incubated at the different temperatures for 10 min, 
immediately chilled on ice for 10 min, and enzyme activity was determined by adding the 
reaction mixture described above and incubating it at 37 °C for 30 min. Enzymatic activity values 
plotted as a function of temperature yielded sigmoidal curves, from which the midpoints of 
thermal inactivation (T½) were obtained from the inflexion point. Two assays were performed for 
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each temperature data point, and the WT GALT thermal inactivation profile was repeated in 
parallel with each tested mutant.  
 
4.3.3 Far-UV circular dichroism spectropolarimetry 
Far-UV circular dichroism (far-UV CD) spectra and thermal denaturation profiles were 
recorded in a Jasco J-710 spectropolarimeter, coupled to a Jasco PTC-348WI Peltier temperature 
controller and a Haake G/D8 water bath. All GALT protein samples were at 0.15 mg/mL, each 
spectrum being the result of six accumulations at a 50 nm/min scan rate, at 20 °C, in a 0.1 cm 
light path cuvette. Thermal denaturation profiles were obtained by monitoring molar ellipticity at 
222 nm, in the 20-90 °C temperature range (1 °C/min slope; data pitch: 1 °C; delay time: 0 sec). 
Temperature scan curves were fitted to a two-state model. 
 
4.3.4 Differential scanning fluorimetry 
Differential scanning fluorimetry (DSF) experiments were performed in a C1000 Touch 
thermal cycler equipped with a CFX96 optical reaction module (Bio-Rad), by having the GALT 
variants at a 0.1 mg/mL (~2.5 µM in monomer) final concentration in buffer A, SYPRO orange 
(Invitrogen Corporation) at a 5x working concentration, in a 50 µL total volume. A 10-min 
incubation step at 20 °C preceded the temperature ramp from 20 to 90 °C at 1 °C/min, with a 1-
sec hold time every 0.2 °C and fluorescence acquisition using the HEX channel (excitation 
maximum at 535 nm, emission maximum at 555 nm). Assays using 2.0 mM Gal-1-P, 0.5 mM 
UDP-Glc, 100 µM Fe2+ and 100 µM Zn2+ were also performed. Control assays in the absence of 
protein were routinely performed. 
Data were processed using CFX Manager software V3.0 (Bio-Rad). Temperature scan 
curves were fitted to a biphasic sigmoidal function and the Tm values were obtained from the 
inflexion points of the first and second transitions. Variations in Tm values are considered 
significant when |ΔTm| ≥ 2 °C (above the standard deviation). 
 
4.3.5 Dynamic light scattering 
Dynamic light scattering (DLS) data were acquired in a ZetaSizer Nano-S (Malvern 
Instrument, UK) particle size analyzer, coupled to a Peltier temperature control unit, using a He-
Ne laser as the light source (633 nm). Prior to data collection, protein samples were centrifuged at 
15,000 xg for 30 min at 4 °C, diluted in buffer A to a final concentration of 0.15 mg/mL, and 
filtered with a 0.22 µm membrane to remove large aggregates. Temperature was ramped from 20 
!!146 
°C to 70 °C at 0.5 °C/min, with the particle size average, distribution and total scattering intensity 
being collected. Data were processed using Zetasizer Nano DTS software v7.01 (Malvern 
Instrument). The aggregation temperature (Tagg), defined as the temperature at which both size 
and intensity start to increase significantly, was determined by fitting the obtained data to a 
plateau followed by one phase association equation. 
The kinetics of thermal aggregation was monitored at 37 °C and 42 °C for 60 min. By 
plotting light scattering intensity as a function of time, sigmoidal curves were obtained and the 
t1/2 was determined as the time elapsed to reach half saturation of aggregated protein in the 
sample. 
 
4.3.6 In silico analysis 
Structural models of WT and mutant human GALT, based on the E. coli GalT structure 
(PDB ID: 1GUP), were obtained from the SWISS-MODEL server (43, 44). Comparative analysis 
of the structural models and the corresponding electrostatic surface maps was done with the 
PyMOL software (37).  
 
4.4 Results 
4.4.1 Impaired catalytic ability of GALT mutants 
The WT recombinant human GALT was isolated in its active state, displaying for 
Gal-1-P a Vmax of 59.1 µmol UDP-Gal.h-1.mg-1 and a KM of 1.08 mM, and for UDP-Glc a Vmax of 
75.5 µmol UDP-Gal.h-1.mg-1 and a KM of 425 µM.   
Aside from the p.N314D mutant, which displayed nearly identical enzymatic activity to 
the WT protein, all the studied GALT mutants presented markedly reduced (≤0.2% of WT for 
p.Q188R, p.S135L and p.G175D) or null enzymatic activity (Table 4.1). Thermal inactivation 
profiles were obtained for the GALT variants exhibiting measurable catalytic activity. All the 
analyzed mutants, namely p.Q188R, p.S135L, p.N314D and p.G175D, displayed lower T½ than 
that of the WT GALT, with ∆T½ ranging from -8.1 °C to -19.9 °C (Table 4.1). 
 
4.4.2 Limited impact of GALT mutations on the secondary and tertiary structure 
Far-UV CD spectra of all GALT variants were very similar to that of WT, with two 
minima at 208 and 222 nm (Figure 4.2). Thermal denaturation curves, obtained by monitoring the 
molar ellipticity at 222 nm as a function of constantly increasing temperature, presented an 
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apparently single transition and were fitted according to a two-state model.  Thermal denaturation 
of the GALT variants appeared to be irreversible, since the spectra collected at 20 °C after 
cooling the denatured samples had lost the spectral features assigned to the different secondary 
structure elements (data not shown). The thermal denaturation profiles of all variants yielded 
similar Tm values (Table 4.1), ranging from 52.6 to 56.7 °C. With the exception of p.R231H, all 
mutants displayed slightly higher Tm values than WT GALT, although all the ΔTm ± SD fall 
below the 2 °C threshold. 
Differential scanning fluorimetry was employed to analyze the mutations’ effects on 
tertiary structure elements. The fluorescence intensity measured in the first asymptote of the 
sigmoidal thermal denaturation profiles (flat over the 20-30 °C range) was normalized with 
respect to the WT values (Supplementary Figure S4.1). As observed, all the variants exhibited 
similar ground-state fluorescence, the sole exception being the p.Q188R mutant, which displayed 
values ~30% higher than those of the WT GALT.  
The DSF thermal denaturation profiles for all variants exhibited two apparent transitions, 
each accounting for 40-60 % of the overall fluorescence increase (Supplementary Figure S4.2). 
The inflexion points of the two transitions, Tm1 and Tm2, fell within a narrow range of 
temperatures, with Tm1 ranging from 42.0 ± 0.4 to 44.3 ± 0.2 °C and Tm2 ranging from 51.0 ± 0.4 
to 53.9 ± 0.1 °C (Table 4.1). None of the GALT mutants exhibited Tm values ≥2 °C higher or 
lower than those determined for the WT GALT.  
Binding of the GALT substrates Gal-1-P and UDP-Glc was tested by DSF assays. 
Neither substrate yielded significant changes in either Tm values (all ΔTm <1 °C, Supplementary 
Table S4.2). Since GALT has two putative mononuclear metal binding sites, one for iron and 
another for zinc, DSF assays were carried out in the presence of either metal. The only GALT 
variant exhibiting a response to Fe2+ was p.P185S, its Tm1 increasing by 2.5 ± 0.5 °C 
(Supplementary Table S4.2). The presence of Zn2+ had two levels of impact on the thermal 
denaturation profiles and their corresponding Tm values (Supplementary Table S4.2). Whereas 
the Tm1 values for p.Q188R, p.N314D, and p.R148Q remained unvaried, WT and all other 
mutants exhibited a decrease in Tm1 from -2.5 ± 0.3 °C to -5.5 ± 0.3 °C. The effect of Zn2+ had a 
deeper impact on the Tm2 values, which decreased significantly (ΔTm2 between -2.9 ± 0.6 °C and -
5.2 ± 1.5 °C) for the WT GALT and all the mutants except p.Q188R.  
 
4.4.3 Disturbed aggregation of GALT mutants 
The propensity of GALT variants to aggregate in solution was analyzed by DLS, 
evaluating the Tagg and also the aggregation kinetics at two different temperatures (37 °C and 42 
°C). Scanning the particle size as a function of temperature, the estimated Tagg were essentially 
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Figure 4.2 - No impact of the studied mutations on human GALT secondary structure. Effect of missense 
mutations on the secondary structure of GALT variants, probed by far-UV circular dichroism spectropolarimetry.  
Panel A: Far-UV CD spectra, collected for GALT variants, at 20 °C, at 0.15 mg/mL, in 50 mM Tris-HCl, 300 mM 
KCl, 10 % glycerol, pH 7.5. Spectra resulted from 6 accumulations at a 50 nm/min scan rate, in a 0.1 cm light path 
cuvette. Panel B: thermal denaturation profiles obtained by monitoring molar ellipticity at 222 nm in the 20-90 °C 
temperature range (1 °C/min slope; data pitch: 1 °C; delay time: 0 sec); temperature scan curves were normalized and 
fitted according to a two-state model (respective Tm values in Table 4.1). 
 
identical for all GALT variants herein studied (ranging from 40.1 ± 1.0 °C to 41.4 ± 0.1 °C), 
except the p.Q188R mutant, which started to aggregate at a lower temperature (∆Tagg of -3.9 °C, 
with respect to the WT GALT) (Figure 4.2.A and Table 4.1). 
The aggregation kinetics was monitored by determining t1/2 at 37 °C and 42 °C, 
representing respectively a physiological body temperature and a thermal insult. At 37 °C, 
whereas the p.K285N, p.R148Q, and p.R231H mutants displayed similar t1/2 as the WT GALT 
(~27 min), the other mutants exhibited disturbed aggregation profiles, aggregating either faster 
(p.Q188R, p.G175D and p.P185S, approximate Δt1/2 respectively -20, -12, and -16 min) or slower 
(p.S135L, p.N314D and p.R231C, approximate Δt1/2 respectively +10, +15, and +22 min) than 
the WT GALT (Supplementary Figure S4.3 and Table 4.1). At 42 °C, the aggregation was sped-
up, lowering the t1/2 of all GALT variants, and the mutants either aggregate as fast as the WT 
GALT (t1/2 ~7 min; p.S135L, p.K285N, p.N314D, and p.R231C) or faster (t1/2 between 2.3 and 5 
min; p.Q188R, p.R148Q, p.G175D, p.P185S, and p.R231H) (Figure 4.2.B and Table 4.1). 
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4.5 Discussion  
Like the majority of genetic disorders, the mutational spectrum of classic galactosemia is 
dominated by missense mutations. Since the current standard of care based on a galactose-
restricted diet is mostly ineffective in preventing the long-term complications, a deeper 
knowledge on the molecular basis of GALT mutations pathogenicity will guide in the design of 
new therapeutic strategies. Herein we report the structural-functional characterization of nine 
clinically relevant GALT mutants, four of which are the most prevalent among GALT mutant 
alleles: p.Q188R, p.S135L, p.K285N and p.N314D. 
The purified recombinant WT GALT displayed enzymatic an activity and kinetic 
parameters towards Gal-1-P and UDP-Glc compatible with reported values obtained by a direct 
UDP-Gal quantitation HPLC assay (41), rather than the often used two-enzyme coupled GALT 
activity assay (35, 45). From all the tested GALT variants, only four mutants displayed detectable 
activity (p.Q188R, p.S135L, p.N314D and p.G175D), even using a 5-fold higher protein 
concentration than WT GALT. Whereas p.N314D had the same specific activity as the WT 
enzyme, the other mutants displayed ≤0.2 % of residual enzyme activity, consistent with previous 
reports (15, 16, 19, 21, 23). Thermal inactivation profiles were obtained, showing that the WT 
GALT is strikingly stable (T1/2 = 55.5 °C), whereas all the mutants with detectable enzymatic 
activity were more sensitive to thermal inactivation, revealing an impaired functional stability 
(Table 4.1).  
Far-UV CD spectropolarimetry was used to probe the impact of the studied mutations on 
the secondary structure elements of GALT mutants. The WT and mutant GALT displayed 
overlapping CD spectral features (Figure 4.2), particularly minima at ~222 nm and ~208 nm, 
consistent with a combination of α-helical and β-sheet secondary structure content (six α-helices 
and thirteen β-sheets). These data show that the studied mutations have no significant effects on 
the secondary structure topology, replicating the previous study on the E. coli GalT and its 
p.Q168R variant, equivalent to human p.Q188R (46). Structural models obtained for each variant 
(Supplementary Figures S4.4) suggest that the side-chains of the substituting residues likely have 
limited or null effects on secondary structure elements. Indeed, thermal denaturation profiles 
(Figure 4.2) confirmed that all mutants displayed thermal stability at the secondary structure level 
very similar to WT GALT, with |ΔTm|± S.D. < 2 °C (Table 4.1).  
Impact of the mutations on the tertiary structure of GALT variants was evaluated by 
DSF, a method whereby a fluorescent dye binds to the proteins buried hydrophobic regions 
exposed upon thermal unfolding. The ‘ground-state’ fluorescence was evaluated for all GALT 
variants and a >30% increase was observed for p.Q188R (Supplementary Figure S4.1), whereas 
the remaining mutants were similar to the WT GALT. This indicates that p.Q188R shows a basal 
destabilization level, possibly caused by a more open conformation and a higher exposure of 
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hydrophobic residues. However, this ~30 % increase is modest, when compared with 
destabilizing mutations in other proteins, such as medium-chain acyl-coA dehydrogenase (47). 
DSF thermal denaturation curves showed two distinct transitions (Supplementary Figure S4.2), 
indicative of two protein regions unfolding almost as separate domains, contrarily to the previous 
report of a single transition in similar experiments, for a different set of GALT variants (35). 
Both Tm values determined for the WT GALT (43.7 ± 0.7 °C and 52.4 ± 1.2 °C) are lower than 
the previously reported single Tm (63 °C) (35). Different experimental details could partially 
explain these distinct observations, particularly a pH closer to physiologic in our assays (7.5 vs. 
pH 8.8 reported in (35)), besides the protein concentrations and the temperature slope (35). 
Concerning the mutants, the Tm values for each transition lie within two temperature ranges 
separated by ~9 °C, and displayed no significant differences relative to the WT GALT (Table 
4.1), since all |ΔTm| < 2 °C. This observation appears to rule out any significant effect of the 
studied mutations on the protein thermal stability, particularly concerning their tertiary structure.  
DSF assays were also employed to evaluate the effect of substrate binding (Gal-1-P and 
UDP-Glc) on the conformational stability of the GALT variants (Supplementary Table S4.2). 
Under the tested conditions, we observed no effect of either substrate on the Tm values for the 
WT GALT and the studied variants, whereas McCorvie et al. previously reported a stabilizing 
effect of both substrates towards the WT GALT and the p.D28Y and p.F194L mutants (35). 
Notably, the structures of the E. coli GalT in the native and nucleotylated states (PDB ID 1HXP 
and 1HXQ) are totally overlapping (27, 48), ruling out major structural conformational changes 
upon substrate binding.  
Zinc and iron were shown to have a structural role in bacterial GalT (49). While the 
mononuclear iron-binding ligands are fully conserved in human GALT, the zinc ligands are only 
partially conserved, which raised the question whether this metal is indeed essential (19). 
Whereas iron had no effect on the WT GALT stability in the DSF assays, zinc had the puzzling 
effect of destabilizing the protein, lowering both Tm values by ~4 °C (Supplementary Table S4.2). 
Since the zinc binding pocket is not fully conserved in human GALT, our results raise the 
possibility that zinc can partly occupy the mononuclear iron-binding site, previously proposed to 
be unable to completely discriminate between iron and zinc (34, 50), as commonly observed in 
mononuclear and binuclear iron-binding proteins. Concerning the mutants, iron had no 
significant effects on any variant except for a slight increase in p.P185S Tm1, whereas zinc had 
major effects on most mutants (Supplementary Table S4.2). The p.Q188R mutant presented the 
most deviant behaviour, being totally insensitive to zinc. Whereas p.N314D and p.R148Q 
showed a decrease only in Tm2 in the presence of zinc, all the other mutants behaved essentially 
as the WT GALT. The mutated serine in p.S135L structurally overlaps with the zinc-binding 
ligand H115 in E. coli GalT. The fact that this mutant displays the same zinc sensitivity as WT 
GALT enforces the idea that the observed zinc-induced destabilization might be related to non-
!!152 
specific binding at the iron-binding site and not at the putative zinc-binding site. Although the 
effect of zinc cannot as yet be rationalized in functional terms, the different impact on the 
conformational stabilities may be suggestive of subtle structural differences between these 
variants.  
Since aggregation in solution is a hallmark of protein misfolding, DLS was used to 
compare the proneness of the different GALT variants to aggregate. For each protein, we 
evaluated the Tagg and the aggregation kinetics at 37 °C and upon a thermal insult at 42 °C 
(Figure 4.3 and Table 4.1). In terms of thermal aggregation profiles, all but the p.Q188R mutant 
exhibited Tagg values close to 41 °C, nearly identical to the WT GALT. The p.Q188R mutant had 
a remarkably disturbed thermal aggregation profile, with a Tagg close to 37 °C, indicating a higher 
propensity to aggregate in solution as compared to WT GALT. Since parameters similar to the 
WT were obtained in the far-UV CD and DSF experiments, differences in conformational 
stability can be discarded. Nevertheless, and taking into consideration that this variant presented 
~30 % higher ground-state fluorescence than the remaining GALT variants, we hypothesize that 
the higher exposure of hydrophobic residues in this mutant may be directing its increased 
tendency to aggregate. The aggregation kinetics at the two different temperatures also highlighted 
the disturbed aggregation behaviour of other variants. At 37 °C, the p.G175D and p.P185S 
mutants also aggregate significantly faster than the WT GALT, whereas the p.S135L, p.N314D 
and p.R231C mutants presented delayed aggregation kinetics, suggestive of subtle structural 
differences that are exclusively reflected on the aggregation propensity. Upon thermal insult at 42 
°C, some of the effects observed at 37 °C were majored, others levelled out, and new effects were 
observed. Besides p.Q188R, p.G175D and p.P185S, also p.R148Q and p.R231H aggregate faster 
than WT GALT at this higher temperature, indicating that the latter two mutants are actually less 
resistant to aggregation under this thermal insult. All the mutants that presented slower 
aggregation at 37 °C were levelled to the WT aggregation kinetics at 42 °C. p.K285N was the 
only mutant showing aggregation parameters essentially identical to the WT GALT.  
The results from the different methodologies herein employed indicate that the major 
structural impact of the studied mutations concerns the aggregation in solution, with no 
significant effects on the secondary and tertiary structures. To support our understanding of the 
molecular basis of each mutation’s pathogenicity, we generated structural models of each mutant 
and attempted to extract subtle structural differences that may provide clues for the functional 
and structural impairment (Supplementary Figure S4.4). The p.Q188R has generally been 
regarded as a functional mutation, since the substituted glutamine establishes through its amide 
moiety two H-bonds towards UDP-Gal, as observed in the bacterial structure (46). In the 
bacterial mutant p.Q168R – equivalent to human p.Q188R – one of these H-bonds is absent. 
However, in the generated p.Q188R model (Supplementary Figure S4.4), it appears there is an 
actual gain in H-bonds in the mutant, since the guanidinium moiety is able to establish three 
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‘new’ H-bonds towards the intermediate phosphate and sugar moieties. The functional 
impairment of p.Q188R may therefore result from an over-stabilization of the substrates and/or 
products in place, thus blocking the enzyme active site for further reaction turnover. On top of the 
local H-bond network differences, we observed a significant change in the electrostatic surface 
surrounding this position (Supplementary Figure S4.4), consistent with the substitution of a 
globally neutral amide with the positively charged guanidinium of arginine. These global charge 
differences may also affect binding of reaction substrates and products, which are all mostly 
negatively charged. The structural model did not provide clues for the increased aggregation of 
p.Q188R, which constitutes the major novelty regarding this mutant. It remains also to be 
clarified how this substitution renders the mutated protein insensitive to zinc-induced 
destabilization. Taken together, these two observations demonstrate how a local subtle change 
can propagate into other regions of the protein with such dramatic global effects.  
 
 
Figure 4.3 - Dynamic light scattering analysis of GALT variants reveals disturbed aggregation. Impact of 
missense mutations on the aggregation of GALT variants in solution, studied by dynamic light scattering (DLS). All 
proteins samples were diluted in 50 mM Tris-HCl, 300 mM KCl, 10 % glycerol, pH 7.5, to a final concentration of 
0.15 mg/mL. Panel A, temperature-induced aggregation profiles, obtained by a linear temperature increase from 20 °C 
to 70 °C at 0.5 °C/min, collecting the particle size average, distribution and total scattering intensity. Scattering 
intensity data were normalized and fitted to a plateau followed by one phase association equation, the aggregation 
temperature (Tagg) being defined as the temperature at which the intensity starts to increase significantly. Panel B, 
kinetics of thermal aggregation monitored at 42 °C for 60 min. Light scattering intensity are plotted as a function of 
A"
B"
0" 5" 10" 15" 20"20" 30" 40" 50" 60"
T (°C) Time (min) 
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time, sigmoidal curves were obtained and the t1/2 was defined as the time elapsed to reach 50% of maximum of 
aggregation. Asymptotes were removed for clarity, due to the data noise in those regions of the profiles.  
 
Most studied mutants that presented disturbed aggregation kinetics also displayed 
predicted effects on their surface electrostatic charges, either inverting the polarity of the local 
charges, or neutralizing them. The surrounding areas of p.G175D and p.N314D (Supplementary 
Figure S4.4) change from slightly positive to negative, though the first mutant residue is slightly 
buried but close to the surface while the latter is fully exposed to surface. More dramatic effects 
are predicted for the p.R148Q, p.R231C and p.R231H mutations (Supplementary Figure S4.4), 
where the highly positive surface charges from arginine guanidinium moieties are obliterated to 
neutrality. Altogether, the predicted significant impact of these mutations on the GALT surface 
charges may account for the observed disturbed aggregation profiles.  
The p.S135L, p.K285N and p.P185S mutations (Supplementary Figure S4.4) remain as 
outliers, as the observed structural and functional impairment cannot be completely rationalized. 
The p.P185S mutation is buried and appears to have no effect on the external surface charge, 
although it aggregates almost as fast as the p.Q188R mutant. Notably, p.Q188R and p.P185S 
have a nearby location and affect catalytically-relevant residues. The p.S135L mutation, 
displaying no predicted dramatic local charges or H-bonds alterations, remains puzzling. Again, 
we can only envisage subtle structural changes protruding onto the surface and causing p.S135L 
to display a slower aggregation profile at 37 °C. The p.K285N is also an intriguing mutation, 
since it displays nearly identical aggregation properties as the WT GALT, despite being slightly 
surface exposed and the substitution resulting in a significant change in the surface charge (from 
positive to negative). Moreover, no net gain or loss of H-bonds or other types of electrostatic 
interactions can be envisaged from the structural model.   
Several studies have aimed to unravel the molecular bases of the most prevalent 
mutations in classic galactosemia. A recent report suggests that misfolding is the underlying 
pathogenic mechanism of several GALT missense mutations, as commonly observed for genetic 
diseases (35, 51). Herein we aimed to shed light on the pathogenic mechanism(s) of the most 
frequent mutations in classic galactosemia that altogether account for the vast majority of mutant 
alleles at a global scale (p.Q188R, p.S135L, p.K285N and p.N314D), by analyzing their impact 
from both functional and structural perspectives. The most striking and novel observation is that 
the mutants display disturbed aggregation profiles, despite the absence of structural effects on 
their secondary and tertiary structures. This is particularly relevant for p.Q188R, the most 
prevalent mutation accounting for ~60 % of the mutant alleles. This observation is extremely 
important, since at the cellular level, the accumulation of aggregation-prone proteins interferes 
dramatically with the cellular homeostasis. Notably, studies on galactosemia models have 
revealed increased ER stress (52), unfolded protein response (53) and oxidative stress levels (54), 
hallmarks of perturbations in the cellular protein homeostasis. At present, there is an increasing 
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awareness that accumulation of damaged or abnormal proteins is the underlying pathogenic 
molecular mechanism of several diseases, and several studies in inherited metabolic disorders 
have unveiled that protein aggregation is actually a more common pathogenic mechanism that 
previously thought (55). Accordingly, the results from the structural analyses of the GALT 
mutants herein analyzed strongly suggest that GALT aggregation might be the major pathogenic 
mechanism, and so we hypothesize that proteostasis modulators might potentially improve GALT 
function in classic galactosemia models. Such proteostasis modulators may extend the life-time 
of the GALT variants in the cell, partially compensating impaired function with enzyme 
availability, and simultaneously preventing accumulation of protein aggregates, which appears to 
be a key feature in classic galactosemia pathogenesis. 
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4.8 Supplementary material  
Supplementary Table S4.1. Oligonucleotides used for site-directed mutagenesis. 
Primers a Sequence (5’→3’) b 
Q188R-F CCC CAC CCC CAC TGC CGG GTA TGG GCC AGC AG 
Q188R-R CTG CTG GCC CAT ACC CGG CAG TGG GGG TGG GG 
S135L -F GCT TCC ACC CCT GGT TGG ATG TAA CGC TGC 
S135L-R GCA GCG TTA CAT CCA ACC AGG GGT GGA AGC 
K285N-F GAA GAA GCT CTT GAC CAA TTA TGA CAA CCT CTT TGA G 
K285N-R CTC AAA GAG GTT GTC ATA ATT GGT CAA GAG CTT CTT C 
N314D-F GGC TGG GGC CAA CTG GGA CCA TTG GCA GCT GC 
N314D-R GCA GCT GCC AAT GGT CCC AGT TGG CCC CAG CC 
R148Q-F GGT CCC TGA GAT CCA GGC TGT TGT TGA TGC 
R148Q-R GCA TCA ACA ACA GCC TGG ATC TCA GGG ACC 
G175D-F GCA GAT CTT TGA AAA CAA AGA TGC CAT GAT GGG CTG TTC 
G175D-R GAA CAG CCC ATC ATG GCA TCT TTG TTT TCA AAG ATC TGC 
P185S-F GCT GTT CTA ACC CCC ACT CCC ACT GCC AGG 
P185S-R CCT GGC AGT GGG AGT GGG GGT TAG AAC AGC 
R231C-F GCT ACT CAG GAA GGA ATG TCT GGT CCT AAC CAG TG 
R231C-R CAC TGG TTA GGA CCA GAC ATT CCT TCC TGA GTA GC 
R231H-F GCT ACT CAG GAA GGA ACA TCT GGT CCT AAC CAG TG 
R231H-R CAC TGG TTA GGA CCA GAT GTT CCT TCC TGA GTA GC 
a F, forward; R, reverse. b mutagenesis sites are underlined 
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Supplementary Figure S4.1. ‘Ground-state’ extrinsic fluorescence of GALT variants in the presence of 
fluorescent dye targeting hydrophobic regions. Thermal denaturation profiles were obtained by differential scanning 
fluorimetry assays, probing the impact of mutations on the tertiary structure of GALT variants. ‘Ground-state’ extrinsic 
fluorescence was estimated as the averaged fluorescence intensities recorded in the first asymptote (20-30 °C) of the 
sigmoidal thermal denaturation profiles. Histogram represents ‘ground-state’ fluorescence of GALT variants 
normalized for the wild-type GALT values. Dashed line represents the wild-type GALT level. 
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Supplementary Figure S4.2 - The studied mutations have a limited impact on the tertiary structure of GALT 
variants. Thermal denaturation profiles were obtained by differential scanning fluorimetry assays, probing the impact 
of somatic mutations on the tertiary structure of GALT variants. The reaction mixture, totaling 50 µl, contained 0.1 
mg/mL protein (~2.5 µM in monomer) in 50 mM Tris-HCl, 300 mM KCl, 10 % glycerol, pH 7.5, and 5x SYPRO 
Orange. After a 10-min incubation at 20 °C, temperature was linearly increased from 20 to 90 °C at 1 °C/min, with 
HEX channel fluorescence acquisition every 0.2 °C. Temperature scan curves were averaged, normalized and fitted to 
a biphasic dose-response. Tm values were estimated from the inflexion points of the first and second transitions (Table 
4.1).  
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Supplementary Figure S4.3 - Thermal aggregation kinetics probed by dynamic light scattering. Kinetics of 
thermal aggregation monitored at 37 °C for 60 min. Light scattering intensity are plotted as a function of time, 
sigmoidal curves were obtained and the t1/2 was defined as the time elapsed to reach 50% of maximum of aggregation. 
Asymptotes were removed for clarity, due to the data noise in those regions of the profiles. 
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Supplementary Figure 4.4. Structural impact of the studied mutations in human GALT. Structural model of 
human mutant GALT (grey cartoon) and opposing monomer from Escherichia coli GalT (orange ribbon, PDB ID: 
1GUP). Substituting residues in red sticks. Surface electrostatics maps: red, negative charge; blue, positive charge; 
white, neutral. Figure generated with PyMOL. 
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5.1. Abstract 
Classic galactosemia is a rare metabolic disease resulting from deficient activity of 
galactose-1-phosphate uridylyltransferase (GALT), a key enzyme in the galactose metabolism. 
This disorder is characterized by a remarkable allelic heterogeneity in the GALT gene, in which 
the vast majority of the variations thus far described are missense mutations. 
Functional-structural studies on several human GALT mutants have demonstrated that 
the most prevalent GALT mutations originate proteins with disturbed aggregation behaviour, 
which is actually an increasingly recognized pathogenic mechanism in several disorders. 
Arginine has been described as a stabilizer of aggregation-prone proteins, with an 
evidence-based therapeutic effect in inherited metabolic disorder. Thus, we have developed a 
prokaryotic model of galactose sensitivity to evaluate human GALT function, particularly of 
clinically relevant mutants. 
Thus far, no clear correlation between specific activity determined in vitro and the degree 
of toxicity could, however, be established. Nevertheless, it is possible that some hGALT mutants 
present some residual activity in vivo that is not detectable when assayed in vitro with purified 
protein. Moreover, arginine revealed to have a mutation-specific beneficial effect, specifically in 
the p.Q188R, p.K285N, and p.G175D GALT mutants, which led us to hypothesize that arginine 
might be of some benefit in classic galactosemia. Further studies are underway to ascertain the 
potential therapeutic effect of arginine. Nonetheless, these results lay a foundation for future 
studies using the prokaryotic model of galactose sensitivity. 
 
5.2. Introduction 
Classic galactosemia (OMIM #230400) is a rare metabolic dis resulting from deficient 
activity of galactose-1-phosphate uridylyltransferase (GALT, EC 2.7.7.12), the second enzyme of 
the Leloir pathway (1). This inherited metabolic disorder is a potentially lethal disorder that 
develops in the neonatal period, upon exposure to galactose in milk (1-3). The present gold 
standard of care is a lifelong dietary galactose restriction, which, notwithstanding its irrefutable 
life-saving role against the acute symptoms, fails to prevent cognitive, motor and fertility 
impairments (1, 4, 5).  
Classic galactosemia is caused by mutations in the GALT gene, in which more than 260 
variations have been described, the majority being missense mutations (>60%) (6). The GALT 
gene is arranged into 11 exons spanning ~4.0 kb of genomic sequence, and encodes a 379 amino 
acid protein, which is assembled as a ~87 kDa homodimer (7, 8). GALT is highly conserved in 
nature, particularly its active site sequence His184Pro185His186, and each monomer has been 
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proposed to contain one zinc ion and one iron ion, based on studies on bacterial GalT (9-11). 
Functional-structural studies on several human GALT mutants have demonstrated that 
the most prevalent GALT mutations do not seem to significantly affect the protein structure either 
at the secondary or tertiary levels; rather, they seem to affect the protein’s aggregation behaviour 
in solution. In particular, p.Q188R, the most prevalent GALT mutation, originates a protein 
considerably more prone to aggregation than the wild-type GALT (12). In fact, protein 
aggregation is an increasingly recognized pathogenic mechanism in several disorders – including 
inherited metabolic disorders – and is believed to severely interfere with the cellular homeostasis 
(13, 14). Notably, studies on galactosemia models have revealed increased ER stress (15), 
unfolded protein response (16) and oxidative stress levels (17), hallmarks of perturbations in the 
cellular protein homeostasis. 
The well-established effect of arginine as aggregation suppressant in globular proteins 
(18, 19), and the previous report of a pyruvate dehydrogenase complex deficient patient whose 
biochemical and clinical symptoms significantly improved due to arginine intake (20, 21), 
prompted us to develop the present study. 
The aim of this study is to develop a prokaryotic model of galactose sensitivity of several 
human GALT mutants and to evaluate the effect of arginine on rescuing galactose-induced 
toxicity.  
 
5.3. Materials and Methods 
The Escherichia coli K-12 ΔgalT strain (JW0741-1; ΔgalT730::kan) with a deletion of 
the endogeneous galT gene was purchased from the Coli Genetic Stock Center (CGSC) (22). The 
human GALT cDNA sequence was cloned into the ampicillin-resistant pTrcHis A plasmid, 
yielding an N-terminally hexa-histidyl-tagged protein. Site-directed mutagenesis (NZY 
mutagenesis kit, NZYTech, Lisbon, Portugal) was employed to introduce all the mutations herein 
under study using the primers listed in Table 1. Direct sequencing in both forward and reverse 
orientations was used to confirm the correct introduction of mutations and to exclude additional 
mutational events. 
Vectors bearing the cDNA encoding the human GALT (hGALT) variants were 
transformed into the above mentioned bacterial strain. Additionally, the human PAH 
(phenylalanine hydroxylase) cDNA, cloned into the pTrcHis A vector, was assayed in parallel, as 
a negative control. All cultures were grown in M9 minimal medium (23) containing glycerol 
(1%) as sole carbon source. A starter culture was used to normalize cell concentration in all 
cultures at a starting optical density at 600 nm (OD600nm) of 0.05. Cultures were grown at 37 °C 
and when an OD600nm of 0.3 was reached, hGALT expression was induced by adding 250 µM 
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isopropyl-D-thiogalactoside (IPTG). Ferrous ammonium sulfate (100 µM) and zinc sulfate (100 
µM) were also added to all cultures, and arginine (25 mM) was added to conditions III and IV 
(Table 2). One hour after inducing hGALT expression, 1% galactose was added to conditions II 
and IV (Table 2). Table 2 describes the four different culture conditions that were used. In order 
to follow culture growth, OD600nm was measured hourly, starting at induction time and up to 9 
hours. Assays were performed in at least three independent experiments. 
 
Table 5.1. Oligonucleotides used for site-directed mutagenesis. 
Primers a Sequence (5’→3’) b 
Q188R-F CCC CAC CCC CAC TGC CGG GTA TGG GCC AGC AG 
Q188R-R CTG CTG GCC CAT ACC CGG CAG TGG GGG TGG GG 
S135L -F GCT TCC ACC CCT GGT TGG ATG TAA CGC TGC 
S135L-R GCA GCG TTA CAT CCA ACC AGG GGT GGA AGC 
K285N-F GAA GAA GCT CTT GAC CAA TTA TGA CAA CCT CTT TGA G 
K285N-R CTC AAA GAG GTT GTC ATA ATT GGT CAA GAG CTT CTT C 
N314D-F GGC TGG GGC CAA CTG GGA CCA TTG GCA GCT GC 
N314D-R GCA GCT GCC AAT GGT CCC AGT TGG CCC CAG CC 
R148Q-F GGT CCC TGA GAT CCA GGC TGT TGT TGA TGC 
R148Q-R GCA TCA ACA ACA GCC TGG ATC TCA GGG ACC 
G175D-F GCA GAT CTT TGA AAA CAA AGA TGC CAT GAT GGG CTG TTC 
G175D-R GAA CAG CCC ATC ATG GCA TCT TTG TTT TCA AAG ATC TGC 
P185S-F GCT GTT CTA ACC CCC ACT CCC ACT GCC AGG 
P185S-R CCT GGC AGT GGG AGT GGG GGT TAG AAC AGC 
R231C-F GCT ACT CAG GAA GGA ATG TCT GGT CCT AAC CAG TG 
R231C-R CAC TGG TTA GGA CCA GAC ATT CCT TCC TGA GTA GC 
R231H-F GCT ACT CAG GAA GGA ACA TCT GGT CCT AAC CAG TG 
R231H-R CAC TGG TTA GGA CCA GAT GTT CCT TCC TGA GTA GC 
a F, forward; R, reverse. b mutagenesis sites are underlined 
 
Growth curves were obtained from plotting OD600 from cultures I and II (Table 2) as a 
function of time. To directly evaluate the galactose toxicity and the arginine effect, ratios – r and 
rarg – were calculated according to equations 1 and 2, respectively, and were plotted as a function 
of time. 
Eq. 1 
r = 
OD600 gal (II) 
OD600 gly (I)
 
Eq. 2 
r arg = 
OD600 gal+arg (IV)
OD600 gly+arg (III)
 
The growth of the non-transformed bacterial strain was also assessed in parallel to the 
bacterial strain expressing the wild-type hGALT, in a M9 minimal medium containing the 
following sugars as sole carbon source:  i) glucose (1%); ii) glucose (1%) and galactose (1%); iii) 
glycerol (1%); or iv) galactose (1%). 
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Table 5.2. Culture conditions used in this study.  
 Supplementation* 
 Galactose Arginine 
I - - 
II + - 
III - + 
IV + + 
* All cultures were grown in M9 minimal medium containing glycerol as carbon source supplemented with 100 µM 
ferrous sulfate and 100 µM zinc sulfate. 
 
Recombinant production of hGALT and hPAH was confirmed by immunoblotting 
analysis. Briefly, 8 µg of total protein (bacterial soluble lysate) were applied on a 12.5% SDS-
PAGE and blotted into a nitrocellulose membrane (Hybond ECL, Amersham, GE Healthcare 
Biosciences, Uppsala, Sweden), which, after a 2-hour blocking with 5 % milk in PBS-T buffer, 
was probed at room temperature with the primary mouse monoclonal anti-GALT antibody at a 
1:1000 dilution (sc-365577, Santa Cruz Biotechnology, Santa Cruz, CA, USA) for hGALT 
variants detection, and with the primary mouse monoclonal anti-His antibody at a 1:1000 dilution 
(27-4710-01, GE Healthcare Biosciences) for hPAH detection. After three washes with PBS-T 
buffer, the membrane was incubated for 1 hour at room temperature with the secondary 
peroxidase-conjugated Affinipure goat anti-mouse IgG (H + L) antibody (Jackson 
ImmunoResearch Laboratories, West Grove, PA, USA), the ECL Prime Western Blotting 
Detection Reagent was used for protein detection (Amersham, GE Healthcare Biosciences). 
  
5.4. Results and Discussion 
5.4.1. Bacterial model of galactose sensitivity 
Previous studies have reported a yeast galactosemia model allowing the evaluation of 
hGALT mutations severity, by assaying the sensitivity of transformed yeast cultures to galactose 
added to the medium. This model presents the inherent advantage of being assayed in vivo, and 
provides valuable insights on mutations impact on hGALT function (24, 25). Since yeast cultures 
are technically more demanding and time-consuming, we sought to develop a prokaryotic model 
to evaluate the ability of previously uncharacterized mutants hGALT in alleviating galactose 
toxicity. 
The growth of the non-transformed ΔgalT strain, in parallel with wild-type hGALT 
transformed strain, was assessed in the presence of glucose (i), glucose and galactose (ii), 
glycerol (iii), and galactose (iv) as sole carbon sources. As expected, in conditions (i) and (ii), the 
growth curves are indistinguishable, since glucose is the favored carbon source, and galactose 
represents no toxicity in the presence of this hexose; in the presence of glycerol (condition iii), 
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the growth is ~50% of that observed in the presence of glucose, confirming that this polyol is not 
as good as glucose as a carbon source; whereas in the presence of galactose (condition iv), the 
growth is practically null, suggesting a high toxicity of this sugar (data not shown). In turn, the 
bacterial strain expressing the wild-type hGALT presented growth curves identical to the non-
transformed strain in conditions i, ii and iii, whereas in the presence of galactose (condition iv), 
the growth was significantly higher. These data strongly suggest the expression of hGALT is 
alleviating galactose toxicity in E. coli ΔgalT. 
 
5.4.2. Recombinant expression of hGALT variants in the bacterial model of 
galactose sensitivity 
Since the bacterial galT gene in the used strain is deleted, the transformed pTrcHis A 
vectors carrying the human GALT cDNAs (wild-type and mutants) are the only source of 
uridylyltransferase activity. Bacterial cultures expressing each of the hGALT variants or hPAH, 
in four different medium conditions (Table 2), were followed by recording OD600 as a function of 
time; the resulting profiles were evaluated focusing on galactose toxicity (Figure 5.1 to 5.4, upper 
panels). Moreover, production of recombinant hGALT variants and hPAH was confirmed by 
immunoblotting analysis (data not shown). 
The bacterial strain expressing wild-type hGALT was used as the positive control, whose 
growth should not be affected by the presence of galactose. Indeed, we could observe that the 
addition of 1% galactose had no significant influence on the bacterial growth, indicating that 
wild-type hGALT is able to alleviate galactose toxicity (Figure 5.1.A, upper panel).  
Bacteria expressing hPAH were used as the negative control, with galactose severely 
arresting the culture growth. Interestingly, using glycerol as sole carbon source (culture condition 
I, Table 2), hPAH culture exhibits a much higher growth rate than hGALT (wild-type and 
mutants) in the same conditions (Figure 5.1.B, upper panel). This may arise from the fact that 
producing different recombinant proteins has different energy costs to the bacterial cells. 
The p.N314D, p.S135L, p.R231C and p.R231H variants show essentially no growth 
arrest upon galactose addition, presenting a galactose growth curve essentially superimposable to 
that of glycerol (Figure 5.2, upper panel). The p.Q188R, p.K285N and p.G175D hGALT mutants 
show a growth profile intermediate between that of positive and negative controls, exhibiting a 
variable galactose toxicity (Figure 5.3, upper panel). On the other hand, the p.R148Q and 
p.P185S hGALT mutants show a galactose-sensitive profile similar to the negative control hPAH 
(Figure 5.4, upper panel). Despite the galactose sensitivity, p.P185S presents the highest absolute 
growth of all hGALT variants (maximum OD600 ~4) (Figure 5.4.B, upper panel). This 
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observation suggests that, not only the production of different proteins, but specifically the 
production of different variants poses different energy costs to the bacteria. 
 
 
Figure 5.1. Growth and ratio curves of wild-type hGALT and hPAH. Growth curves (upper panel) of wild-type 
hGALT (A., positive control) show growth is not affected by the presence of galactose, whereas those of hPAH (B., 
negative control) show growth is severely arrested by the presence of galactose. The ratio curves (lower panel) of 
wild-type hGALT (A., positive control) show a slight degree of response to arginine, whereas those of hPAH (B., 
negative control) show no decrease in galactose toxicity due to the presence of arginine. (WT – wild-type) 
 
No clear correlation between specific activity and degree of toxicity could be established. 
Most of the studied variants present specific activities either essentially null (p.K285N, p.R148Q, 
p.P185S, p.R231C and p.R231H) or ≤ 0.2% of wild-type activity (p.Q188R, p.S135L, p.G175D) 
(12). Indeed, taking also into account the severe galactose toxicity exhibited by hGALT mutants 
in the yeast model (25), many of these variants were expected to exhibit growth profiles similar 
to the negative control. Therefore, it is possible that some hGALT mutants present some residual 
activity in vivo that, however, when determined in vitro with the isolated proteins, is not 
detectable. Another hypothesis for the absence of a clear inverse correlation between hGALT 
activity in vitro and galactose sensitivity in vivo would be existence of an alternative bacterial 
pathway to the galactose metabolism. This hypothesis was, however, excluded by evaluating the 
bacterial growth of the non-transformed strain, which, as described above, exhibited an essential 
null growth in the presence of galactose.  
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Figure 5.2. Growth and ratio curves of p.N314D, p.S135L, p.R231C and p.R231H hGALT mutants. Growth 
curves show essentially no growth arrest upon galactose addition (upper panel); and ratio curves suggest an overall 
insensitivity to arginine supplementation (lower panel). 
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Figure 5.3. Growth and ratio curves of p.Q188R, p.K285N and p.G175D hGALT mutants. Growth curves show a 
growth profile intermediate between that of positive and negative controls (upper panel); and ratio curves (lower panel) 
suggest a partial rescue by arginine (rarg > r, shaded area). 
 
 
Figure 5.4. Growth and ratio curves of p.R148Q and p.P185S hGALT mutants. Growth curves suggest a 
galactose-sensitivity profile similar to that of the negative control hPAH (upper panel) and ratio curves show 
unresponsiveness to arginine supplementation (lower panel). 
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5.4.3. Arginine effect on the bacterial model of galactose sensitivity  
Arginine has been described as therapeutically beneficial in a number of studies (20, 26). 
In fact, arginine is a long-recognized protein stabilizer that has been proposed to exert an  
anti-aggregation effect by increasing the activation energy of protein association/aggregation 
(18). Since the most prevalent hGALT variants revealed to be more prone to aggregation than the 
wild-type hGALT (12), arginine could potentially exert a protective stabilizing effect and 
constitute a novel therapeutic agent in classic galactosemia. 
From the ratio curves, we can observe that the wild-type hGALT culture presents a slight 
degree of response to the medium supplementation with arginine (Figure 5.1.A, lower panel), 
which is not surprising since it has been described that arginine is also able to stabilize the 
proteins’ native state (27). In contrast, the hPAH ratio curves are superimposable, indicating its 
insensitivity to arginine supplementation. 
Interestingly, p.N314D, which is believed to be the ancestral allele (28), appears to be 
essentially insensitive to arginine (figure 5.2 A lower panel); as the same for the p.S135L and 
p.R231H cultures, which show essentially overlapping ratio curves (Figure 5.2, B. and D., lower 
panel). The p.R231C mutant, affecting the same residue as the latter variant, also presents almost 
superimposable ratio curves, but with the puzzling feature of a slightly increased toxicity in the 
presence of arginine. The p.Q188R, p.K285N, and p.G175D cultures are partially rescued by 
arginine, with rarg > r (Figure 5.3, lower panel). The rescue of p.Q188R is particular intriguing, 
since it is considered a severe mutation and has been described as particularly prone to 
aggregation (12). Immunoblotting analysis of the soluble lysate revealed that this mutant is 
actually highly expressed, which may account for the unexpected high tolerance (data not 
shown). In turn, p.R148Q and p.P185S ratio curves are very similar to the hPAH negative 
control, revealing their functional impairment and unresponsiveness to the potential stabilizing 
effect of arginine (Figure 5.4, lower panel). 
The reproducibility of the ratio curves clearly indicate that the arginine mode of action is 
mutation-specific, suggesting it is indeed alleviating the galactose toxicity in the p.Q188R, 
p.K285N, and p.G175D mutants. These results here presented put forward the hypothesis that 
arginine might be of some benefit in classic galactosemia and, despite being preliminary, set the 
stage for further detailed studies.  
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The present work aimed to provide new insights on the molecular bases of classic 
galactosemia, and thus broaden the understanding on this enigmatic disorder. Our first goal 
focused on further elucidating the genetic bases of classic galactosemia, by characterizing the 
mutational spectrum in the Portuguese galactosemic population, since previous studies postulated 
that GALT genotyping provides added value in the establishment of prognosis for galactosemic 
patients (1, 2). This disorder is characterized by a wide clinical variability, and a long-pursued 
goal has been the identification of predictive factors to distinguish patients who will thrive in the 
long run from those who will experience complications (1). Accordingly, this work initiated with 
the molecular characterization of GALT deficient Portuguese patients, which revealed a marked 
allelic heterogeneity, as described for other populations (3, 4). Nevertheless, some mutations 
present a noteworthy prevalence, such as the missense p.Q188R mutation, which represents the 
vast majority of all mutant alleles (67%), followed by the splicing mutation, c.820+13A>G (8%). 
Establishment of genotype-phenotype correlations was subsequently attempted; however, no 
correlation was observed between GALT genotype and either biochemical or clinical phenotypes, 
even among siblings. In fact, recent studies involving siblings have shown that a too stringent 
diet may actually be harmful, reinforcing the idea that GALT genotyping is a determinant factor 
in classic galactosemia pathophysiology but only to a certain degree (5). Classic galactosemia 
has, in fact, been described as a complex disorder (1), characterized by a large biochemical and 
clinical variability (6), and whose pathophysiology, albeit being essentially unknown, is 
unquestionably also determined by other factors, such as genetic, epigenetic and environmental 
factors. Ultimately, the phenotype is beyond the control of the single gene itself (1). 
In recent years, there has been an increasing awareness that deep intronic variations, and 
not just variations in the canonical splice sites, may affect splicing. Molecular characterization of 
Portuguese galactosemic patients revealed that the second most prevalent mutation is an intronic 
variation, until now classified as benign (7). Thus, we have characterized this mutation from a  
functional viewpoint by both in vitro and in vivo approaches. Our results confirmed that 
c.820+13A>G is a disease-causing mutation, whose underlying pathogenic mechanism involves 
the activation of a cryptic donor site located immediately downstream the variation. Intronic 
mutations activating cryptic splice sites are particularly amenable to antisense therapy, since the 
canonical splice sites remain intact, retaining the potential for restoring constitutive splicing (8). 
Hence, LNA oligonucleotides were designed to specifically recognize the mutation and have 
proved to successfully restore the constitutive splicing profile, thus establishing a proof-of-
concept for the application of antisense therapy for mis-splicing mutations in classic 
galactosemia. It should be noted, however, that antisense therapy is a mutation-specific 
therapeutic approach and, thus, if proved to be applicable for galactosemic patients, it would be 
targeted to specific patients. 
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Missense mutations dominate the mutational spectrum of classic galactosemia, as for 
many other genetic disorders, and are undeniably the most common type of mutations in 
inherited metabolic disorders. Initially thought to affect exclusively the protein’s functional 
residues, missense mutations are known to also affect the protein’s conformational stability. In 
the GALT gene, patient-identified missense mutations are scattered throughout the whole coding 
region, which strongly suggests that GALT deficiency does not arise exclusively from mutations 
in functional sites. In reality, a number of GALT mutations have been described to originate 
misfolded proteins (9). In what regards the most prevalent missense mutations, several studies 
have focused on their functional characterization (10-14); however, a characterization of these 
variants focusing on different structural features was still lacking. Thus, we have performed a 
thorough structural-functional characterization of nine recombinant GALT variants, four of 
which result from the most prevalent mutations identified in GALT mutant alleles. Remarkably, 
no major structural effects were detected on their secondary and tertiary structures. Rather, most 
mutants displayed disturbed aggregation profiles. In particular, p.Q188R, the most prevalent 
GALT mutation, was shown to give rise to a protein considerably more prone to aggregation than 
the wild-type GALT. This observation, a novelty resulting from this work, is extremely important 
since, at the cellular level, the accumulation of aggregation-prone proteins interferes dramatically 
with the cellular homeostasis. Thus, classic galactosemia pathogenesis may be related, not merely 
with a deficient GALT activity, but also with its proteotoxicity. Notably, studies on galactosemia 
models have revealed increased ER stress, unfolded protein response and oxidative stress levels, 
hallmarks of perturbations in the cellular protein homeostasis (15-17). Furthermore, studies on 
inherited metabolic disorders had already disclosed that protein aggregation was actually a more 
common pathogenic mechanism than previously thought (18, 19), and classic galactosemia may 
now constitute another example of a metabolic disorder whereby protein aggregation is linked to 
disease. Identifying the possible layers of interaction between GALT mutants and the intricate 
protein quality control system will likely provide new insights on the molecular mechanisms 
involved in GALT mutants proteotoxicity, and possibly provide new clues on the phenotypic 
heterogeneity.  
Our findings have important therapeutic implications, since one of the treatment 
strategies intensively explored in the last decade consists of the discovery and development of 
GALK inhibitors (20, 21). Nevertheless, if GALT mutants do indeed lead to proteotoxicity, this 
line of approach might be insufficient, since it would essentially control the Gal-1-P intracellular 
levels, and would, thus, fail to prevent GALT mutants aggregation toxicity. 
We hypothesize that a reasonable strategy might be the use of proteostasis modulators, 
which would potentially extend the life-time of the GALT variants in the cell, partially 
compensating impaired function with enzyme availability, and simultaneously preventing 
accumulation of protein aggregates. Hopefully, this approach has the potential advantage of not 
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being mutation-specific and would thus have a therapeutic indication for a wider number of 
galactosemic patients. 
We also sought to develop a prokaryotic model of galactose sensitivity, based on the 
previous description of a yeast model (22, 23). This bacterial model, lacking the endogenous galT 
gene, presents the inherent advantage of being assayed in vivo, which, in fact, might be crucial 
for some human GALT mutants, since their expression in our bacterial model was able to 
alleviate the galactose-induced toxicity, whereas in vitro exhibited essentially null specific 
activity. Furthermore, this unicellular model also presents the remarkable advantage of allowing 
the evaluation of potential therapeutic agents inferred from their ability to rescue galactose 
toxicity when expressing a specific human GALT mutant.  
The previous report of a pyruvate dehydrogenase complex deficient patient whose 
biochemical and clinical symptoms significantly improved upon arginine intake (24, 25), and the 
long-recognized effect of arginine as anti-aggregation stabilizer in globular proteins (26, 27), set 
the stage for this particular study. Thus, we have expressed several human GALT in the 
Escherichia coli ΔgalT strain, and evaluated the alleviation of galactose-toxicity. The p.R148Q 
and p.P185S curves suggested a severe functional impairment and a complete unresponsiveness 
to arginine, whereas the p.S135L, p.N314D, p.R231C and p.R231H present no significant 
improvement upon arginine supplementation, in line with the essentially absent galactose-
induced toxicity. Hence, only the p.Q188R, p.K285N, and p.G175D variants were partially 
rescued and stand that arginine might be of some benefit for these GALT mutants. 
These are, however, preliminary results, and further studies are underway to understand 
this mutation-specific mode of action of arginine. Nevertheless, this prokaryotic model shows 
high potential for the screening of possible therapeutic agents in classic galactosemia. 
 
With the post-genomic era, has arisen the concept of personalized medicine, whereby the 
design of new therapeutic strategies is based on how the mutations take their toll (28). 
Accordingly, in this work, we have performed detailed molecular studies in classic galactosemia. 
We have described a particularly high prevalent intronic variation in the GALT gene and, 
accordingly, have developed a mutation-specific antisense therapy, thus establishing a proof-of-
concept for this treatment approach in classic galactosemia. Moreover, this work provides a new 
piece in the complicated puzzle that classic galactosemia constitutes, by elucidating that the 
underlying molecular mechanism of several mutants – particularly of the most prevalent mutants 
– is mainly related to protein aggregation. Accordingly, we hypothesize that new therapeutic 
approaches, focusing on either preventing aggregation or promoting the degradation of these 
potentially toxic aggregates, may be beneficial in classic galactosemia. These insights constitute, 
indeed, a breakthrough in this enigmatic disorder, opening new avenues of research with the 
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long-term goal of developing new alternative therapies that can overcome the dramatic long-term 
complications experienced by most patients. 
Despite the marked clinical heterogeneity and the complex pathophysiology, classic 
galactosemia is a single gene disorder, whose prospectives of treatment are, like for other 
monogenic disorders, closer than for non-mendelian disorders (29). Indeed, the future is now for 
rare genetic disorders (29). The future is now for classic galactosemia. 
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